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With the rapid spread of drug resistance to chloroquine, the development of effective, safe, 
and affordable antimalarial drugs has become one of the most pressing health priorities 
worldwide. Two azafluorenone alkaloids isolated from Mitrephora diversifolia have been 
proved to possess antimalarial activity against chloroquine-resistant Plasmodium falciparum. 
To explore the structure-activity relationship of the azafluorenone family, twenty four 
analogues with various structural modifications have been prepared via a concise synthetic 
route utilising Suzuki cross-coupling reactions and intramolecular Friedel-Crafts acylations 
as the key steps. A series of hybrid molecules conjugating the azafluorenone core and the 
amino side chains present in 4-aminoquinoline antimalarial agents have also been 
synthesised. Fourteen of the azafluorenones have been evaluated for antiplasmodial activity 
by [3H]hypoxanthine-incorporation assay. Eight azafluorenones display activity against 
chloroquine-sensitive Plasmodium falciparum 3D7, and nine azafluorenones are active 
against chloroquine-resistant Plasmodium falciparum K1. The hybrid molecules prepared 
possess a much higher antimalarial potency than the other azafluorenones, which can be 
attributed to the additional interaction between the amino side chains and the target site. An 
in vitro β-haematin inhibition assay has been conducted to probe the mode of action of the 
azafluorenones. However, only two azafluorenones show mild inhibitory activity against 
β-haematin formation. Four distinct synthetic routes have been investigated for the total 
synthesis of the parent antimalarial natural product. However, each of these fails to afford the 
desired alkaloid. 
  
An efficient one-pot method for the synthesis of pyrido[3,2-c]coumarins has been developed. 
Twenty seven pyrido[3,2-c]coumarin derivatives have been prepared in moderate to excellent 
yields under the optimised thermal conditions, confirming the versatility of this protocol. Nine 
pyrido[3,2-c]coumarin analogues have been synthesised in moderate to good yields under 
microwave-assisted conditions. The mechanism of this one-pot reaction has been explored. 
The good yields, concise synthetic route, wide availability of substrates and milder reaction 
conditions render this one-pot protocol superior to other commonly used methods and make it 
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1.1  Introduction 
 
Malaria, a tropical disease caused by unicellular protozoan parasites of the genus 
Plasmodium, has remained a global public health concern for centuries. Currently, 
approximately 40% of the world’s population lives in regions with a high risk of 
malaria (Figure 1.1).1 Malaria is transmitted via the bite of a female anopheles 
mosquito. The parasites infect and destroy red blood cells where they multiply rapidly 
giving rise to fever, severe anaemia, coma, and even death if untreated. There are five 
Plasmodium species infecting humans, which can be distinguished by morphology, 
Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, Plasmodium malariae 
and Plasmodium knowlesi which was recently identified.2 Plasmodium falciparum, the 
most prevalent species across the globe, can cause the infection of erythrocytes in the 
vessels of brain, giving rise to fatal cerebral malaria.3 According to World Malaria 
Report 2014 by World Health Organisation, there were approximately 198 million 
documented cases of malaria and an estimated 584 000 deaths in 2013. The actual 
number of deaths may be significantly higher, as the precise data is not available in 
many rural areas, and many cases are undocumented in these areas. Moreover, since 
international travel has become commonplace, malaria is no longer confined to the 
tropical regions and imported malaria has become an increasing public health issue 




Figure 1.1 Countries with ongoing transmission of malaria, 2013.4 
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The most intractable problem for the control and prevention of malaria currently is the 
wide spread of resistance to the mainstay antimalarial chloroquine.3 In addition, the 
recent emergence of resistance towards the antimalarial drug artemisinin in southeast 
Asia also poses a serious threat to the global control of malaria.4 Owing to the rapid 
spread of drug resistance, the development of effective, safe, and affordable drugs for 
the treatment of malaria remains one of the most pressing health priorities worldwide. 
 
1.1.1 Life Cycle of Malaria Parasites and Clinical Symptoms of Malaria 
 
The infectious stages of the malaria parasite reside in the salivary glands of female 
anopheles mosquitoes that bite humans. As shown in Figure 1.2, the sporozoite form of 
the parasite is transferred into the blood stream during blood extraction of mosquitoes. 
Sporozoites rapidly enter the liver cells, where they conceal themselves from the host’s 
immune system.3 These sporozoites turn into hepatic schizonts, encompassing a 
tremendous number of merozoites. The rupture of mature schizonts gives rise to the 
release of numerous merozoites into the blood stream, initiating the erythrocytic phase 
of the parasite’s life cycle. Alternatively, by developing into dormant hypnozoites, some 
sporozoites of Plasmodium vivax and Plasmodium ovale will remain in liver cells and 
result in the reactivation and relapse months or even years after the initial infection. In 
contrast, Plasmodium falciparum and Plasmodium malariae lack this liver-persistent 
phase. The merozoites entering the blood stream rapidly invade red blood cells, where 
they fuel their activity by consuming host’s haemoglobin. In the erythrocyte, parasites 
develop from the ring stage via the trophozoite stage into the blood schizont, leading to 
the burst of erythrocyte and the release of a number of new merozoites into the blood 
stream as well. The newly released merozoites invade other red blood cells, 
commencing a new erythrocytic cycle (Figure 1.2). This process, from invasion of the 
erythrocytes to the rupture of the blood schizont, is referred to as the asexual life cycle, 
whilst the clinical signs and symptoms of malaria emerge due to the release of 
parasites’ waste and cell debris.3  
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Figure 1.2 Life cycle of malaria parasites. 
 
After a number of asexual life cycles, some merozoites evolve into gametocytes, the 
sexual form of parasites ready for the migration to an Anopheles through a subsequent 
blood meal. These gametocytes undergo sexual reproduction in the gut of Anopheles 
and are transferred to the salivary gland, awaiting the commencement of a new 
infection cycle (Figure 1.2).3 
 
The clinical symptoms of malaria include fever, chill, headache, abdominal and back 
pain, nausea, diarrhoea and vomiting. Although the symptoms of Plasmodium vivax, 
Plasmodium ovale, and Plasmodium malariae infections can be sometimes severe in 
patients, seldom do these parasites induce fatal diseases. In contrast, Plasmodium 
falciparum malaria can develop from uncomplicated to severe malaria within a few 
days, giving a fatal outcome in 10-40% of the severe malaria cases.5 
 
 
1.1.2  Established Antimalarial Drugs 
 
Currently used antimalarial agents stem from five major drug classes. In most cases, 
antimalarials target against the asexual erythrocytic stage of the parasite. The main 
classes of blood schizontocides encompass 4-aminoquinolines, arylamino-alcohols, and 
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antifolate agents. The natural endoperoxide artemisinin and its semisynthetic 
derivatives as well as the synthetic analogues represent the newer antimalarial drugs. 
Contrasting with the other antimalarials, 8-aminoquinolines are active against both the 
pre-erythrocytic liver stage and the sexual gametocyte stage.5  
 
1.1.2.1  4-Aminoquinolines 
 
4-Aminoquinolines are the main family of antimalarial drugs used in the treatment and 
prophylaxis of malaria.3 These drugs can be readily synthesised and are of low cost. 
The widely accepted theory regarding the mode of action of 4-aminoquinolines is 
related to their inhibition of haemozoin formation.6 In the erythrocytic cycle, malaria 
parasites acquire essential amino acids as nutrients for the growth and proliferation by 
degrading the haemoglobin of the host red blood cell. Digestion of this food source 
takes place in the acidic compartment known as the digestive vacuole, which is a 
lysosome-type organelle with a pH value of approximately 5. During the degradation of 
haemoglobin, the toxic and soluble haems are generated as a by-product. The parasite 
disposes of these free haems by crystalising them into an insoluble and nontoxic 
polymer haemozoin to achieve the detoxification. The 4-aminoquinoline in the 
digestive vacuole of a parasite forms a quinoline-haem complex, which adsorbs onto 
the actively growing face of haemozoin, capping the haemozoin crystal and blocking 
the growth of the haemozoin polymer (Figure 1.3).6 As a consequence, a great number 




Figure 1.3 Model of inhibition of haemozoin formation by 4-aminoquinolines.6 
 
 
Chloroquine 1 (Figure 1.4), introduced in the 1940s, has been the mainstay of therapy 
and prophylaxis of malaria for forty years. The excellent clinical efficacy, low host 
toxicity, along with the low cost of chloroquine accounts for its extensive clinical use.7 
In 1994, chloroquine was still the third most widely used drug in the world after aspirin 
and paracetamol.8 Chloroquine is well tolerated in the treatment and prophylaxis of 
malaria. Only mild and moderate adverse effects have been identified, including 




Figure 1.4 Structure of chloroquine. 
 
The high selectivity of chloroquine action can be attributed to its target, the 
parasite-specific hemoglobin digestion process and its high rate of accumulation in 
malaria parasites. The unprotonated form of chloroquine can readily traverse the 
membranes of erythrocyte, parasite as well as digestive vacuole via simple diffusion. 
Once inside the acidic digestive vacuole whose pH is 4.8-5.2, chloroquine becomes 
protonated and is rendered impermeable to the membrane of digestive vacuole.5 As a 
result, chloroquine is trapped in the acidic compartment of the parasite, where the 
concentration builds up.5 
 
However, the value of chloroquine has been seriously eroded due to the development 
and spread of parasite resistance.10 Currently, more than 80% of wild strains of 
Plasmodium falciparum are resistant to chloroquine.4 Chloroquine resistance was 
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observed in Southeast Asia and South America at the end of the 1950s. In the late 1970s, 
the resistance also emerged in Africa. The accumulation of chloroquine in the acidic 
digestive vacuole significantly decreases in the case of chloroquine-resistant strains due 
to the Plasmodium falciparum chloroquine resistance transporter (PfCRT).3 PfCRT, 
located in the digestive vacuole, belongs to the drug metabolite transporter superfamily. 
The mutation of the PfCRT gene in chloroquine-resistant strains results in the 
expression of the mutated PfCRT which is able to recognise and facilitate the efflux of 
chloroquine from the digestive vacuole.5 
 
Owing to the global spread of chloroquine resistance, numerous attempts have been 
made to develop effective and safe agents for the treatment of chloroquine-resistant 
parasites. One of the most successful strategies to circumvent drug resistance is the 
modification of the aminoalkyl group in chloroquine, resulting in a series of 
chloroquine derivatives 2-5 (Figure 1.5). The variation of the side chain imparts activity 
against chloroquine-resistant Plasmodium falciparum to these analogues,10 which is 
attributed to the fact that these derivatives cannot be recognised by the muted PfCRT, 
leading to the escape of these analogues from the structure-specific efflux.5 AQ-13 (2, 
Figure 1.5) has been selected as an antimalarial candidate drug for clinical trials. The 
Phase I trial revealed a similar safety profile of AQ-13 compared with chloroquine. No 
serious toxic effects were identified in this study. Only moderate side effects occurred 
to some volunteers, including headache, dizziness and gastrointestinal symptoms such 
as nausea, vomiting, and diarrhea.11 Commenced in 2013, the Phase II clinical trial of 





Figure 1.5 Chloroquine analogues with modified side chains. 
 
 
Compound 1 2 3 4 5 
IC50 (NF54) (nM) 16 18 24 22 25 
IC50 (K1) (nM) 315 59 49 50 61 
 
Table 1.1 Activity of chloroquine and its analogues.  
 
Incorporation of an aromatic ring into the chloroquine side chain affords amodiaquine 6 
(Figure 1.5), which has been proved to be more effective than chloroquine in treating 
many chloroquine-resistant strains of Plasmodium falciparum.12 Amodiaquine is on the 
World Health Organisation's List of Essential Medicines 2013, a list of the most 





1.1.2.2  Arylamino-alcohols 
 
Quinine 7 (Figure 1.6), the active component of cinchona bark which was introduced 
into Europe from South America in the 17th century, has been utilised for the treatment 
of malaria for over 350 years.14 Quinine remained the first-choice antimalarial drug 
until World War II, when other drugs such as chloroquine with greater tolerance 
replaced it. Currently, oral quinine is used for the treatment of uncomplicated malaria, 
which is a disease not causing severe organ dysfunction. In the case of severe malaria, 
quinine is administered by intramuscular injection or intravenous infusion.15 However, 
quinine displays multiple adverse effects, including nausea, headache, tinnitus, hearing 
impairment, dysphoria, and blurred vision. More importantly, it induces a significant 
increase in insulin secretion, giving rise to severe hypoglycaemia.16 Investigations have 
confirmed that quinine acts by inhibiting polymerisation of the haems released during 




Figure 1.6 Antimalarial arylamino-alcohols: quinine and mefloquine. 
 
Mefloquine 8 (Figure 1.6), as a structurally simplified quinine molecule, is a blood 
schizonticide active against the erythrocytic stages of Plasmodium falciparum and 
Plasmodium vivax. Ninety of the ninety-two chloroquine-resistant plasmodium strains 
show to be sensitive to mefloquine, indicating the potent antimalarial activity of 
mefloquine.12 Mefloquine is utilised not only for the treatment of malaria but also for 
the prophylaxis.17,18 However, the resistance to mefloquine has also emerged and 
continues to spread, especially in Southeast Asia.19 In addition, the usage of mefloquine 
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is associated with significant neuropsychiatric adverse effects, such as dizziness, 
headache, insomnia and even epilepsy, which severely limits its utilisation.16 As a 
derivate of quinine, mefloquine is also believed to act as an inhibitor of polymerisation 
of the haems.6  
 
Halofantrine 9 and pyronaridine 10 (Figure 1.7) are also representative of 
arylamino-alcohol antimalarial agents. They are both effective against 
chloroquine-resistant plasmodium strains.12 Nevertheless, the severe cardiac toxicity of 
halofantrine, including ventricular arrhythmias, significantly restricts the widespread 
use.9 As a consequence, halofantrine has been withdrawn from the list of the first-line 
drugs recommended for the treatment of malaria by the World Health Organisation.20 
 
 
 Figure 1.7 Antimalarial arylamino-alcohols: halofantrine and pyronaridine. 
 
1.1.2.3  Artemisinin and its Derivatives 
 
Artemisinin 11 (Figure 1.8) is an endoperoxide sesquiterpene lactone produced by 
aerial parts of Artemisia annua. The earliest report of Artemisia annua extracts being 
used in the treatment of malarial dates back to the 4th century AD, described in “The 
Handbook of Prescriptions for Emergencies” (Zhouhou Beiji Fang) by Ge Hong during 






Figure 1.8 Artemisinin and its semisynthetic derivatives. 
 
To date, artemisinin and its derivatives (12-14, Figure 1.8) have become one of the 
most efficacious classes of antimalarial agents and serve as the first-line treatment for 
multidrug-resistant malaria.20 Artemisinin, a molecule poorly soluble in both water and 
oil, possesses a low bioavailability which limits its effectiveness. To address this 
problem, the three semisynthetic derivatives 12-14 were developed. Two of these 
derivatives are oil-soluble ethers: artemether 12 and arteether 13; the other is a 
water-soluble hemisuccinate: artesunate 14. Artemisinin derivatives clear parasitemia 
more rapidly than all the other currently available antimalarial agents, and they are the 
only antimalarials, apart from the cinchona alkaloids, used to treat severe falciparum 
malaria.23 Two multi-centre, open-label and randomised trials for the evaluation of the 
efficacy of artesunate in the treatment of severe malaria were undertaken, which 
demonstrated that intravenous artesunate offered a significant reduction in mortality 
compared with intravenous quinine for patients suffering from severe malaria.24,25 On 
the basis of these trials, WHO revised its Guidelines for the Treatment of Malaria in 
2010, establishing parenteral artesunate in preference to quinine as the therapy of 
choice for severe malaria.20  
 
The endoperoxide bridge has been demonstrated to play a crucial role in the activity of 
artemisinin and its derivatives. Research reveals 10-deoxoartemisinin 15 (Figure 1.9) 
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retains the antiplasmodial activity, whereas 1-carba-10-deoxoartemisinin 16 





Figure 1.9 Artemisinin and deoxoartemisinins. 
 
It has been demonstrated that artemisinins exert the antimalarial effect by the radical 
formation dependent on the endoperoxide moiety. In the presence of the haem 
generated in the haemoglobin metabolism by parasite, the endoperoxide bridge of 
artemisinin is broken, followed by the formation of drug-derived carbon-centred 
radical.27 A mechanism proposal for this process has been put forward (Figure 1.10).28 
The reductive activation of artemisinin by FeII-haem (Fe(II)PPIX) leads to the cleavage 
of the endoperoxide bond and affords the oxygen-centred radical 17, with the 
simultaneous oxidation of the iron(II) centre in the haem. This radical is promptly 




 Figure 1.10 Mechanism proposal for the generation of carbon-centred radical.  
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This reactive alkyl radical is able to act as an alkylating agent toward haem to form an 
adduct responsible for the antimalarial activity (Figure 1.11).27 Alkylation of haem by 
artemisinin in vivo has been attested by the successful identification of 
haem-artemisinin adduct in the spleen extracts of parasite-infected mice treated with 
artemisinin.29 No haem-artemisinin adduct has been detected in the healthy mice treated 
with artemisinin. These observations demonstrate the alkylation of haem is a 
parasite-specific process in the action of artemisinin.29 Haem-artemisinin adduct can 
inhibit the formation of haemozoin, which is the detoxification process of free haems 
by plasmodium, resulting in the death of parasite.30  
 
Another proposal for the mode of action of artemisinin ascribes the antimalarial activity 
to its interference with the plasmodial haemoglobin catabolic pathway as well as the 
detoxification process of haem (Figure 1.11).31 Aspartic and cysteine proteases are 
significant enzymes responsible for the proteolysis of haemoglobin in parasites. By the 
interaction with aspartic and cysteine proteases, artemisinin can disrupt the 
haemoglobin degradation, blocking the nutrient source for the parasite.31 In addition, 
artemisinin is also able to interact with the haemozoin which is already formed in the 
parasite digestive vacuole, resulting in the breakdown of the haemozoin and the 
liberation of free haems.31 Pandey has speculated this process might be related to the 
collapse of bond between iron and carboxylate in hemozoin caused by artemisinin.31 





Figure 1.11 Comprehensive action mode of artemisinin.  
 
Compared to other commonly employed antimalarial drugs, artemisinin derivatives 
have an excellent safety profile at the dosage recommended for treatment of a single 
malaria episode (4 mg/kg/day for 3 days).32 Only mild and infrequent adverse effects 
including nausea, vomiting, anorexia and dizziness have been reported.33 Nonetheless, 
higher doses administered over longer periods (6 mg/kg/day for 7 days) display a high 
rate of neutropenia (19%), suggesting the administration of artemisinins should strictly 
comply with the recommended dosage.33 
 
The wide use of artemisinins have substantially reduced global morbidity and mortality 
from malaria.4 Nevertheless, the prospect for the elimination of malaria is threatened by 
the emergence of artemisinin resistant Plasmodium falciparum.23,34 The resistance has 
been confirmed across the five countries of the Greater Mekong subregion up to 
September 2014 (Figure 1.12).34 Moreover, the relatively high cost and erratic supply 





TIER I: Areas with 
credible evidence of 
artemisinin resistance; 
 
TIER II: Areas with 
significant inflows of 
migrant populations 
from tier I areas or 
shared borders with tier 
I areas;   
 
TIER III: Plasmodium 
falciparum endemic 
areas without evidence 
of artemisinin resistance   
 
 
Figure 1.12 Tier map of the Greater Mekong subregion with artemisinin resistance.34 
 
To halt and contain the spread of artemisinin resistance, World Health Organisation 
launched the Global Plan for Artemisinin Resistance Containment (GPARC) in 2011 to 
promote the application of artemisinin-based combination therapy. For instance, 
amodiaquine/artesunate fixed-dose combination has become a new effective medication 
for the treatment of Plasmodium falciparum malaria in Africa.35 In addition, the 
combination therapy of artesunate and mefloquine has also been proved to be a safe, 
well tolerated and effective regimen in the treatment of multi-drug resistant falciparum 
malaria and is widely used in Southeast Asia.36  
 
1.1.2.4  8-Aminoquinolines 
 
Primaquine 19 (Figure 1.13) distinguishes itself from other antimalarial agents, as it 
displays activity against the hypnozoites and the sexual gametocytes of all the five 
Plasmodia infecting humans. Primaquine is also effective on the asexual erythrocytic 
stage of Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and 
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Plasmodium knowlesi, whereas it is only weakly active against the erythrocytic stage of 
Plasmodium falciparum.37 Owing to its unique feature, primaquine is widely used in 
prophylaxis and treatment of Plasmodium vivax and Plasmodium ovale.37 By clearing 
the latent hypnozoites developed in the hepatic stage of these two Plasmodia, 
primaquine is able to prevent the relapse of Plasmodium vivax and Plasmodium ovale, 
which occurs months or even years after the initial infection.38  
 
 
Figure 1.13 8-Aminoquinoline antimalarial agents: primaquine and tafenoquin. 
 
In addition, the application of primaquine as a gametocytocide to reduce the 
transmission of falciparum malaria is also recommended by World Health 
Organisation.39 Gametocytes of Plasmodium falciparum are relatively insensitive to 
artemisinins, so patients with transmissible gametocytes may remain infectious to 
mosquitoes for many days after receiving artemisinin-based combination therapy. 
Addition of primaquine to the artemisinin-based combination therapy can clear mature 
gametocytes effectively, blocking the infection of parasites to mosquitoes which serve 
as malaria vectors.38 Notwithstanding these advantages, the major problem of 
primaquine limiting its use is the serious toxicity towards patients with 
glucose-6-phosphate dehydrogenase deficiency.37 Therapeutic or higher doses of 
primaquine can induce acute haemolytic anemia or fatal haemolysis in G6PD-deficient 
individuals. In Arab populations living in malaria-risk areas, more than 30% of the 
patients show evidence of this deficiency in general, with an incidence of about 
10-20%.16   
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Tafenoquine 20 (Figure 1.13), developed by Walter Reed Army Institute of Research in 
USA, is a primaquine analogue with a longer elimination half-life (14 days compared 
with 4 hours for primaquine). Tafenoquine is more potent against erythrocytic stage of 
Plasmodium falciparum than primaquine and also exhibits greater 
transmission-blocking activity.37 However, tafenoquine possesses a similar haemolytic 
toxicity in G6PD-deficient patients. Phase-IIb studies are under way to determine risks 
and optimise dosing currently.37 
 
1.1.2.5 Antifolates  
 
Antifolates 21-27 (Figure 1.14) inhibit the synthesis of parasitic deoxythymidylate, and 
thereby halt the synthesis of parasitic DNA.5 There are two classes of antifolates 
applied to the treatment of malaria: dihydrofolate reductase (DHFR) inhibitors such as 
pyrimethamine 21, proguanil 22 and chlorproguanil 23 (Figure 1.14);  dihydropteroate 
synthase (DHPS) inhibitors including sulfadoxine 24 and dapsone 25 (Figure 1.14). A 
dihydrofolate reductase inhibitor is usually used in combination with a dihydropteroate 




Figure 1.14 Antifolate antimalarial agents: DHFR and DHPS inhibitors. 
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Folate derivatives play a vital role in the biosynthesis of deoxythymidylate (dTMP). 
Mammals can obtain dihydrofolic acid from their diet, whereas malaria parasites 
completely depend on the biosynthesis of dihydrofolic acid from simple precursors to 
accomplish the de novo synthesis pathway of dTMP, which is critical to the parasites’ 
survival.40 As shown in Figure 1.15, 7,8-dihydro-6-hydroxymethylpterin pyrophosphate 
28 (Figure 1.15) is condensed with p-aminobenzoic acid 29 to yield dihydropteroate 30 
under the action of dihydropteroate synthase. Dihydrofolate 32 derived from the 
coupling between glutamic acid and dihydropteroate enters the folate cycle. In the 
presence of dihydrofolate reductase, dihydrofolate 32 is reduced to tetrahydrofolate 33, 
which undergoes hydroxymethyl transferase-mediated conversion to yield 
5,10-methylenetetrahydrofolate 36. With 5,10-methylenetetra- hydrofolate serving as 
the methyl donor, the conversion of dUMP to dTMP is finally achieved under the action 
of thymidylate synthase. Dihydropteroate synthase is completely absent in humans, and 
the structure of protozoal dihydrofolate reductase is significantly different from that of 






Figure 1.15 Folic acid metabolic pathway and its antagonists.  
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Owing to their structural resemblance to p-aminobenzoic acid, sulfadoxine 24 and 
dapsone 25 exert their activity by mimicking the normal substrate p-aminobenzoic acid 
to competitively bind to dihydropteroate synthase and block the biosynthesis of 
dihydropteroate 30, resulting in the disruption to DNA synthesis (Figure 1.15).5 It is the 
absence of dihydropteroate synthase in mammalian cells that renders sulfadoxine and 
dapsone selectively toxic towards malaria parasites. 
 
Dihydrofolate reductase is another important enzyme targeted by inhibitors towards 
folic acid metabolic pathway. Possessing a high affinity to dihydrofolate reductase, 
pyrimethamine 21 is able to compete with dihydrofolate to bind tightly to the enzyme, 
impeding the conversion of dihydrofolate to tetrahydrofolate, thus blocking the 
synthesis of dTMP (Figure 1.15). Proguanil 22 and chlorproguanil 23 are prodrugs 
metabolised into the active components cycloguanil 26 and chlorcycloguanil 27 
respectively, which also act by inhibiting reduction of dihydropteroate. The structural 
distinction between the dihydrofolate reductase in protozoans and its counterpart in 
mammals makes the DHFR inhibitors selectively recognise the protozoal enzyme and 
exert their activity against Plasmodia instead of humans.5 
 
Pyrimethamine-sulfadoxine is a drug combination with two antifolates towards two 
different enzymes respectively. It has been extensively used for the treatment of 
falciparum malaria in Africa, including many least developed countries, due to the low 
cost of these drugs.41 However, increased resistance to pyrimethamine-sulfadoxine has 
given rise to a decline in its effectiveness.41 Moreover, the adverse effects of this 
combination is another issue requiring concerns. Higher doses of 
pyrimethamine-sulfadoxine cause megaloblastic anemia and toxic epidermal 
necrolysis.16 
 
To tackle the problem of resistance towards pyrimethamine-sulfadoxine, LapDap®  
combining dapsone and chlorproguanil was developed by GlaxoSmithKline and 
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approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) 
for the treatment of uncomplicated Plasmodium falciparum malaria in 2003.42 The 
double-blind, randomised trial undertaken in Africa has manifested 
dapsone-chlorproguanil possesses greater efficacy than pyrimethamine-sulfadoxine.41 
Unfortunately, dapsone-chlorproguanil combination was withdrawn from the market in 
2008 due to the incidents of drug-induced significant reductions of haemoglobin levels 
and haemolytic anaemia in patients with inherited glucose-6-phosphate dehydrogenase 
deficiency.42 
 
A good number of antimalarial drugs have been discovered and developed in the 20th 
century, saving numerous lives all over the world. Nevertheless, the rapid spread of 
drug resistance has significantly eroded the value and reduced the effectiveness of these 
established antimalarial drugs. In addition, severe adverse effect caused by some of the 
antiplasmodial drugs is another issue limiting their wide application. Given the various 
problems encountered in the treatment of malaria, the development of novel effective, 
safe, and affordable drugs for the control and prevention of malaria is still one of the 
most pressing public health priorities worldwide.  
 
 
1.1.3  Novel Antimalarial Azafluorenone Alkaloids 
 
During a drug discovery programme aimed at the identification of new antimalarial 
leads from a natural product library, 
5-hydroxy-6-methoxy-1-methyl-4-azafluoren-9-one 37 and 5,8-dihydroxy- 
6-methoxy-1-methyl-4-azafluoren-9-one 38, isolated from the Australian tree 





Figure 1.16 Novel antimalarial azafluorenone alkaloids. 
 
When tested against two different strains of the Plasmodium falciparum, 
chloroquine-sensitive strain 3D7 and chloroquine-resistant strain Dd2, alkaloid 37 
displayed IC50 values of 9.9 and 11.4 μM, respectively. In contrast, alkaloid 38 showed 
weak activity, with inhibition values of 87% and 80% at 120 μM against the 3D7 and 
Dd2 strains, respectively, and IC50 values for 38 were not provided.
43  
 
The core of these alkaloids is not present in the existing antimalarial drugs, providing 
an original entry point into the development of novel antiplasmodial agents. Possessing 
a number of positions available for further modifications, this structure affords a parent 





1.1.4 Review of Synthetic Methods for Azafluorenones 
 
Currently, the methods available for the synthesis of azafluorenones encompass three 
distinct approaches. The first method makes use of the degradation of 
nitrogen-containing fused compounds into tricyclic azafluorenones. The second 
approach is to increase the number of fused rings by annelation of indene or indane 
derivatives to construct the tricyclic system. The third strategy involves various 




1.1.4.1 Oxidative Degradation of Azaphenanthrenes 
 
A good example utilising the first strategy is the two-step method developed by Kloc 
(Scheme 1.1).44 Oxidation of 1-azaphenanthrene 39 and 4-azaphenanthrene 42 with 
iodine pentoxide yielded 1-azaphenanthrene-5,6-dione 40 and 
4-azaphenanthrene-5,6-dione 43. Treatment of the two diones with 10% sodium 
hydroxide solution at 85 °C afforded 1-azafluorenone 41 and 4-azafluorenone 44 in 
88% and 70% yields, respectively. The limitation of this method is that 




Scheme 1.1 Reagents and conditions: (a) I2O5, AcOH, reflux; (b) 10% NaOH aq, 85 °C. 
 
 
1.1.4.2 Condensations involving Indene or Indane Derivatives 
 
A variety of azafluorenone analogues have been synthesised from diverse indane and 




This strategy was firstly employed by Oliver in 1973 (Scheme 1.2).45 Piperidine 
enamine 46 prepared from 45 is subjected to the one-pot two-step reaction involving a 
nucleophilic addition and a subsequent intramolecular nucleophilic substitution, which 
constructs the tricyclic framework. Further dehydrogenation of 
tetrahydroindenopyridine 47 provides 48 in a yield of 75%. The conversion of 48 to 
azafluorenone 49 was achieved in 36% yield via the oxidation by oxygen in the 
presence of benzyltrimethylammonium hydroxide. The major defect limiting the wide 
application of this method is the use of highly toxic nitrobenzene and harsh conditions 




Scheme 1.2 Reagents and conditions: (a) piperidine, TsOH, toluene, reflux; (b) Br(CH2)3NH2·HBr, 
DMF, 100 °C; (c) 10% Pd/C, nitrobenzene, reflux; (d) O2, benzyltrimethylammonium hydroxide, Py, 
rt. 
 
Another synthesis of halogenated azafluorenones from 5-halo-1-indanones is based on 
the thermolysis of O-allyl oxime ethers (Scheme 1.3).46 5-Chloro-1-indanone 50 was 
readily converted to the oxime ether 52 via base-catalysed O-alkylation of the 
corresponding oxime 51. Thermolysis of 52 at 200 °C in a sealed tube provided 
azafluorene 53 in 15% yield, which was oxidised in the presence of oxygen and 
benzyltrimethylammonium hydroxide to furnish azafluorenone 54 in 33% yield. The 
major problem of this method lies on the low yield of the thermolysis (15%), which 
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Scheme 1.3 Reagents and conditions: (a) H2NOH·HCl, EtOH, Py; (b) CH2=CHCH2Br, NaOEt, 
EtOH; (c) sealed tube, 200 °C; (d) O2, benzyltrimethylammonium hydroxide, Py, rt. 
 
 
An improved synthetic strategy with Michael addition and aza-Wittig reaction as the 
key steps was developed by Makoto (Scheme 1.4).47 Treatment of 3-azidoindene 55 
with tributylphosphine in toluene yielded tributyl(inden-3-ylimino)phosphorane 56. 
The reaction of 56 with 3-butene-2-one involved a 1,4-addition and intramolecular 
aza-Wittig reaction, followed by the dehydrogenation to give azafluorene 57. Treatment 
of 57 with chromium trioxide and tert-butyl hydroperoxide afforded azafluorenone 58 
in a yield of 62%. In comparison to the previous methods initiating from indanone 
derivatives, this protocol avoids the extra high temperatures, broadening the substrate 




Scheme 1.4 Reagents and conditions: (a) PBu3, toluene, 0°C; (b) 3-butene-2-one, 10% Pd/C, 
toluene, reflux; (c) CrO3, 
tBuOOH, CH2Cl2, rt. 
 
 
A protocol for the preparation of azafluorenones employing the condensations of indane 




Scheme 1.5 Reagents and conditions: (a) NH4OAc, DMF, 120 °C, microwave irradiation. 
 
In the presence of ammonium acetate, the microwave-assisted one-pot condensation of 
aromatic aldehyde 59, 1,3-indanedione 60 and aromatic ketone 61 via successive 
Michael reaction and nucleophilic additions afforded disubstituted azafluorenone 62 in 
57-89% yields. This one-pot reaction affords a concise and efficient method for the 
synthesis of 1,3-diaryl-azafluorenones. However, only aromatic aldehydes and aromatic 
ketones have been utilised as the reactants for this method. More non-aromatic 




1.1.4.3 Cyclocondensations of Substituted Arylpyridines or Aroylpyridines 
 
This strategy employs intramolecular cyclisations of the pyridines with aryl 
substitutions at the α-position or the pyridines with aroyl groups attached at the 
β-position The wide availability of diverse pyridine derivatives provides a broad scope 
for the synthesis of azafluorenones with various structural modifications. 
 
In the synthesis of halogenated 4-azafluorenone developed by DuPriest, 
2-aryl-3-methylpyridines 66 and 67 were accessed through the treatment of 
2-fluoro-3-methylpyridine 65 with the corresponding aryllithium generated in situ 
(Scheme 1.6).49 Subsequent oxidation of the azabiaryls 66 and 67 by potassium 
permanganate provided 3-nicotinic acids 68 and 69. The intramolecular cyclisation of 
these two precursors was achieved in hot polyphosphoric acid, affording 
4-azafluorenones 49 and 54 in 85% and 82% yields, respectively. This method follows 
a concise synthetic route employing the strategy of cyclocondensation of arylpyridine. 
Nonetheless, the utilisation of moisture sensitive lithium reagent brings some 








Bracher described another method based upon the cyclisation of 
arylpyridine (Scheme 1.7).50 2-Bromo-5-methoxybenzaldehyde 70 was converted to the 
β-keto ester 71 through the treatment with ethyl diazoacetate and tin(II) chloride. 
Michael addition of crotonic aldehyde to 71 followed by the reaction with 
hydroxylamine hydrochloride gave arylpyridine ester 72. Saponification of this ester 
furnished the cyclisation precursor 73. Nicotinic acid 73 was cyclised into 
azafluorenones 74 in a yield of 79%, under the catalysis of polyphosphoric acid at 
130 °C. Compared with DuPriest’s protocol,49 the temperature for the PPA-catalysed 
cyclisation in this method is reduced to a lower temperature (130 °C), which has been 
demonstrated to be equally efficient for the intramolecular acylation. This refinement 
improves the functional group tolerance of this method and broadens the substrate 
scope applicable to this cyclisation, providing a viable approach for the synthesis of the 
antimalarial natural product 37 and its analogues. However, the use of the toxic reagent 
tin(II) chloride is the major defect of this protocol. It is necessary to make some 
improvement for the preparation of the arylpyridine before its application to the 
synthesis of alkaloid 37.  
 
 
Scheme 1.7 Reagents and conditions: (a) N2CHCOOEt, SnCl2, CH2Cl2, rt; (b) crotonic aldehyde, 
benzyltrimethylammonium hydroxide, dioxane, rt;  (c) H2NOH·HCl, EtOH, reflux; (d) KOH, 
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EtOH, H2O, reflux; (e) PPA, 130 °C.  
 
Kraus developed an alternative approach utilising an intramolecular Heck reaction as 
the key step in the synthesis of azafluorenones (Scheme 1.8).51 Different from the 
previous methods based on the α-arylpyridine, this protocol employs the carbonyl 
group to link the phenyl ring with the pyridyl moiety at the β-position prior to the 
connection at the α-position. The reaction of a substituted bromobenzaldehyde with the 
lithiopyridine derived from metal-halogen exchange afforded an alcohol intermediate, 
which was readily oxidised by manganese dioxide. The intramolecular Heck reactions 
of bromobenzophenones 76-78 provided azafluorenones 79-81 in 53%, 47% and 50% 
yields, respectively.  
 
 
Scheme 1.8 Reagents and conditions: (a) n-BuLi, substituted bromobenzaldehydes, THF, -100 to 
-78 °C; (b) MnO2, benzene, reflux; (c) Pd(OAc)2, Na2CO3, DMF, 130 °C. 
 
This protocol provides a concise route for the preparation of azafluorenones. 
Nevertheless, the strong basic condition required for the first step limits its application 
to the pyridine substrates bearing vulnerable functionalities such as carbonyl group, 
ester group and so forth. The low temperature (-100 °C) and the utilisation of highly 
moisture sensitive n-butyllithium also renders the experimental operation inconvenient.  
Ray developed a protocol for the synthesis of azafluorenones via a Grignard reaction 
followed by an intramolecular Heck reaction (Scheme 1.9).52 Treatment of 
2-bromonicotinaldehyde 81 with Grignard reagents 82-89 provided the condensation 
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products 90-97 in 73-95% yields, which were subjected to the subsequent Heck 
reactions. In the presence of palladium acetate and sodium acetate, the intramolecular 
cyclisation was fulfilled at 100 °C to afford azafluorenones 44 and 98-105 in moderate 




Scheme 1.9 Reagents and conditions: (a) ether, 0 °C; (b) Pd(OAc)2, NaOAc, DMF, 100 °C. 
 
Entry R1 R2 R3 R4 Product Yield (%) 
1 H H H H 44 95 
2 OMe H H H 98 78 
3 H H Cl H 99 75 
4 H Me H Me 100 93 
5 H Cl H Cl 101 74 
6 H Cl Cl H 102 68 
7 Benzo H H 103 53 
8 H H F H 104 61 
 
Table 1.2 Synthesis of azafluorenones via intramolecular Heck reactions. 
 
Compared with the method developed by Kraus,51 this protocol utilises Grignard 
reaction to replace the original condensation employing the lithiopyridine at the extra 
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1.1.5 Aim of the Project 
 
Since only a preliminary study was conducted looking into the antimalarial activity of 
alkaloids 37 and 38 by Quinn,43 our initial focus will be to accomplish the total 
synthesis of natural product 37, with which more elaborate and deeper investigations 
into its antimalarial activity can be conducted. On the basis of the current methods 
available for the preparation of azafluorenones, a synthetic route will be developed 
towards alkaloid 37. Possessing the structure with a number of positions available for 
modification, the parent core provides a good starting point for the development of a 
variety of derivatives. Having developed the synthetic route to the natural product, 
diverse analogues of alkaloid 37 will be prepared in a similar manner to explore the 
structure-activity relationship of the class of azafluorenones Moreover, it is also 
planned to explore the mechanism of action, which will set the stage for the further 









1.2 Synthesis of Antimalarial Natural Product 37 and Azafluorenone Analogues 
 
1.2.1 Design of Azafluorenone Analogues  
 
As a classical bioisostere of hydroxyl group,53,54 fluorine has been incorporated into 
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drug molecules to replace a hydroxyl group to ameliorate biological activity.55 The 
unique natures of fluorine, including the high electronegativity, the ability of forming 
hydrogen bonds, the high lipophilicity of fluoroaryl groups and the great strength of 
carbon-fluorine bond, impart distinctive chemical and biological properties to 
organofluorine compounds. The introduction of fluorine into organic molecules usually 
improves the molecules membrane permeability and metabolic stability, and increases 
the affinity towards the protein targets.56 Accordingly, a large number of organofluorine 
compounds exhibit enhanced biological activity compared to their non-fluorinated 
analogues.56 Consequently, azafluorenone analogue 106, with the 5-hydroxyl group 
replaced by a bioisosteric fluorine, was designed to mimic the natural product 37, 
hoping to acquire enhanced antimalarial activity (Figure 1.17).  
 
 
Figure 1.17 Structure of the fluorinated mimic of alkaloid 37. 
Alkaloid 38 has been proved to display a lower activity against Plasmodium falciparum 
(3D7 and Dd2 strains) than 37 (Figure 1.18),43 implying that the 8-hydroxyl group in 
alkaloid 38 is not essential for the antimalarial activity. The presence of the 8-hydroxyl 
group might obstruct the interaction between the alkaloid and the target site. Thus, there 
is a question as to whether all of the functional groups present in alkaloid 37 are 
required for the antimalarial activity. Consequently, the simplified analogue 107 
(Figure 1.19) would be synthesised to determine whether the 





Figure 1.18 Structures of the antimalarial alkaloids 37 and 38. 
 
To investigate whether the 5-hydroxyl group or 6-methoxyl group is crucial for the 
antimalarial activity, analogues with 5-hydroxyl group and 6-methoxyl group deleted 
respectively were designed (azafluorenones 108 and 109, Figure 1.19). With the 
purpose of probing into the interaction between the functional groups at the 5-position 
and the target site, it was decided to append electron-withdrawing and 
electron-donating groups to this position respectively, with azafluorenones 110 and 111 
designed. Likewise, azafluorenones 112 and 113 were also designed to explore the 
interaction between the functional groups at the 7-position and the target site. By 
making these simplifications and modifications, we will identify the minimal active 
fragment possessing antimalarial activity and acquire a preliminary structure-activity 
relationship regarding the phenyl moiety. 
 
 
Figure 1.19 Structures of azafluorenones with modifications on the phenyl moiety. 
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To explore the structure-activity relationship around the pyridyl moiety, a series of 
analogues decorated on the pyridyl ring were designed based on commercially available 
nicotinates (Figure 1.20). To explore the role of the methyl group in the antiplasmodial 
activity, azafluorenone 114 with the methyl group moved to the 3-position was 
designed. To investigate the interaction between the functional groups at the 3-position 
and the target site, it was decided to append electron-withdrawing and 
electron-donating groups to this position respectively, with azafluorenones 115 and 116 
designed. Likewise, azafluorenones 117 and 118 were also designed to probe the 




Figure 1.20 Structures of azafluorenones with modifications on the pyridyl moiety. 
 
The structures of many currently and previously utilised antimalarial agents contain a 
common amino side chain (Figure 1.21). This amino side chain has been shown to play 
a vital role in the antiplasmodial activity of these compounds, facilitating the 





Figure 1.21 Structure of antimalarial drugs bearing a dialkyl tertiary amino group. 
 
Modifications of the side chain of chloroquine, such as altering the length of the side 
chain, has been shown to impart activity against chloroquine-resistant strains for 
analogues 2-5 (Figure 1.22).10 This is attributed to fact that analogues with the 
decorated side chains cannot be recognised by the muted Plasmodium falciparum 
chloroquine resistance transporter (PfCRT). The mutation of the gene coding PfCRT in 
chloroquine-resistant strains results in the expression of the mutated PfCRT which is 
able to recognise and facilitate the efflux of chloroquine from the digestive vacuole.5 
The variation of the side chain makes these derivatives not recognised by the mutated 
PfCRT, escaping from this structure-specific efflux.5 Amodiaquine 6 (Figure 1.22), as a 
derivative of chloroquine, is an extensively used 4-aminoquinoline antimalarial drug. 
The replacement of the original amino side chain in chloroquine by the aromatic ring 
not only provides a higher activity against chloroquine-sensitive strains, but also 





Figure 1.22 Structures of antimalarial molecules with different side chains. 
 
Accordingly, it would be of value to conjugate these structural fragments with the 
azafluorenones to create hybrid molecules 122-126 (Figure 1.23) and investigate the 
effects of different side chains on the antiplasmodial activity of the azafluorenones. The 
introduction of a range of amino side chains would be anticipated to facilitate the 
accumulation of these modified azafluorenones in the parasite acidic digestive vacuole 
due to the increased basicity. The higher concentration of hybrid molecules present in 





Figure 1.23 Structures of designed hybrid molecules. 
 
 
1.2.2 Synthetic Routes towards Natural Prodcut 37 
 
The attempt to synthesise a related derivative of antimalarial alkaloid 37 was described 
by Kraus,51 employing an intramolecular Heck reaction as the key step. The 
condensation between 3-lithio-2-bromopyridine 127 and 
3-hydroxy-4-methoxybenzaldehyde was successful. Nonetheless, subsequent 
cyclisation via the Heck reaction failed to afford the target tricyclic product 130 
(Scheme 1.10).  
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Scheme 1.10 Reagents and conditions: (a) 3-hydroxy-4-methoxybenzaldehyde, THF, rt; (b) 
Pd(OAc)2, Na2CO3, DMF, 130 °C. 
 
Different from Kraus’ strategy, our retrosynthetic analysis of natural product 37 is 
shown in Figure 1.24. The formal synthesis involves two key steps, the construction of 








As an extensively utilised catalyst for intramolecular Friedel-Crafts acylation 
reactions,57 polyphosphoric acid (PPA) would be applied to the intramolecular 
cyclisation, constructing the tricyclic ring parent core. The palladium-catalysed 
Suzuki-Miyaura cross-coupling reaction would be exploited to achieve the formation of 
the azabiaryl.58 Since the polar and amphiphilic characters of arylboronic acids often 
render their isolation and purification difficult59 and free hydroxyl groups do not 
obstruct the Suzuki cross-coupling,58,60 it was planned to protect the free hydroxyl 
group after the cross-coupling reaction. The preparation of the decorated nicotinate 
would be fulfilled in two steps according to literature methods.61  
 
The selection of the protecting group for the free hydroxyl group in precursor 132 is 
crucial. Since the PPA-catalysed cyclisation occurs at 140 °C, a protecting group that is 
completely stable under the acidic conditions and at high temperature is needed. 
Sulfonates are stable under acidic conditions and widely used for the protection of 
phenols.62 Accordingly, it was decided to employ the methanesulfonyl (Ms) protecting 
group in the synthesis. After the intramolecular Friedel-Crafts acylation, the Ms group 
would be removed using sodium hydroxide in methanol/water solution.63 The complete 
synthetic route towards alkaloid 37 is shown in Scheme 1.11. This synthetic route is 
sufficiently versatile to achieve the preparation of alkaloid analogues starting from 





Scheme 1.11 Reagents and conditions: (a) DMF acetal, EtOH, reflux; (b) 30% HBr-AcOH, AcOH, 
55 °C; (c) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C; (d) MsCl, Et3N, CH2Cl2, rt; (e) PPA, 140 °C; 
(f) NaOH aq, MeOH, 60 °C. 
 
To confirm the stability of aryl methanesulfonate esters under the proposed 
PPA-catalysed cyclisation condition, two model reactions were carried out. The 
mesylations of 2,6-dimethyl-4-nitrophenol 144 and phenol 146 were achieved in the 
presence of methanesulfonyl chloride and triethylamine, affording 145 and 147 in 81% 
and 90% yields, respectively (Scheme 1.12). The mesylated products 145 and 147 were 
then stirred in polyphosphoric acid at 200 °C, a higher temperature than required for the 
PPA-catalysed cyclisation. There was no decomposition detected for either of the two 
methanesulfonate esters after 6 hours, indicating that aryl methanesulfonate esters can 





Scheme 1.12 Reagents and conditions: (a) MsCl, Et3N, CH2Cl2, rt, 6 h; (b) PPA, 200 °C, 6 h. 
  
1.2.3 Synthesis of Parent Core 1-Methyl-4-azafluoren-9-one 
Prior to the synthesis of natural product 37, it was decided to prepare the simplified 
azafluorenone 107 to confirm the feasibility of the proposed synthetic route. 
 
The reaction of ethyl 2-cyano-3-methyl-2-butenoate 138 with N,N-dimethylformamide 
dimethyl acetal afforded diene 137. The electrophilic addition of hydrogen bromide to 
the nitrile group followed by an acid-catalysed cyclisation provided the decorated 
nicotinate 139 in a good yield of 62% over two steps (Scheme 1.13).61 
 
 
Scheme 1.13 Reagents and conditions: (a) DMF acetal, EtOH, reflux; (b) 30% HBr-AcOH, 
AcOH, 55 °C. 
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As one of the most efficient methods for the construction of carbon-carbon bonds, the 
Suzuki-Miyaura cross-coupling reaction plays a vital role in synthetic organic chemistry. 
The mild reaction conditions, being unaffected by the presence of water, tolerating a 
broad range of functional groups, the low-toxicity and wide commercial availability of 
arylboronic acids contribute a lot to the versatility of this reaction.58  
 
In the presence of tetrakis(triphenylphosphine)palladium(0) and 2 M sodium carbonate 
solution, the Suzuki-Miyaura cross-coupling reaction was carried out at 80 oC under 




Scheme 1.14 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C. 
 
A general catalytic cycle for the Suzuki-Miyaura cross-coupling reaction encompasses 
four key steps, oxidative addition, ligand exchange, transmetallation and reductive 





Figure 1.25 Mechanism for the Suzuki cross-coupling.  
 
The oxidative addition of the decorated nicotinate 139 with the palladium(0) reagent 
150 forms a σ-aryl-Pd(II)-Br species 151.58 The base present in the reaction mixture 
serves a dual role in the catalytic cycle. The boron atom can be quaternised to form the 
reactive hydroxyboronate anion 153. The nucleophilicity of the aryl group in the 
boronic acid is enhanced by the coordination of the negatively charged base. 
Meanwhile, the bromide present in the σ-aryl-Pd(II)-Br species 151 can be displaced 
via ligand exchange by a hydroxide ion, affording the aryl-Pd(II)-OH species 154. The 
palladium-oxygen bond, which consists of a soft Lewis acid and a hard Lewis base, is 
more reactive than a palladium-bromine bond, accelerating the subsequent 
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transmetallation.58 Reductive elimination from organopalladium species 154 yields 
azabiaryl 149 and palladium(0) reagent 150, which re-enters the catalytic cycle.  
 
Having obtained the cyclisation precursor 149, subsequent intramolecular 
Friedel-Crafts acylation was performed. Polyphosphoric acid, whose pKa is 2.1, serves 
as a mild reagent in organic reactions.65 This accounts for the versatility and extensive 
application of PPA. Compared with aluminium chloride, it is less moisture sensitive and 
does not generate hydrogen chloride in reactions. In comparison to concentrated 
sulphuric acid, PPA does not lead to oxidation of organic compounds. Consequently, 
PPA usually causes fewer side reactions than other acids used for Friedel-Crafts 
acylations, such as concentrated sulphuric acid or aluminium chloride.57  
 
Although it is usually a carboxylic acid that is exploited in the PPA-catalysed 
intramolecular acylation,65-67 some examples have shown that esters can also be 
cyclised as readily as the acids from which they are derived.68,69 By heating in 
polyphosphoric acid,69 azabiaryl 149 was smoothly cyclised to the fused tricyclic 




Scheme 1.15 Reagents and conditions: (a) PPA, 140 °C. 
 
The successful preparation of the simplified analogue 107 demonstrates that the 




1.2.4 Studies towards the Synthesis of Natural Product 37 and its Analogue 109  
1.2.4.1 Synthesis of Analogue 109 from Unprotected Arylboronic acid 
Prior to the synthesis of natural product 37, the preparation of related analogue 109 was 
investigated since 2-hydroxy-3-methoxyphenylboronic acid, the starting material for 
alkaloid 37, is of high cost (Scheme 1.16).   
 
 
Scheme 1.16 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C; (b) MsCl, Et3N, 
CH2Cl2, rt; (c) PPA, 140 °C; (d) NaOH aq, MeOH, 60 °C. 
 
Nicotinate 139 and 2-hydroxyphenylboronic acid 155 were subjected to the previously 
employed cross-coupling conditions. However, 4-methylpyrido[3,2-c]coumarin 159 
was formed in a yield of 92%, instead of the desired coupled product (Scheme 1.17).  
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Scheme 1.17 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C. 
Given the ester functional group in the nicotinate 139 and the free hydroxyl group in 
the arylboronic acid 155, the formation of pyrido[3,2-c]coumarin 159 is predicted to 
have arisen from a base-catalysed lactonisation after the initial cross-coupling. The 




Figure 1.26 Proposed mechanism of the one-pot synthesis of pyrido[3,2-c]coumarin. 
 
Initially, the Suzuki-Miyaura cross-coupling is achieved under the 
palladium(0)-catalysed conditions, yielding azabiaryl 160. Under the basic condition, 
the phenol hydroxyl group is deprotonated to form the phenolate anion, whose 
nucleophilicity is much greater than the phenol. Intramolecular nucleophilic attack of 
the phenolate anion to the ester group generates tetrahedral intermediate 161, which 
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collapses with the loss of ethoxide, affording the tricyclic lactone 159.  
 
An alternative possibility is that the base-catalysed esterification takes place first, 
followed by the intramolecular Suzuki-Miyaura cross-coupling. However, there would 
be a significant steric hindrance in intermediate 162 (Figure 1.27) for the subsequent 
oxidative addition, which would retard the formation of the σ-aryl-Pd(II)-Br species. 
Consequently, we believe that the cross-coupling occurs prior to esterification.   
 
Figure 1.27 Postulated intermediate obtained from the esterification. 
 
Since nitriles are significantly less reactive than the corresponding esters under basic 
conditions,70 it was planned to utilise nitrile substrate 163 to replace ester 139 in the 
Suzuki reaction with 2-hydroxyphenylboronic acid to construct the azabiaryl. By this 
means, the undesired lactonisation would be precluded. Nevertheless, when 
2-chloronicotinonitrile was subjected to the cross-coupling conditions for 
chloro-substrates,71 pyrido[3,2-c]coumarin 164 was still afforded in 84% yield 
(Scheme 1.18).  
 
 
Scheme 1.18 Reagents and conditions: (a) Pd(PPh3)4, DME/H2O, 2 M K2CO3 aq, 80 °C. 
 
The lactonisation of nitriles under these conditions has not been reported in the 
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literature. Hence, it would be of value to explore this novel method for the formation of 
pyrido[3,2-c]coumarins. In addition, these observations suggest that the protection of 
the ortho-hydroxyl group in the arylboronic acid is required prior to cross-coupling for 
the synthesis of alkaloid 37 and related analogue 109.  
 
 
1.2.4.2 Preparation of the Arylboronic Ester for Alkaloid 37 
 
The preceding work has shown that only arylboronic acids with the ortho-hydroxyl 
group protected can afford the desired cross-coupling product for the synthesis of 
natural product 37. Since 2-hydroxy-3-methoxyphenylboronic acid, the starting 
material for alkaloid 37, is of high cost, it was planned to prepare the requisite protected 
arylboronic acid from the corresponding precursor 2-bromo-6-methoxyphenol. 
However, due to the high polarity and amphiphilicity of arylboronic acids, their 
isolation and purification is usually difficult. As an alternative to arylboronic acids, 
arylboronic esters also perform efficiently in palladium-catalysed Suzuki-Miyaura 
cross-coupling reactions.59 The loss of hydrogen bond donor capability renders boronic 
esters less polar, dissolvable in apolar solvents and are easier to purify.59 Commonly 
used methods for the preparation of arylboronic acids or arylboronic esters involve 
transmetallation of Grignard reagents or aryllithium with trialkyl boronic esters 
(Scheme 1.19).72,73 However, these methods generally utilise strong basic reagents and 
are incompatible with susceptible functional groups, such as ester, sulfonate, aldehyde 





Scheme 1.19 Reagents and conditions: (a) Mg, THF, reflux; (b) B(OMe)3, -78 °C; 
(c) HOCH2CH2OH, toluene, reflux; (d) n-BuLi, B(O
iPr)3, -40 °C; (e) 2 N HCl aq, -20 °C. 
The palladium-catalysed Miyaura borylation, involving the cross-coupling between aryl 
halides and bis(pinacolato)diboron, possesses higher functional-group compatibility 
and has been widely used as a viable alternative for the synthesis of arylboronic 
esters.74 Although a range of boronic esters have been prepared by this method, 
borylations of ortho-substituted aryl halides have been reported to give low yields, on 
account of the steric hindrance of the ortho substituent (Scheme 1.20).75  
 
Scheme 1.20 Reagents and conditions: (a) bis(pinacolato)diboron, Pd(dppf)Cl2, KOAc, DMSO, 
80 °C.  
 
By employing the less hindered bis(neopentyl glycolato)diboron, the yield of the 
borylation has been increased (Scheme 1.21).76 Consequently, it was attempted to apply 
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this method to the synthesis of the corresponding arylboronic ester for the target natural 
product 37. 
 
Scheme 1.21 Reagents and conditions: (a) bis(neopentyl glycolato)diboron, Pd(dppf)Cl2, KOAc, 
DMSO, 80 °C.  
 
Initially, the methanesulfonyl group was employed to protect the hydroxyl group prior 
to borylation. In the presence of triethylamine, mesylation of 




Scheme 1.22 Reagents and conditions: (a) MsCl, Et3N, CH2Cl2, rt. 
In the presence of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium 
(PdCl2(dppf)) and potassium acetate, the borylation of 
1-methoxy-2-mesyloxy-3-bromobenzene was performed with bis(neopentyl 
glycolato)diboron at 80 ºC. However, chromatography gave the desired 
2-methoxy-6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl methanesulfonate 175 in 
only 7% yield, while 2,2'-methanesulfonyloxy-3,3'-dimethoxybiphenyl 176 was 




Scheme 1.23 Reagents and conditions: (a) bis(neopentyl glycolato)diboron, Pd(dppf)Cl2, KOAc, 
DMSO, 80 °C.  
 
The formation of biaryl 176 is attributed to the additional Suzuki cross-coupling 
between arylboronic ester 175 and its precursor 174. A similar phenomenon has been 
described in literature with bromide 177 (Scheme 1.24).77  
 
Scheme 1.24 Reagents and conditions: (a) bis(pinacolato)diboron, Pd(dppf)Cl2, KOAc, DMSO, 
80 °C.  
 
Based on the catalytic cycle of the Miyaura borylation,74 we can elucidate the formation 




Figure 1.28 Proposed mechanism for the borylation of 174. 
 
Similar to Suzuki cross-coupling reaction, the palladium-catalysed Miyaura borylation 
involves oxidative addition, ligand exchange, transmetallation and reductive 
elimination. The ligand exchange after oxidative addition accelerates the subsequent 
transmetallation step. It is because that σ-aryl-Pd(II)-OAc species 181, containing a 
palladium-oxygen bond composed of a soft Lewis acid and a hard Lewis base, is more 
reactive than σ-aryl-Pd(II)-Br 180 with a palladium-bromine bond. The palladium (II) 
complex 183 is produced via the following transmetallation. After the reductive 
elimination, the desired borylated product 175 is generated, with the palladium (0) 
complex 179 re-entering the catalytic cycle. 
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However, transmetallation could also occur between σ-aryl-Pd(II)-OAc species 181 and 
the quaternised arylboronic ester 185 produced from the borylation, initiating the 
further Suzuki cross-coupling cycle. Hence, biaryl product 176 would be afforded by 
the subsequent reductive elimination, with palladium (0) complex 179 being 





Figure 1.29 Integrated catalytic cycle for the borylation and formation of the biaryl. 
 
To reduce the undesired side cross-coupling reaction, an attempted optimisation of the 
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borylation was conducted (Table 1.2). We envisioned that if a larger quantity of the 
borylating reagent was utilised with the reaction temperature raised, the borylation 
would be promoted and completed in a shorter time. In this case, to reduce the reaction 
time might make more boronic ester not participate in the further Suzuki cross-coupling. 
Thus, the borylation would probably become the major reaction within the shortened 
time. Moreover, the excess borylating reagent would compete with the quaternised aryl 





Scheme 1.25 Reagents and conditions: (a) bis(neopentyl glycolato)diboron, Pd(dppf)Cl2, KOAc, 



















1 1.2 equiv. 3 equiv. 12 80 7 36 0 
2 5 equiv. 3 equiv. 6 100 13 33 0 
3 5 equiv. 3 equiv. 4 100 11 27 19 
4 5 equiv. 1.5 equiv. 5 100 10 21 28 
 
Table 1.2 Attempted optimisation of the borylation. 
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Borylation with 5 equivalents of bis(neopentyl glycolato)diboron at 100°C for 6 hours 
did increase the arylboronic ester and reduce the biaryl product (Entry 2). To further 
decrease the undesired Suzuki reaction, a shorter reaction time was investigated, 
resulting in 19% unreacted starting material after 4 hours (Entry 3). These observations 
indicate that it might take 4-6 hours to accomplish the borylation. Based upon the 
catalytic cycle, a smaller quantity of potassium acetate might decrease the formation of 
the quaternised aryl boronate 185, which would also lead to a reduction of the 
cross-coupled product. Unfortunately, no improvement in borylation was obtained 
when 1.5 equivalents of potassium acetate were used (Entry 4). This result indicates 
that decreasing the base might not only reduce the generation of the quaternised aryl 
boronate 185, but also retard the desired ligand exchange for the borylation. Given the 
critical role played by the base in the catalytic cycle, employing alternative bases would 
be a rational approach to the improvement of borylation.  
 
 
1.2.4.3 Selective Mesylation of 2-Hydroxyphenylboronic Acid 
 
Since the borylation of the aryl bromide had proved unsatisfactory, we had to use the 
corresponding arylboronic acid instead. A crucial problem is how to protect the 
ortho-hydroxyl group of 2-hydroxyphenylboronic acid 155 prior to the Suzuki 
cross-coupling reaction. Lautens described the selective protection of the 
para-hydroxyl group of 4-hydroxyphenylboronic acid with tert-butyldimethylsilyl 
(TBDMS) group (Scheme 1.26).78 This indicates that the phenol hydroxyl group 
possesses a higher nucleophilicity than the boronic acid hydroxyl groups. Owing to the 
low stability of tert-butyldimethylsilyl ether under acidic conditions,62 TBDMS cannot 
be utilised as a protecting group for the synthesis of azafluorenones 37 and 109. Based 
on the difference in reactivity, we hoped to selectively protect the ortho-hydroxyl group 




Scheme 1.26 Reagents and conditions: (a) TBDMSCl, imidazole, DMF, rt. 
 
Due to the poor solubility of arylboronic acid in dichloromethane, pyridine was 
employed as a solvent, which would also serve as the auxiliary base absorbing the acid 
produced in the mesylation. To ensure the boronic acid hydroxyl groups would not be 
mesylated, a model reaction with phenylboronic acid as the substrate was attempted. 
No mesylated product was detected after 10 hours, validating the inertness of boronic 
acid hydroxyl groups towards mesylation. The selective mesylation of 
2-hydroxyphenylboronic acid was carried out using methanesulfonyl chloride in 
pyridine (Scheme 1.27). However, no mesylated product was detected by TLC after 12 
hours at room temperature, with a complete recovery of the starting material 155. Given 
its accelerating effect on acylations, 4-dimethylaminopyridine (DMAP) was also 





Scheme 1.27 Reagents and conditions: (a) MsCl, Py, rt; (b) MsCl, DMAP, Py, rt. 
 
Due to the presence of the ortho-hydroxyl group, 2-hydroxyphenylboronic acid is prone 
 71 
to form intramolecular hydrogen bonds (Figure 1.30). By virtue of the valence electron 
deficiency of boron, boronic acids can act as mild Lewis acids coordinating basic 
groups. Consequently, there is still an intramolecular hydrogen bond even in the ionised 
molecule (Figure 1.30). The stable six-membered ring renders this binding 
extraordinarily strong. We believe it is this strong intramolecular hydrogen bond that 




Figure 1.30 Intramolecular hydrogen bonds in 155 and its ionised counterpart. 
 
 
To overcome the intramolecular hydrogen bonds and promote the mesylation, the 
reaction temperature was raised to 60 °C (Table 1.3, Condition i), whereas no product 
formation was detected. Triethylamine is frequently exploited as an alternative for 
pyridine in acylations. Hence, triethylamine was employed instead in the mesylation to 
serve as an auxiliary base absorbing the acid produced (Condition ii). However, this 
mesylation failed again. Since treatment with p-toluenesulfonyl chloride in the presence 
of potassium carbonate under reflux in acetone is a widely utilised condition for the 
tosylation of phenols,79 attempted mesylation under conditions iii and iv were 
conducted accordingly. Unfortunately, neither of the two attempts provided the desired 






Conditions Catalytic Base Solvent Temperature  (°C) 
i DMAP Pyridine 60 
ii DMAP, Et3N THF 55  
iii K2CO3 Acetone 60 (reflux) 
iv K2CO3, DMAP Acetone 60 (reflux) 
 
Table 1.3 Attempted mesylation under different conditions.   
 
Since these attempts failed to bring about improvements in the mesylation, it was 
planned to utilise some reagents to weaken the intramolecular hydrogen bonds in 
arylboronic acid 155. The negative charge and small size of the fluoride anion enable it 
to be a good hydrogen bonding acceptor.80 Therefore, it was envisaged that the addition 
of fluoride anion would weaken the inherent intramolecular hydrogen bonds in 
2-hydroxyphenylboronic acid by forming intermolecular hydrogen bonds between the 
hydroxyl group and fluoride anion and thus facilitate mesylation (Figure 1.31).  
 
 
Figure 1.31 Attempt at weakening the intramolecular hydrogen bonds in ionised 155.  
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Nevertheless, the attempts at mesylation with tetrabutylammonium fluoride (TBAF) as 
the source of fluoride anion also failed to afford the desired product, with only 




Scheme 1.28 Reagents and conditions: (a) MsCl, DMAP, TBAF, Py, 60 °C; (b) MsCl, DMAP, 
TBAF, Et3N, THF, 55 °C. 
 
These attempts suggest that the inherent intramolecular hydrogen bond in 
2-hydroxyphenylboronic acid is too strong to overcome. Accordingly, the strategy was 
modified to protect the boronic acid hydroxyl groups before the mesylation. Under 
basic conditions, there would be no such intramolecular hydrogen bonds retarding the 
mesylation of the corresponding arylboronic ester. 
 
 
1.2.4.4 Synthesis of Azafluorenone 109 from Mesylated Arylboronic Ester   
 
The protection of the boronic acid hydroxyl groups was accomplished through the 
treatment with 2,2-dimethylpropane-1,3-diol, affording the arylboronic ester 196 in an 
excellent yield (Scheme 1.29). This conversion was achieved via a nucleophilic 






Scheme 1.29 Reagents and conditions: (a) toluene, Dean-Stark apparatus, reflux. 
 
Mesylation of the arylboronic ester 196 was conducted using methanesulfonyl chloride. 
Unexpectedly, after 6 hours at room temperature, the product obtained was deprotected 
2-hydroxyphenylboronic acid 155, instead of the desired mesylated product 197 




Scheme 1.30 Reagents and conditions: (a) MsCl, Et3N, CH2Cl2, rt. 
 
It has been reported that the arylboronic esters protected by 
2,2-dimethylpropane-1,3-diol are unstable.81 Boronic ester 196 decomposes under the 
mesylation conditions to afford 2-hydroxyphenylboronic acid which can not be 
mesylated owing to the strong intramolecular hydrogen bonds. 
 
Pinacol is another diol commonly used for the protection of arylboronic acids.59 With a 
larger and sterically bulky group, the hydrolysis of the boronic ester would be less 
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facile. Therefore, pinacol was employed to protect the arylboronic acid hydroxyl groups. 
With anhydrous magnesium sulphate and molecular sieve being used to remove the 
water generated, the conversion was achieved in a yield of 83% (Scheme 1.31).  
 
 
Scheme 1.31 Reagents and conditions: (a) MgSO4, molecular sieve, CH2Cl2, rt. 
 
The mesylation of the arylboronic ester 199 was performed with methanesulfonyl 
chloride in the presence of triethylamine, with the anticipated mesylated product 200 




Scheme 1.32 Reagents and conditions: (a) MsCl, Et3N, CH2Cl2, rt. 
 
In the presence of tetrakis(triphenylphosphine)palladium(0) and 2 M sodium carbonate 
solution, the cross-coupling between the mesylated product 200 and nicotinate 139 was 
achieved in 75% yield  (Scheme 1.33). This result demonstrates that our method 
developed for the cross-coupling of arylboronic acid substrates is also efficient for the 





Scheme 1.33 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C. 
 
The previous model reactions had verified the stability of methanesulfonate esters 
under the PPA-catalysed cyclisation conditions. Accordingly, azabiaryl 201 was 
subjected to the intramolecular acylation catalysed by PPA. However, 
pyrido[3,2-c]coumarin derivative 159, rather than the desired azafluorenone 158, was 
formed after 5.5 hours again (Scheme 1.34). This can be speculated to arise from the 




Scheme 1.34 Reagents and conditions: (a) PPA, 130 °C. 
 
The literature reveals that methanesulfonic acid is another reagent widely applied to 
acid-catalysed acylations (Scheme 1.35).82  
 
 
Scheme 1.35 Reagents and conditions: (a) MsOH, 65 °C. 
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Since the hydrolysed product of methanesulfonate ester is just methanesulfonic acid, an 
excess of methanesulfonic acid present in the reaction mixture would be anticipated to 
inhibit the equilibrium of the hydrolysis shifting towards the undesired hydrolysed 
product. Model reactions with 149 as the cyclisation precursor were screened for the 
suitable alternative cyclisation conditions with methanesulfonic acid for our substrates 




Scheme 1.36 Reagents and conditions: (a) MsOH, T °C. 
 
Attempted acylations at 65 °C and 75 °C both failed to yield the desired cyclisation 
product after 24 hours, with substrate 149 recovered from the reaction mixture. When 
the reaction temperature was increased to 95 °C, the anticipated azafluorenone 107 was 
afforded after stirring in methanesulfonic acid for 24 hours, with only a little unreacted 
substrate 149 recycled. Further increase of the reaction temperature to 100 °C achieved 
the complete conversion in 24 hours and improved the yield to 71% (Table 1.4). 
 
Entry Reaction Temperature (°C) Yield (%) 
1 65 0 
2 75 0 
3 95 62 
4 100 71 
 
Table 1.4 Screening cyclisation conditions for the azabiaryls with MsOH. 
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Having established a procedure for the methanesulfonic acid-catalysed acylation, 
azabiaryl 201 was subjected to these conditions (Scheme 1.37). However, 




Scheme 1.37 Reagents and conditions: (a) MsOH, 100 °C. 
This result can be ascribed to the high stability of the conjugated tricyclic structure of 
lactone 159 which served as the impetus to make the reaction equilibrium shift towards 
the cleavage of methanesulfonate ester group, affording pyrido[3,2-c]coumarin 159.  
 
All of these attempts suggest that the synthetic route involving the cross-coupling and 
PPA-catalysed intramolecular Friedel-Crafts acylation may be inappropriate for the 
preparation of the natural product 37 and its analogue 109. Another strategy employing 
a Grignard reaction to connect the pyridyl and phenyl moieties at β-position followed 
by an intramolecular Heck reaction to construct the tricyclic ring system might be an 
alternative approach for the synthesis of alkaloid 37 and its analogue 109.52 
 
1.2.5 Synthesis of Azafluorenone Analogues Modified on the Phenyl Moiety 
 
To explore the structure-activity relationship concerning the phenyl moiety, a series of 
azafluorenone analogues with modifications on the phenyl ring were prepared utilising 
the synthetic route for the parent core 107.  
 
In the presence of palladium reagent and 2 M sodium carbonate solution, 
Suzuki-Miyaura cross-coupling reactions between nicotinate 139 and a range of 
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commercially available arylboronic acids were achieved at 80 oC under nitrogen. The 




Scheme 1.38 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C. 
 
The results for the Suzuki reaction with various boronic acid substrates are summarised 
in Table 1.5. The cross-couplings were more facile when the boronic acid substrate 
possessed an electron-donating group (Entry 2 versus Entry 1) and were retarded in the 
case of the boronic acids bearing an electron-withdrawing group (Entry 3 versus 
Entry 1). This can be attributed to the effects these functional groups exerted on the 






R1 R2 R3 Product Yield (%) 
1 148 H H H 149 88 
2 206 H OMe H 211 95 
3 207 F H H 212 72 
4 208 Me H H 213 91 
5 209 H H F 214 78 
6 210 H H Me 215 89 
Table 1.5 Suzuki cross-couplings of different arylboronic acid substrates. 
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In the transmetallation step, the aryl group in boronic acid 216 is transferred to the 
electrophilic palladium complex 152 (Figure 1.32). An electron-donating group 
enhances the electron density and hence the nucleophilicity of the arylboronic acid, 
greatly facilitating this nucleophilic transfer and promoting the cross-coupling reaction. 
Conversely, an electron-withdrawing group reduces electron density on the arylboronic 
acid and retards the transmetallation step. 
 
      
 
Figure 1.32 Transmetallation in the Suzuki cross-coupling catalytic cycle. 
 
Having obtained the cyclisation precursors, intramolecular acyalations were achieved 
through treatment of the azabiaryls with polyphosphoric acid at 140 °C (Scheme 1.39). 
The results for cyclisations are summarised in Table 1.6. In the case of substrate 211 
bearing a methoxy group, both 6-methoxy-1-methyl-4-azafluoren-9-one 108 and 
8-methoxy-1-methyl-4-azafluoren-9-one 218 were afforded, due to the 
ortho-/para-directing effect of the methoxy group. It was noteworthy that 
6-hydroxy-1-methyl-4-azafluoren-9-one 219 was also obtained, as a result of the 
cleavage of the methoxy group under the acidic reaction condition and high 





Scheme 1.39 Reagents and conditions: (a) PPA, 140 °C. 
 
Two plausible mechanisms might be responsible for the PPA-catalysed intramolecular 
cyclisations. One is the pathway via an acylium ion intermediate, outlined in 
Figure 1.33. Protonation of the ethoxyl group in 205 forms a good leaving group 
ethanol, which is ejected to afford the acylium ion 221. The aromatic carbon-carbon 
double bond in 221 serves as a nucleophile to attack the electrophilic acylium ion. 
Subsequent removal of the proton from the ring reforms the carbon-carbon double bond 





Figure 1.33 Proposed mechanism of cyclisation involving acylium ion.  
 
Alternatively, the PPA-catalysed intramolecular cyclisations might be achieved via 
another mechanism involving a tetrahedral intermediate (Figure 1.34). Protonation of 
the carbonyl oxygen increases the degree of positive charge at the carbonyl carbon and 
thus makes it a better electrophile. The nucleophilic attack from the aromatic 
carbon-carbon double bond results in the formation of the tetrahedral intermediate 224 
and constructs the fused tricyclic system simultaneously. The proton transfer from the 
phenyl to the ethoxyl group gives 225, which then collapses, with ethanol ejected as the 





Figure 1.34 Proposed mechanism of cyclisation via tetrahedral intermediate.  
 
In terms of electronic and steric effects on the key intermediates, we believe the second 
mechanism proposal is more reasonable. In the first proposed pathway, the generation 
of intermediate 221 is the rate-determining step (Figure 1.33). In theory, the positively 
charged acylium ion can be stabilised by an electron-donating group. However, the 
acylium ion in 221 is attached to the electron-deficient pyridine ring, which cannot 
serve as an efficient electron-donating group to stabilise this acylium ion intermediate. 
Accordingly, the formation of acylium ion 221 is not favoured. In the second 
mechanism, the formation of the tetrahedral intermediate 224 is the rate-determining 
step (Figure 1.34). The steric effect is a key factor influencing the efficiency of 
addition-elimination pathway of esters. When the ester group contains a bulky alkoxy 
group, such as tert-butoxy group, the attack from nucleophiles will be retarded. 
However, the ethoxy group present in 220 is relatively small, which will not block the 
nucleophilic attack from the aromatic carbon-carbon double bond to afford the 
tetrahedral intermediate 224.  
 
As shown in Table 1.6, the intramolecular acylations of fluorinated azabiaryls are 
severely retarded (substrates 212 and 214). Several factors account for the low yields 
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observed for the cyclisations of the 2’-fluoro- and 4’-fluoro-substrates.  
 
Scheme 1.40 Reagents and conditions: (a) PPA, 140 °C. 
 
Substrate R1 R2 R3 Product 





149 H H H 107 78 0 
211 H OMe H 108, 218, 219 
Compound 108, 33 
0 Compound 218, 28 
Compound 219, 24 
212 F H H 110 31 54 
213 Me H H 111 80 0 
214 H H F 112 26 51 
215 H H Me 113 75 0 
 
Table 1.6 Summary of the PPA-catalysed cyclisations. 
 
Firstly, due to the high electronegativity of fluorine, the electron-donating resonance 
effect involving the lone pairs of fluorine is insufficient to overcome its strong 
electron-withdrawing inductive effect on the arene. Consequently, the electrophilic 
substitution is deactivated by the overall electron-withdrawing effect. Although 
deactivated, the attack tends to occur at the ortho or para position, because fluorine can 
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stabilise the carbocation intermediate derived from ortho or para attack by resonance. 
When the electrophilic attack takes place at the ortho position, there is an additional 
canonical structure 229 accessible for the resonance hybrid of the intermediate (Figure 
1.35). The stable canonical form 229 contributes most to the intermediate.83 As a result, 
the carbocation intermediate generated by the ortho attack can be stabilised to some 
extent, owing to the existence of the additional canonical form 229. A similar situation 
arises for para substitution. 
 
 
Figure 1.35 Carbocation intermediates in the acylation of fluorinated substrate. 
 
Although the ortho or para acylation is favoured in terms of the electronic effect, the 
corresponding product yielded by the ortho or para attack contains sp2-hybridised 
carbons located at the bridgeheads of the bridged ring system, which is of high 
instability according to Bredt's rule.84 Consequently, the cyclisation has to take place at 
the meta position of the 2’-fluoro- or 4’-fluoro-substrate to form a planar fused tricyclic 
structure, although it is the most deactivated way of acylation. These factors gave rise 
to the low yields for the cyclisation of fluorinated precursors 212 and 214.  
 
 86 
1.2.6 Synthesis of 5-Fluoro-6-methoxy-1-methyl-4-azafluoren-9-one  
 
By employing an identical strategy towards the synthesis of azafluorenone modified on 
the phenyl moiety, the fluorinated analogue of the natural product was prepared using a 
concise synthetic route.  
 
The Suzuki cross-coupling of nicotinate 139 with arylboronic acid 243 was performed 
in the presence of tetrakis(triphenylphosphine)palladium(0) and sodium carbonate to 




Scheme 1.41 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M Na2CO3 aq, 80 °C. 
 
 
The tricyclic core was assembled again by an intramolecular cyclisation of 244 
promoted by polyphosphoric acid at 130 °C. Azafluorenones 106 and 245 were both 
obtained from this intramolecular acylation, in 53% and 13% yield, respectively 




Scheme 1.42 Reagents and conditions: (a) PPA, 130 °C. 
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1.2.7 Synthesis of Azafluorenone Analogues Modified on the Pyridyl Moiety 
 
To investigate the structure-activity relationship regarding the pyridyl moiety, a range 
of azafluorenone analogues with modifications on the pyridyl ring were synthesised 
based on the bioisostere 106.  
 
The preparations of 3-chlorinated azafluorenone 115 and 3-methoxylated azafluorenone 
116 were commenced from N-oxide 246 due to the higher reactivity of this substrate 
(Figure 1.37). In the structure of N-oxide 246, the nitrogen is endowed with stronger 
electron-withdrawing capacity because it’s positively charged. As a result, the 
3-position is rendered more electron-deficient and more susceptible to nucleophilic 
attack relative to analogue 106.    
 
 
Figure 1.37 Retrosynthetic analysis for azafluorenones 115 and 116. 
 
 
The oxidation of 106 was achieved through treatment with 30% hydrogen peroxide 
aqueous solution in acetic acid at 80 ºC, providing N-oxide 246 in 61% yield 





Scheme 1.43 Reagents and conditions: (a) 30% H2O2 aq, AcOH, 80 °C. 
 
Chlorination of pyridine N-oxides through treatment with phosphorus oxychloride84 not 
only provided the target azafluorenone 115 in a yield of 34%, but also afforded its 
isomers 247 and 248 (Scheme 1.44).  
 
S
cheme 1.44 Reagents and conditions: (a) POCl3, 100 °C. 
 
The generation of 115 is supposed to follow the mechanism shown in Figure 1.38. 
Nucleophilic attack from the negatively charged oxygen in N-oxide 246 to phosphorus 
oxychloride generates the adduct 250, which ejects chloride anion as the leaving group 
to yield intermediate 251. The chloride anion generated attacks the activated α-position 
to form adduct 252. Elimination of dichlorophosphate and proton restores the 





Figure 1.38 Proposed mechanism for the formation of 115. 
 
The electron-withdrawing effect of the positively charged nitrogen renders the γ-methyl 
group in 253 susceptible to the loss of a proton to yield intermediate 254 (Figure 1.39). 
The exocyclic methylene group in 254 is susceptible to nucleophilic attack due to the 
presence of the good leaving group dichlorophosphate. The chloride anion formed from 





Figure 1.39 Proposed mechanism for the formation of 248. 
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The formation of β-chlorinated product 247 may undergo the pathway shown in Figure 
1.40. The β-carbon of 254 is also rendered electrophilic due to the presence of the good 
leaving group dichlorophosphate. Hence, the nucleophilic attack of chloride anion can 
also occur at the β-carbon to afford adduct 255. Subsequent intramolecular proton 




Figure 1.40 Proposed mechanism for the formation of 247. 
 
 
Methoxylation was achieved by the nucleophilic aromatic substitution via an 
addition-elimination mechanism. The treatment of chlorinated azafluorenone 115 with 
sodium methoxide in anhydrous methanol provided azafluorenone 116 in 51% yield 




Scheme 1.45 Reagents and conditions: (a) NaOMe, MeOH, reflux. 
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Starting from the 2-chloro-6-methylnicotinic acid 256, azafluorenone 114 was prepared 
in a concise manner (Scheme 1.46). In the presence of potassium carbonate, nicotinic 
acid 256 was treated with iodomethane, affording ester 257 in excellent 98% yield. The 
formation of azabiaryl 258 was fulfilled by the palladium-catalysed cross-coupling of 
257 and arylboronic acid 243 in the presence of potassium carbonate.85 Subsequent 
PPA-promoted intramolecular acylation of 258 provided azafluorenones 114 and 259 in 




Scheme 1.46 Reagents and conditions: (a) K2CO3, DMF, rt; (b) Pd(PPh3)4, THF, 2 M K2CO3 aq, 
80 °C; (c) PPA, 130 °C. 
 
The Suzuki cross-coupling of 2-chloro-4-methoxy-6-methylnicotinate 260 with 
arylboronic acid 243 afforded cyclisation precursor 261 in a yield of 86% 
(Scheme 1.47). Subsequent intramolecular cyclisation was accomplished through the 
treatment of 261 with polyphosphoric acid at 130 °C to afford azafluorenones 118 and 
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262 in 27% and 35% yield, respectively. 
 
Scheme 1.47 Reagents and conditions: (a) Pd(PPh3)4, THF, 2 M K2CO3 aq, 80 °C; (b) PPA, 130 °C. 
1.2.8 Synthesis of Azafluorenone Hybrid Molecules  
 
The hybrid molecules will be prepared following the retrosynthetic analysis depicted in 
Figure 1.41. Starting from the commercial available nicotinate 265, regioselective 
cross-coupling provides cyclisation precursor 264. The azafluorenone framework is 
assembled by a ring closure of azabiaryl 264 to furnish the fused tricyclic ring system. 
The introduction of different amino side chains to the azafluorenone via a nucleophilic 
aromatic substitution completes the synthesis of hybrid molecules.  
 
Figure 1.41 Retrosynthetic analysis towards hybrid molecules. 
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1.2.8.1 Regioselective Cross-coupling Reaction of Nicotinate 265 
 
The key problem to be overcome in the proposed synthetic route is the regioselective 
cross-coupling of ethyl 2,4-dichloro-6-methylnicotinate 265. Kohlmann has described a 
method for the selective Suzuki cross-coupling between nicotinate 266 and 
phenylboronic acid.86 Catalysed by palladium reagent and potassium carbonate in a 
mixture of dimethoxyethane and isopropyl alcohol, cross-coupling is accomplished in 
1 hour at 95 ºC, providing exclusively arylpyridine 267 in a yield of 61% 




Scheme 1.48 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, DME, iPrOH, 95 °C, 1 h. 
 
Employing the identical conditions, the Suzuki cross-coupling of nicotinate 265 and 
arylboronic acid 243 was performed. However, in addition to the desired mono-coupled 
product 264 being formed in 42% yield, the bis-coupled product 268 was also obtained 






Scheme 1.49 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, DME, iPrOH, 95 °C, 1 h. 
 
13C NMR spectroscopy has been utilised to confirm the structural identity of the 
mono-coupling product as azabiaryl 264, rather than the 4-coupled isomer. In the 
13C NMR spectrum of nicotinate substrate 265, the chemical shifts of C-2 and C-4 are 
147.6 and 142.9 ppm, respectively (Figure 1.42). In the 13C NMR spectrum of 
bis-coupled product 268, the peaks for C-2 and C-4 are shifted to 152.8 and 143.8 ppm, 
respectively, suggesting the introduction of the aryl moiety brings about a downfield 
shift of signal relative to the original chlorinated carbon. In the 13C NMR spectrum of 
mono-coupled product, the peaks for C-2 and C-4 are located at 153.2 and 142.1 ppm, 
respectively. The downfield shift of C-2 confirms that the mono-coupling reaction 




Figure 1.42 Chemical shifts of C-2 and C-4 in 264, 265 and 268. 
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Different from the previous Suzuki cross-coupling reactions performed at 80 ºC, this 
cross-coupling was conducted at 95 ºC. It should be the higher energy provided by this 
increased temperature that facilitated the occurrence of the second cross-coupling at the 
less reactive 4-position in 264.  
 
It was decided to reduce the reaction temperature to avoid the undesired cross-coupling 
at the 4-position. Blackaby described a regioselective Suzuki cross-coupling between 
2,4-dichloropyridine and 2-cyanophenylboronic acid at 80 ºC.87 Accordingly, another 
attempt to preparation of azabiaryl 264 was made under these reaction conditions.87 
Although selective coupling occurred, there was still a significant amount of unreacted 
265 recovered after 16 hours (Scheme 1.50). 
 
 
Scheme 1.50 Reagents and conditions: (a) Pd(PPh3)4, K2CO3, DME, CH3CN, H2O, 80 °C, 16 h. 
 
Caesium carbonate, another widely utilised base in Suzuki cross-coupling reactions, has 
been shown to be efficient in regioselective cross-couplings of 
polychloropyridine (Scheme 1.51).88 Therefore, caesium carbonate was also 
investigated for the selective preparation of azabiaryl 264. 
 
 
Scheme 1.51 Reagents and conditions: (a) Pd(PPh3)4, Cs2CO3, CH3CN, H2O, 100 °C. 
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In the presence of tetrakis(triphenylphosphine)palladium(0) and ceasium carbonate, 
treatment of nicotinate 265 with arylboronic acid 243 at 80 oC achieved the desired 
selective cross-coupling after 16 hours in a good yield of 83%, with no starting material 




Scheme 1.52 Reagents and conditions: (a) Pd(PPh3)4, Cs2CO3, DME, CH3CN, H2O, 80 °C, 16 h. 
 
These investigations confirm that the 2-position of nicotinate 265 is more reactive than 
the 4-position in Suzuki cross-coupling reactions. The regioselectivity should arise 
from the directing effect of the pyridine nitrogen (Figure 1.43). The lone pair of the ring 
nitrogen not participating in the resonance is available for pre-coordinating the 
palladium(0) reagent. This pre-coordination favours subsequent oxidative addition at 
the 2-position.89 In addition, this coordination not only enhances the electron density of 
the palladium(0) reagent and its nucleophilicity, but also diminishes the electron 
density of the nitrogen and thus renders the 2-carbon more electron-deficient and more 
electrophilic, due to the stronger inductive effect of nitrogen. Nevertheless, there is no 
such directing effect of nitrogen in the case of oxidative addition at the 4-position. 





Figure 1.43 Directing effect of the pyridine nitrogen on the oxidative addition. 
 
All the other conditions except the base employed are identical in the two Suzuki 
cross-couplings shown in Scheme 1.50 and Scheme 1.52. The different yields of these 
reactions imply that caesium carbonate exerts a more powerful effect upon the Suzuki 
cross-coupling than potassium carbonate. 
 
To date, the selection of different bases for Suzuki cross-couplings is largely empirical. 
The origin of different effects by various bases remains to be elucidated and clarified.90 
In our opinion, the different effects observed for caesium carbonate and potassium 
carbonate may arise from different cation sizes, which ultimately results in the different 
quantities of hydroxide ion participating in the catalytic cycle. As displayed in Table 1.7, 
caesium cation possesses a much larger cationic radius than potassium cation.91  
 
 
Cation Li+ Na+ K+ Rb+ Cs+ 
Cationic Radius (Å) 7.30 32.55 36.64 38.25 47.24 
 
Table 1.7 Cationic radii of alkali metal ions.91 
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Investigations have shown two general principles with respect to ion pairing.92 Firstly, 
association between cation and anion is stronger as the size of ions decrease. Secondly, 
there is a simple gradation in the association behaviour within the same metal family. 
 
During the transmetallation step in the cross-coupling process, the quaternised 
arylboronic acid reacts with σ-aryl-Pd(II)-OH species 276, accomplishing the 
nucleophilic transfer of the aryl group to the electrophilic palladium complex with the 
substitution of chloride. Hydroxide ions play a vital role in this process, by means of 
coordinating the arylboronic acid and enhancing the electron density as well as 
nucleophilicity of the boronic acid. Thus, the hydroxide ion derived from the hydrolysis 
of carbonate promotes the transmetallation between σ-aryl-Pd(II)-OH species 276 and 
arylboronic acid 243 (Figure 1.44). 
 
 
Figure 1.44 Function of the base in the transmetallation process. 
 
Owing to the larger cationic radius of the caesium cation, caesium carbonate tends to 
dissociate to a greater extent than potassium carbonate, according to the foregoing ion 
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pairing principles.92 It is the free carbonate ion that serves as the reactive species in the 
hydrolysis rather than the associated form.93 Therefore, more hydroxide ions are 
yielded for the transmetallation in the case of caesium carbonate, leading to a more 




1.2.8.2 Cyclisation of Azabiaryl 264 
 
Having obtained the target cross-coupling product 264, the intramolecular acylation 
was conducted under our previously developed PPA-catalysed condition. However, the 
desired cyclisation product 117 and the demethylation product 280 were obtained in 
very poor yields (Scheme 1.53). This might be attributed to the instability of cyclisation 




Scheme 1.53 Reagents and conditions: (a) PPA, 130 °C. 
 
Eaton’s reagent, a combination of phosphorus pentoxide and methanesulfonic acid, acts 
as an efficient alternative for polyphosphoric acid in promoting intramolecular 
Friedel-Crafts acylations.94 Li has described the utilisation of Eaton’s reagent in the 
synthesis of fused quinolines (Scheme 1.54), fulfilling the intramolecular Friedel-Crafts 








Scheme 1.54 Reagents and conditions: (a) Eaton’s reagent, 80 °C. 
 
Product X R1 R2 R3 Yield (%) 
286 O Me H H 69 
287 S H H H 76 
288 S H H Me 70 
289 O H OMe H 63 
290 O H H Cl 60 
 
Table 1.8 Eaton’s reagent-mediated synthesis of fused quinolines.95 
 
Accordingly, Eaton’s reagent was employed for the cyclisation of azabiaryl 264 
(Scheme 1.55). The intramolecular Friedel-Crafts acylation was optimised by varying 
the reaction temperature and time (Table 1.9). It has been proved that treatment of 
















1 85 24 35 30 
2 95 24 47 21 
3 110 30 58 0 
 
Table 1.9 Optimisation of Eaton’s reagent-catalysed cyclisation.  
 
It is noteworthy that the application of Eaton’s reagent not only accomplished the 
cyclisation more efficiently than PPA did, but also avoided the demethylation of the 
azafluorenone 117, which can be ascribed to the presence of phosphorus pentoxide in 
Eaton’s reagent. Unlike polyphosphoric acid, there are no traces of water present in 
Eaton’s reagent, due to the excellent desiccant capability of phosphorus pentoxide. In 
addition, phosphorus pentoxide is able to readily react with alcohols to yield mono- and 
di-alkyl phosphoric acid esters (Scheme 1.56).96,97 Hence, the ethanol yielded during 
the cyclisation is consumed by phosphorus pentoxide, which facilitates the equilibrium 
of the intramolecular acylation shifting towards the azafluorenone formation, according 




Scheme 1.56 Reagents and conditions: (a) 50 °C. 
 
Consequently, the potential demethylation of the 6-methoxyl group in azafluorenone 






1.2.8.3 Amination of azafluorenone 117 
 
The introduction of a range of amino side chains was achieved by employing a similar 
method utilised in the synthesis of chloroquine.98 Treatment of azafluorenone 117 with 
2-amino-5-diethylaminopentane at 160 ºC in the presence of catalytic sodium iodide 




Scheme 1.57 Reagents and conditions: (a) NaI, PhOH, 160 °C. 
 
When the crude product was purified by silica gel chromatography, a severe tailing was 
observed, resulting in a poor isolated yield (13%) of azafluorenone 122. It is due to the 
fact the basic nitrogen atoms of the side chain strongly adsorb to acidic silica gel. 
Accordingly, neutral aluminium oxide was utilised for subsequent purification, 
providing the desired hybrid molecule 122 in an improved yield of 33%. 
 
It is noteworthy that the carbonyl group in 117 provides an alternative reactive site 
leading to the formation of side products. It has been shown that even the relatively 
stable carbonyl group present in fluorenone 296, is capable of reacting with primary 
amines to yield imines under Bronsted acid catalysis (Scheme 1.58).99 
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Scheme 1.58 Reagents and conditions: (a) AcOH, EtOH, 80 °C. 
 
 
Although we were unable to isolate the corresponding imine derived from 
azafluorenone 117 due to the complex mixture of products formed, there is a good 
reason to speculate that the nucleophilic addition from amine 295 to the carbonyl group 
in 117 could be a competing side reaction giving the low yield of azafluorenone 122 
observed.    
 
Given the relatively low boiling point of 1-amino-2-diethylaminoethane 
(145-147 ºC),100 the amination of 117 with the amino chain 299 had to be carried out at 
a reduced temperature. In the presence of catalytic sodium iodide, azafluorenone 117 
reacted with 1-amino-2-diethylaminoethane in phenol at 130 ºC, giving hybrid product 
124 in a yield of 47% (Scheme 1.59). Similarly, aminated azafluorenone 123 was 





Scheme 1.59 Reagents and conditions: (a) NaI, PhOH, 130 °C. 
 
The two aminations performed at the lower reaction temperature (130 °C) afforded the 
corresponding products in higher yields than the reaction involving amine 295 at 
160 °C. Firstly, the absence of 1’-methyl group on these two amino chains may reduce 
steric hinderance during the nucleophilic aromatic substitution, which facilitates the 
amination. In addition, the lower reaction temperature may be unfavourable for the 
competing imination of the carbonyl group in 117. Both of these two factors may 
contribute to the enhanced yield for the preparation of 123 and 124.  
 
Since 2-amino-1-dimethylaminopropane possesses a even lower boiling point 
(110-111 ºC),101 the reaction temperature was further reduced. Azafluorenone 117 was 
treated with amine 301, under the catalysis of sodium iodide at 100 ºC, providing 
aminated product 125 in a yield of 60% (Scheme 1.60). The yield of azafluorenone 125 
is higher than 124, implying the reaction temperature is indeed a key factor influencing 
the competing imination. From the perspective of steric hinderance, the amination by 
299 should have been favoured over the amination by 301. However, the competing 
imination by 301 is retarded in comparison with 299, due to the lower reaction 
temperature. The retardation of the competing imination may serve as the predominate 
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Scheme 1.60 Reagents and conditions: (a) NaI, PhOH, 100 °C. 
 
Finally, an aromatic side chain was appended to the azafluorenone utilising the method 
used in the synthesis of amodiaquine.102 Treatment of azafluorenone 117 with 
4-amino-2-diethylaminomethylphenol 302 at 120 ºC afforded the desired hybrid 
product 126 in a yield of 57%.  
 
Scheme 1.61 Reagents and conditions: (a) 2-ethoxyethanol, 120 °C. 
 
The presence of two nucleophilic centres in 302 enables the nucleophilic aromatic 
substitution to provide two plausible products. However, only the target azafluorenone 
126 was obtained, which is attributable to two factors. Firstly, owing to the higher 
electronegativity, the hydroxyl oxygen nucleus possesses a stronger capability to absorb 
the extranuclear electrons than the amino nitrogen. As a result, the lone pair of the 
hydroxyl group is rendered less reactive than that of amino group, so that the amino 
group displays a higher nucleophilicity. Secondly, the presence of the tertiary 
alkylamino group at the ortho-position results in a steric hindrance to the hydroxyl 
group, which also precludes the nucleophilic attack of the phenol hydroxyl group.  
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1.3 Antiplasmodial Evaluation of Azafluorenones Analogues 
 
Fourteen azafluorenones have been evaluated for antiplasmodial activity utilising a 
[3H]hypoxanthine-incorporation assay by Miss Katharina Schuh in Professor Katja 
Becker’s group at Justus Liebig University Giessen in Germany.  
 
The [3H]hypoxanthine-incorporation assay is the standard test for screening potential 
antimalarial agents.103 Malaria parasites exploit exogenous purines in the synthesis of 
their nucleic acids. It has been demonstrated that hypoxanthine is the major purine base 
absorbed and utilised by Plasmodium falciparum as the precursor for the synthesis of 
adenosine and guanosine nucleotides and nucleic acids.40 Thus, the utilisation of 
labelled hypoxanthine results in the incorporation of tritium into the parasite DNA 
during biosynthesis. The radioactivity measured, which represents the quantity of 
[3H]hypoxanthine incorporated, is proportional to the growth of parasites in culture,103 
enabling this assay to be applied to the evaluation and development of potential 
antimalarial agents.  
 
Fourteen azafluorenones were evaluated for antimalarial activity against both 
chloroquine-sensitive Plasmodium falciparum strain (3D7) and chloroquine-resistant 
Plasmodium falciparum strain (K1). In this assay, parasites were incubated with the 
azafluorenones at a parasitemia of 0.125% and 1.25% hematocrit, and 0.5 μCi of 
[3H]hypoxanthine was added for the growth of parasites. The IC50 values of 





















30.4 + 0.48 > 44.0 
 
> 47.0 > 47.0 
 








2.16 + 0.18 0.94 
 






> 47.0 > 47.0 
 
> 44.0 > 44.0 
 
> 39.0 33.3 
 
Table 1.10 Antiplasmodial activity of azafluorenone analogues. 
 
In general, the activity against the chloroquine-resistant strain K1 is similar to the 
activity against the chloroquine-sensitive strain 3D7 for each azafluorenone. The result 
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of the antiplasmodial activity assay shows a number of features allowing the 
elucidation of structure-activity relationship for azafluorenone analogues. Firstly, the 
6-methoxy group is essential for antimalarial activity, as a loss of activity is observed 
when the 6-methoxy group is removed (azafluorenone 110 versus azafluorenone 106) 
or displaced by hydroxyl group (azafluorenone 219 versus azafluorenone 108, 
azafluorenone 245 versus azafluorenone 106). Secondly, replacement of the 5-hydroxyl 
group in natural product 37 with the bioisostere fluorine retains the antiplasmodial 
activity (azafluorenone 106). Thirdly, the substituent at the 5-position, which can serve 
as a hydrogen acceptor, is vital for the antimalarial activity, since the activity declines 
when the 5-position hydrogen acceptor is removed (azafluorenone 108 versus 
azafluorenone 106). Fourthly, the presence of an electron-donating group present at the 
3-position exerts a negative effect upon the activity, demonstrated by the comparison 
between azafluorenone 116 and azafluorenone 106. The 3-substituent might interfere 
with the interaction between the azafluorenone and target site. 
 
The effects of substituents at the 1-position are more complicated. The presence of 
hydrophobic groups at this site seem to be favourable towards the activity, as the 
analogue bearing the lipophilic chlorine (azafluorenone 117) is more potent than the 
one with the comparatively hydrophilic methoxy group (azafluorenone 118). However, 
the introduction of amino side chains to the 1-position induces a remarkable elevation 
of the antimalarial activity (azafluorenones 122-126). There are two possible 
explanations for this result. If the mode of action of the hybrid molecules is inhibition 
of haemozoin formation within the digestive vacuole, the enhancement of the 
antiplasmodial activity could be attributed to the stronger interaction between these 
azafluorenones and haematins. In the acidic digestive vacuole, the protonated dialkyl 
tertiary amino group of the side chain in the hybrid molecule provides an additional 
electrostatic interaction with the carboxylate group of haematin, leading to the 
strengthened interplay between the azafluorenone and haematin and resulting in the 
improved antiplasmodial activity. If the hybrid molecules exert the antimalarial activity 
through binding to another target in the weakly basic cytoplasm of the parasite, the 
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uncharged amino groups might provide additional hydrogen bonding interactions with 
the target, promoting the binding of the azafluorenones to the target site and inducing 
the enhancement of the antiplasmodial activity.  
 
The data shows that the variation of the amino side chains does not bring about a 
significant change of the activity. This can be ascribed to the fact that the aminoalkyl 
chains with different lengths are flexible. The flexibility allows the conformational 
adjustment of the side chains to adapt and match the binding position well, facilitating 
the effective interaction of azafluorenone and target. Therefore, the alternation of the 
side-chain length within a certain range will not result in a significant fluctuation of the 
antimalarial activity. 
 
In order to acquire a comprehensive understanding of the effects exerted by diverse 
substituents at different positions, more azafluorenones will be prepared and evaluated. 
For example, the comparison among the antiplasmodial activities of azafluorenone 106, 
azafluorenone 116 and 3-chloro-1-methyl-4-azafluoren-9-one 115 will further clarify 










1.4  Mechanism Exploration into the Action of Azafluorenones 
 
To date, several modes of action have been identified for the current antimalarial agents, 
including inhibition of haemozoin polymerisation, alkylation of haem, and inhibition of 
dihydrofolate reductase or dihydropteroate synthase. Having synthesised a series of 
azafluorenone analogues, it is of great interest to explore the mechanism by which these 
molecules act utilising well-developed protocols. 
 
1.4.1 Lipid Bodies-mediated Polymerisation of Haemozoin 
 
During the intra-erythrocytic life stage, the parasite ingests haemoglobin of the host to 
acquire nutrients. In this catabolism process, considerable ferroprotoporphyrin IX 
(Fe(II)PPIX), known as haem, is also generated as a by-product (Figure 1.45). 
Ferroprotoporphyrin IX (Fe(II)PPIX) is converted to ferriprotoporphyrin IX 
(Fe(III)PPIX) readily in the digestive vacuole, which displays high toxicity towards the 
parasite by inducing lysis of malaria parasites.104  
 
 
Figure 1.45 Structures of Fe(II)PPIX and Fe(III)PPIX.  
 
In mammals, Fe(II)PPIX is catabolised to bilirubin in two steps (Figure 1.46).105 Under 
the action of NADPH and haem oxygenase, the tetrapyrrolic ring of Fe(II)PPIX is 
initially cleaved to afford biliverdin 304, with the liberation of carbon monoxide and 
ferrous ion. Biliverdin 304 is further converted to bilirubin 305 by biliverdin reductase, 
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in the presence of NADPH.  
 
 
Figure 1.46 Catabolism of haem in mammals.  
 
The malaria parasite does not possess the haem oxygenase enzyme and has to 
circumvent haem toxicity through the polymerisation of ferroprotoporphyrin IX 
molecules into the innocuous biomineral haemozoin. Haemozoin, also known as the 
malaria pigment, is a crystal composed of reciprocal head-to-tail dimeric units of 
ferriprotoporphyrin IX (Figure 1.47). The dimeric unit consists of two Fe(III)PPIX 
molecules connected by the linkages between the propionate oxygen atom in one 
monomer and the iron centre in the other monomer. Haemozoin is a polymer formed 
via the hydrogen bonds between different dimeric units. 
 
   
 
Figure 1.47 Structure and scanning electron microscopy of haemozoin.106  
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Egan has proposed the mechanism for the generation of haemozoin precursor, which is 
shown in Figure 1.48. Two molecules of H2O-Fe(III)PPIX,  derived from Fe(II)PPIX 
molecules, could form a π-stacked dimer 306. The shift of two monomers forms dimer 
307, which facilitates the interaction between the propionate groups and iron centres. 
Subsequent ligand exchange and the displacement of the axial water molecules afford 
the head-to-tail dimer 309, which acts as the unit cell of haemozoin.106  
 
Figure 1.48 Proposed mechanism for the generation of dimeric unit of haemozoin.106 
 
With the formation of the unit cell of haemozoin, further interactions between propionic 
acid groups from different dimeric units constitute an extended network of hydrogen 
bonds, achieving the assembly of the haemozoin crystal.106 The complete course of the 





Figure 1.49 Pathway of haemozoin formation. 
 
Recent studies have shown that neutral lipid bodies present in the parasite play a vital 
role in the biocrystallisation of haemozoin. Lipid bodies, also known as lipid particles, 
are intracellular storage compartments for neutral lipids.107 Within the digestive vacuole 
of the parasite, a large quantity of monoglyceride and diglyceride is synthesised and 
packaged into neutral lipid bodies. This specialised organelle is believed to promote the 
process of haemozoin formation by serving as the scaffold and site for the nucleation 
and crystal growth of haemozoin.108,109 Hoang believes that the mono- and diglyceride 
molecules stored in lipid bodies assemble with their polar hydroxyl groups facing 
outwards, forming the interface between lipid bodies and water. Fe(III)PPIX molecules 
accumulate at the surface of the lipid bodies. The hydroxyl groups exposed at the 
surface interact with Fe(III)PPIX molecules, allowing the pre-organisation of 
Fe(III)PPIX molecules to take place.109 This pre-organisation facilitates the further 




1.4.2 In Vitro β-Haematin Inhibition Assay  
 
Numerous investigations have shown that a range of antimalarial drugs, including 
chloroquine, amodiaquine and quinine exert the antiplasmodial activity via inhibition of 
haemozoin formation. By forming a drug-haem complex, which adsorbs onto the 
actively growing face of haemozoin, these antimalarial agents cap the haemozoin 
crystal and impede the extension of polymer.6 As a consequence, toxic free haems 
accumulate within the Plasmodium, prompting the death of parasite. The resistance 
towards chloroquine has been proved to occur via a structure-specific efflux 
mechanism.5,108 The mutated PfCRT is able to recognise chloroquine and facilitate the 
efflux of chloroquine from the digestive vacuole.5,108 Since the occurrence of 
chloroquine resistance does not directly originate from the process of haemozoin 
inhibition,5 inhibition of haemozoin biomineralisation still remains a significant and 
viable target for the development of antimalarial agents.108 
 
As a synthetic polymer, β-haematin is structurally identical to the native haemozoin.110 
In vitro assays evaluating the inhibitory capabilities of compounds against β-haematin 
formation can serve as a feasible and efficient approach for the evaluation of 
antimalarial compounds. In Carter’s study, various detergents have been examined for 
their capacity for mediating formation of β-haematin in vitro, among which detergent 
Nonidet P-40 (NP-40) has been shown to be the optimal promoter mimicking the native 
lipid bodies in the digestive vacuole.110 The azafluorenone analogues synthesised share 
some structural features in common with the haemozoin inhibitor chloroquine, both 
possessed a conjugated planar core. In order to probe the mechanism of azafluorenone 
antimalarial activity, it was decided to explore their inhibitory activity against 
β-haematin formation utilising the NP-40 detergent-mediated assay.110  
 
Prior to the evaluation of the inhibitory capacity of azafluorenones, a model assay 
employing the positive control amodiaquine was conducted to probe the reproducibility 
of the method. Nine different concentrations of amodiaquine similar to those tested in 
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Carter’s trial were selected in our assay. Haematin was incubated under the established 
conditions to allow β-haematin formation to occur.110 The different solubilities of 
haematin and β-haematin in the mixed solution of sodium bicarbonate and sodium 
dodecyl sulphate (SDS) served as the basis for this protocol and were exploited in the 
purification of β-haematin product after incubation. After the centrifugation and 
removal of the supernatant, the solution of sodium bicarbonate and sodium dodecyl 
sulphate was added to selectively dissolve the unconverted haematin monomer in the 
mixture of haematin and β-haematin. The further centrifugation achieved the separation 
between β-haematin precipitate and haematin. The purified β-haematin was finally 
dissolved in the solution of sodium hydroxide and sodium dodecyl sulphate, whose 
absorbance was measured at 400 nm. The quantity of β-haematin was calculated 
according to the reported extinction coefficient.110 
 
However, significant defects were identified in this protocol. Firstly, the triplicate data 
for each concentration of amodiaquine deviated significantly, indicating poor 
reproducibility of this method. The triplicate raw data of absorbance for each 
concentration are displayed in Table 1.11. This deviation originates from the two steps 
of supernatant removal. It was found that the sedimentation of β-haematin after the 
centrifugations was poor, which made the supernatant removal difficult to achieve. 
β-Haematin precipitate floated up during pipetting and was discarded with the 




411.2 205.6 102.8 51.4 25.7 12.85 6.43 
1 0.310 0.477  0.298 0.323 0.633 1.247 1.659 
2 0.178 0.256 0.623 0.387 0.524 1.172 1.861 
3 0.136 0.382 0.515 0.586 0.481 1.528 2.037 
 





In addition, the complicated procedure involving twice lengthy centrifugations also 
reduces the efficiency of this protocol, rendering this method inappropriate for 
automated high-throughput screening.  
 
To resolve these problems, another protocol quantifying the unconverted haematin, 
instead of β-haematin, has been developed for the evaluation of β-haematin inhibitory 
activity.108 It has been demonstrated that in an aqueous solution containing 5-10% (v/v) 
pyridine, buffered at neutral or mildly basic pH, pyridine molecules are able to 
selectively coordinate the iron centre in the Fe(III)PPIX monomer molecule and form a 
pyridine-haematin complex.105 This complex possesses a strong and distinctive 
absorption at 405 nm and exhibits a characteristic orange-pink colour.111 However, 
pyridine solution at this concentration and pH cannot react with β-haematin. This 
special absorption obeys Beer’s Law, allowing the quantitative determination of free 
haematin in a mixture of haematin and β-haematin. 
 
Accordingly, assessment of β-haematin inhibitory activity of azafluorenones was 
modified according to the colorimetric pyridine protocol developed by Sandlin.108 
Model assays evaluating the efficacy of the positive controls amodiaquine and quinine 
in inhibiting β-haematin formation were performed initially. After the incubation of 
haematin with a range of concentrations of amodiaquine or quinine, the assay was 
analysed utilising the colorimetric pyridine-based method, with the addition of the 
previously prepared pyridine solution. The absorbance of the resulting complex was 
finally measured at 405 nm.  
 
The inhibition percentage for this assay is calculated according to the following 
equation: 
I = (As – Ain)/(A0 – Ain)  100% 
I: inhibition percentage 
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As: absorbance of the solution with haematin and tested drug incubated in the presence 
of NP-40; 
Ain: absorbance of haematin incubated in the presence of NP-40; 
A0: absorbance of haematin in the absence of tested drug and NP-40. 
 
Based upon the inhibition percentage calculated from the raw data of absorbance at 405 
nm, sigmoidal concentration response curves as well as the IC50 values were acquired 
using GraphPad Prism v5.0 (Figure 1.51). 
 
     
                       
IC50 = 20.3 μM                        IC50 = 83.9 μM 
 
Figure 1.51 Inhibitory activities of AQ and QN against β-haematin formation.  
 
As shown in Figure 1.51, both amodiaquine and quinine exhibit potent inhibitory 
activity against β-haematin formation. Amodiaquine possesses an IC50 value of 20.3 μM, 
quinine possesses an IC50 value of 83.9 μM, suggesting that amodiaquine has a higher 
inhibitory activity against β-haematin formation than quinine does. The IC50 value of 
amodiaquine acquired from this model assay correlates with the value obtained in the 
literature using the same method (21.0 μM).108 This validates the reproducibility of the 
colorimetric pyridine method.  
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In this assay, sodium acetate-acetic acid buffer solution at pH 4.9 and the incubation at 
37 °C furnish a physiological environment resembling that within the parasite’s acidic 
digestive vacuole. Thus, crystallisation of β-haematin was promoted by detergent 
NP-40, which served as a mimic for neutral lipid bodies. 
 
Nonidet P-40 is a nonionic surfactant possessing a hydrophilic polyether chain and a 
hydrophobic alkylphenyl group (Figure 1.52). It is the hydrophilic head group and the 
lipophilic tail group within NP-40 that enable these surfactant molecules to function 
similarly to the amphiphilic neutral lipid bodies present in the digestive vacuole. In the 
acetate buffer solution, NP-40 molecules organise into spherical aggregates with their 
polar and hydrophilic head groups facing outwards.112 In this way, NP-40 molecules 
interact with Fe(III)PPIX molecules via the hydrogen bonding between the polar head 
groups of NP-40 and the propionic acid groups of Fe(III)PPIX, which results in the 
accumulation of Fe(III)PPIX molecules on the surface of spherical NP-40 aggregates. 
Once the dimeric unit of Fe(III)PPIX is formed, it can enter the spherical structure, 
where the lipophilic tail groups provide a hydrophobic environment stabilising and 
protecting this unit cell of β-haematin by precluding the attack from water molecules to 
the iron centre which gives rise to the dissociation of this dimer. These hydrophobic 
surroundings can also favour the construction of the hydrogen bonding network 
between different dimeric Fe(III)PPIX units via obviating the competitive hydrogen 




Figure 1.52 Structure of Nonidet P-40 molecule. 
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In comparison with the method described by Carter,110 the new pyridine-based protocol 
avoids the difficult and time-consuming manual removal of the supernatant and does 
not require lengthy centrifugations, significantly enhancing the efficiency of this assay. 
More importantly, the convenient manipulation of the colorimetric pyridine-based 
method makes this an ideal approach for the high-throughput screening (HTS) of 
β-haematin inhibitors. Promising inhibitors identified using this assay can then be 
further profiled in antiplasmodial assays to evaluate their antimalarial potency.   
 
Having verified the reliability and reproducibility of the colorimetric pyridine-based 
method, four different concentrations of each azafluorenone, ranging from 1.645 mM to 
205.6 μM, were used to evaluate their inhibitory potency against β-haematin formation 
in a preliminary assay. The compounds showing promising activity were then 
investigated more thoroughly and further profiled at nine concentrations to provide 
accurate IC50 values. In the assays, amodiaquine was employed as the positive control 




However, most of the azafluorenones tested displayed very poor inhibitory activity 
against β-haematin formation. Only azafluorenones 245 and 262 exhibited some 
inhibitory potency. On the basis of the inhibition percentage calculated from the data 
obtained in the further assays, sigmoidal concentration response curves as well as the 





                     
IC50 = 521.2 μM                     IC50 = 685.8 μM 
 
Figure 1.54 Inhibitory activity of 245 and 262 against β-haematin formation.  
 
In comparison with the other azafluorenone anologues, 245 and 262 display much 
higher inhibitory activity against the β-haematin formation, with IC50 value at 521.2 and 
685.8 μM, respectively. This enhancement in activity is attributable to the presence of 
the hydroxyl group in both molecules. The planar azafluorenone core can form a π-π 
stacking interaction with the porphyrin in Fe(III)PPIX molecule, while the 6-hydroxyl 
group provides an additional hydrogen bonding interaction with carboxyl acid group in 
Fe(III)PPIX, reinforcing the overall interaction between the azafluorenone and 
Fe(III)PPIX. Thus, the azafluorenone-Fe(III)PPIX complex formed can adsorb onto the 
growing face of β-haematin, capping the β-haematin crystal and precluding the 
extension of polymer. The slightly improved inhibitory activity which might originates 
from this hydrogen bonding interaction is also observed in the comparison between 
azafluorenones 259 and 114, 219 and 108. 
 
However, the results of the in vitro β-haematin inhibition assays reveal no correlation 
with the data of the antiplasmodial assays. For example, azafluorenone 245 is the most 
active β-haematin inhibitors among the analogues synthesised, whereas it exhibits a 
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poor antiplasmodial activity in the tests conducted by Prof Becker’s group. 
Azafluorenone 106 displays a higher antimalarial activity than azafluorenone 262, 
while azafluorenone 262 is a stronger β-haematin inhibitor than azafluorenone 106. 
These results along with the poor inhibitory activity of most of the analogues prepared 
imply that the azafluorenone class might act via another mechanism other than the 
inhibition of β-haematin formation. 
 
A series of azabiaryls, the precursors of the azafluorenones, were also evaluated for the 
inhibitory activity against the formation of β-haematin by this assay. However, none of 
these compounds displayed significant activity. The results of these tests are displayed 
in bar charts in Appendix II. The single carbon-carbon bond connecting the two rings in 
the azabiaryl makes the intramolecular rotation of the two moieties possible to occur. 
Hence, the π-π stacking interaction between the azabiaryl and Fe(III)PPIX molecule is 
weaker due to the absence of the rigid planar tricyclic backbone. This could explain 
their poor inhibitory activity against β-haematin formation. 
 
Since most of the azafluorenones displays poor inhibitory activity against β-haematin 
formation, it is necessary to consider other mechanisms which might be responsible for 




1.5  Summary and Conclusions 
 
To explore the structure-activity relationship of the azafluorenone family of alkaloids, 
twenty four analogues with various structural modifications have been synthesised. 
Palladium-catalysed Suzuki-Miyaura cross-coupling reactions were exploited to 
prepare the azabiaryl cyclisation precursors in good to excellent yields. Polyphosphoric 
acid catalysed Friedel-Crafts acylations were then applied to the intramolecular 
cyclisations to construct the conjugated tricyclic ring framework. Structural 
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modifications at the 3-position were achieved via a linear synthetic route, involving 
oxidation, phosphorus oxychloride-mediated chlorination and nucleophilic aromatic 
substitution. A series of hybrid molecules conjugating the azafluorenone core and the 
amino side chains present in other antimalarial agents were also prepared. The synthesis 
of these hybrid molecules was fulfilled via the selective Suzuki-Miyaura cross-coupling, 
Eaton’s reagent-promoted cyclisation and the subsequent nucleophilic aromatic 
substitution. Four distinct synthetic routes were investigated for the total synthesis of 
the parent antimalarial natural product 37. However, each of these failed to afford the 
desired natural product. 
 
Fourteen of the synthesised azafluorenone analogues were evaluated for antiplasmodial 
activity by Prof Katja Becker. The [3H]hypoxanthine-incorporation assay revealed that 
eight azafluorenones exhibited activity against chloroquine-sensitive Plasmodium 
falciparum 3D7, and nine azafluorenones were active against chloroquine-resistant 
Plasmodium falciparum K1. The analysis of the antiplasmodial data provides several 
significant conclusions for the structure-activity relationship of the azafluorenones. 
Replacement of the 5-hydroxyl group in natural product 37 with bioisostere fluorine 
retains the antiplasmodial activity of azafluorenones. The substituent at the 5-position, 
which can serve as a hydrogen acceptor, and the 6-methoxy group of the azafluorenone 
analogues are essential for the antimalarial activity. In addition, the hybrid molecules 
prepared were proved to possess a much higher potency than the other azafluorenones. 
The amino side chains appended might bring about additional interaction with the target 
site, significantly facilitating the binding of the azafluorenones to the target. 
 
To probe the mode of action of the azafluorenones, an in vitro β-haematin inhibition 
assay was conducted. It was found that only two azafluorenones showed mild inhibitory 
activity. Moreover, no correlation was identified between the result of antiplasmodial 
activity and that of the inhibition of β-haematin formation, suggesting these analogues 





1.6 Plans for Future Work 
 
Our attempts to prepare natural product 37 suggest that the synthetic route involving the 
cross-coupling and PPA-catalysed intramolecular Friedel-Crafts acylation may be 
inappropriate for the synthesis of alkaloid 37. Another synthetic route with Grignard 
reaction and intramolecular Heck reaction as the key steps can be applied to the 
preparation of natural product 37 (Scheme 1.62).52 The protection of the free hydroxyl 
group with a benzyl group will provide a base-tolerant substrate for the preparation of 
Grignard reagent 313. Subsequent Grignard reaction will conjugate the pyridyl and 
phenyl moieties at the β-position. The oxidation of 315 will yield the precursor for the 
intramolecular cyclisation. Subsequent Heck reaction will ultimately achieve the 
construction of the tricyclic ring system. Removal of the benzyl group will provide the 
target alkaloid 37. 
 
 
Scheme 1.62 Reagents and conditions: (a) BnBr, K2CO3, acetone; (b) Mg, THF, reflux; (c) ether, 




An important issue that cannot be neglected for hybrid molecule 126 is the potential 
hepatotoxicity originating from the aromatic side chain of amodiaquine.9 The 
p-aminophenol moiety present in amodiaquine is prone to undergo the 
biotransformation to the quinone imine 318 (Figure 1.58), which is an active 
electrophilic metabolite showing a high affinity for the thiol groups in proteins. The 
nucleophilic attack of a thiol group to quinone imine 318 results in the conjugation of 
amodiaquine to the protein, giving rise to hepatotoxicity.5,9 Hence, it is necessary to 





Figure 1.58 Amodiaquine and its toxic metabolite. 
 
Numerous studies have demonstrated improved metabolic stability of 
fluorine-containing drugs.56 Accordingly, replacing the hydroxyl group present in the 
p-aminophenol side chain with the bioisostere fluorine is anticipated to block this 





Figure 1.59 Modification of the hybrid molecule containing p-aminophenol moiety. 
 
 
2,4-Diamino-N10-methylpteroic acid 321 (DAMPA, Figure 1.60), a newly developed 
folate synthesis antagonist, has been proved to be an efficient antimalarial agent.115 As a 
mimic of dihydropteroic acid which is a key intermediate in the folic acid metabolic 
pathway of malarial parasites, DAMPA is able to act as a competitive inhibitor 
interfering with the biosynthesis of dihydrofolic acid and interrupt the parasites’ de 
novo synthesis of dTMP. DAMPA exhibits a high activity against both 
pyrimethamine-sensitive Plasmodium falciparum (M24) and pyrimethamine-resistant 




Figure 1.60 Structures of DAMPA and dihydropteroic acid.  
 
The presence of the carboxyl group in DAMPA affords a potential site for appending 
additional fragments. Accordingly, it is planned to synthesise the prodrug-like 
dual-acting molecule 322 conjugating DAMPA with an azofluorenone (Figure 1.61). 
The ester linker connecting the two moieties is expected to be cleaved by esterase 
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enzymes to release two molecules that would act independently.116 It is anticipated that 
the fusion of the two components towards two independent targets would bring about a 




Figure 1.61 Design of hybrid molecule 322.  
 
The synthesis of dual-acting molecule 322 will be achieved by the condensation 
between alkaloid 37 and the acyl chloride 327 derived from DAMPA (Scheme 1.63). 
DAMPA 321 can be prepared from the commercially available 
2,4,5,6-tetraaminopyrimidine via an annelation followed by nucleophilic substitution.117 
Protection of the two amino groups will be necessary before activation of the carboxyl 
group by conversion to the corresponding acyl chloride 327.119 The condensation of the 
two moieties will be achieved in the presence of pyridine.118 The deprotection of the 
two amino groups under basic conditions will afford the desired hybrid 
molecule 322.119  
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Scheme 1.63 Reagents and conditions: (a) 1,1,3-tribromoacetone, HCl aq, EtOH, 50 °C; 
(b) 4-(methylamino)benzoic acid, NaOH, 40 °C; (c) (CF3CO)2O, Py, CH2Cl2, rt; (d) SOCl2, reflux; 




































2.1 Introduction and Background 
 
Coumarin and its derivatives are a significant class of oxygen-containing heterocyclic 
compounds.122 The coumarin moiety is present in a number of molecules with high 
biological activity, such as nonpeptidic HIV protease inhibitors,123 and tyrosine kinase 
inhibitors.124 Pyrido-fused coumarins have also been reported to possess significant 
biological activity. For example, compounds 331 and 332 containing a pyridocoumarin 
moiety exhibit inhibitory activity towards Staphylococcus epidermidis.125 Polycyclic 
compound 333 have been proved to possess antituberculosis potency, as it is active 




Figure 2.1 Pyridocoumarin derivatives with biological activities. 
 
Recently, a series of polycyclic analogues of pyrido[3,2-c]coumarin have been 
synthesised (Figure 2.2), among which compounds 334, 335, 337, 338, 340 and 341 
display good inhibitory activity against Gram-positive (Staphylococcus aureus and 
Streptococcus pyogenes) and Gram-negative (Pseudomonas phaseolicola and 
Pseudomonas fluorescens) bacteria, while compounds 334, 336, 339, 341 and 342 show 




Figure 2.2 Pyrido[3,2-c]coumarin analogues with antibacterial and antifungal activity. 
 
In addition, compounds 343-347 (Figure 2.3) have been proved to exhibit significant 
antibacterial activity towards Bacillus subtilis, Staphylococcus aureus, Escherichia coli 
as well as Salmonella typhimurium.128 Compounds 343, 344 and 346 display antifungal 




Figure 2.3 Pyrido[3,2-c]coumarin derivatives with antimicrobial activity. 
 
Owing to the significant biological activities, the synthesis of pyrido-fused coumarins 
has remained an active subject of interest. As described in Chapter One, an efficient 
one-pot synthesis of pyrido[3,2-c]coumarins based on nicotinates or nicotinonitriles 
was discovered by us (Scheme 2.1). Given the significant biological properties of 
pyrido[3,2-c]coumarins, it would be of value to develop this one-pot synthesis of 
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pyrido[3,2-c]coumarin analogues.   
 
 
Scheme 2.1 Reagents and conditions: (a) Pd(PPh3)4, THF/H2O, 2 M Na2CO3 aq, 80 °C; (b) 
Pd(PPh3)4, DME/H2O, 2 M K2CO3 aq, 80 °C.   
 
2.2 Review of Synthetic Methods for Pyrido[3,2-c]coumarins 
Previous methods for the synthesis of pyrido[3,2-c]coumarins can be divided into four 
main classes, including cyclisation of substituted coumarins, cyclisation of substituted 
arylpyridines, condensation of phenols with piperidones, and condensation of salicylic 
aldehydes with reactive methylene compounds in the presence of ammonia. 
 
2.2.1 Cyclisation of Substituted Coumarin Analogues 
Heber developed a synthetic method for pyrido[3,2-c]coumarin analogues starting from 
aminocoumarin (Scheme 2.2).129 Vilsmeier-Haack acetylation of aminocoumarin 348 
afforded ketone 349 in a yield of 61%. Under the conditions of Vilsmeier reaction, 
phosphorus oxychloride-mediated chlorination of the enol derived from ketone 349 is 
achieved. Subsequent nucleophilic attack to the Vilsmeier reagent generated in situ 
affords β-chlorovinyliminium salt 350, which underwent a nucleophilic intramolecular 
cyclisation followed by the elimination of dimethylamine, fulfilling the annelation and 





Scheme 2.2 Reagents and conditions: (a) POCl3, DMA, rt; (b) POCl3, DMF, 45 °C. 
 
Vilsmeier reagent 356, the reactive iminium salt which plays a crucial role in this 
synthetic protocol, is formed through the reaction of amide with phosphorus 
oxychloride (Figure 2.4). 
 
 
Figure 2.4 Formation of Vilsmeier reagent 356. 
 
The initial Vilsmeier-Haack formylation of the hydroxycoumarin 358 gave aldehyde 
359.130 The Wittig reaction of 359 afforded vinylcoumarin 360 in 73% yield. 
Methylaminocoumarin 361 derived from 360 was then subjected to Vilsmeier reaction 
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to provide pyrido[3,2-c]coumarin 363 in 40% yield. This cyclisation proceeds via the 
intermediate dimethyliminium salt 362, generated by the nucleophilic attack of 
4-methylamino group to the Vilsmeier reagent. The nucleophilic attack of chloride ion 
to N-alky group in 362 provokes the intramolecular cyclisation. With the elimination of 
dimethyliminium, the ring closure is achieved to give the target pyrido[3,2-c]coumarin 





Scheme 2.3 Reagents and conditions: (a) POCl3, DMF, 60 °C; (b) Ph3P=CHCO2Et, DMF, 0 °C; 
(c) MeNH2, EtOH, rt; (d) POCl3, DMF, 90 °C. 
 
 
Different from the previous method utilising Vilsmeier-Haack reaction to fulfil the 
annelation, Mulwad developed an alternative strategy employing intramolecular 
Friedel-Crafts acylation to achieve the cyclisation (Scheme 2.4).131 Firstly, 
4-chlorocoumarin 364 was treated with anthranilic acid 365 in the presence of copper(I) 
chloride and triethylamine at 160 °C for 22 hours, fulfilling the Ullmann condensation 
in 45% yield. Further treatment of condensation product 366 with phosphorus 
oxychloride at 110 °C for 3 hours afforded the desired product 367 in a yield of 80%. 
This cyclisation involves three major steps. Carboxylic acid 366 is initially activated by 
the conversion to acyl chloride mediated by phosphorus oxychloride, which readily 
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participates in the intramolecular Friedel-Crafts acylation. Subsequent chlorination is 
achieved by phosphorus oxychloride to provide the target product 
pyrido[3,2-c]coumarin analogue 367. However, the requirement for long-time harsh 
conditions (160 °C) and the low yield (45%) of Ullmann condensation are the major 
defects limiting the wide application of this protocol. 
 
 
Scheme 2.4 Reagents and conditions: (a) CuCl, Et3N, DMF, 160 °C, 22 h; (b) POCl3, 110 °C, 3 h. 
 
 
The key building block 2-(2-methyl-1,3-dioxolan-2-yl)ethanamine 370 was prepared 
from α, β-unsaturated ketones 368 following a three-step synthetic route 
(Scheme 2.5).132 Condensation of hydroxycoumarin 358 with amine 370 gave the 
corresponding aminocoumarin 371, which underwent an intramolecular cyclisation 
catalysed by boron trifluoride. Oxidation with DDQ afforded 
4-methylpyrido[3,2-c]coumarin 159. The overall yield for this synthetic route is 45%. 
However, the lengthy multi-step sequences and the utilisation of toxic hydrazine133 





Scheme 2.5 Reagents and conditions: (a) phthalimide, trimethylbenzylammonium hydroxide, 
EtOAc, reflux; (b) HOCH2CH2OH, TsOH, toluene, reflux; (c) NH2NH2, MeOH, reflux; (d) 
camphorsulfonic acid, toluene, Dean-Stark, reflux, 6h; (e) BF3∙Et2O, toluene, reflux; (f) DDQ, 
CH2Cl2, rt,. 
 
The formylation of hydroxycoumarin 373 with Vilsmeier reagent furnished 
carbaldehyde 374 in 78% yield (Scheme 2.6).127 Subsequent annelations were achieved 
by the reactions of coumarin aldehyde 374 with different cyclic ketones in the presence 
of ammonium acetate in glacial acetic acid, affording the desired polycyclic analogues 
of pyrido[3,2-c]coumarin in 52-58% yields. This protocol provides a good approach to 
the preparation of polycyclic pyrido[3,2-c]coumarins. However, the comparatively low 




Scheme 2.6 Reagents and conditions: (a) POCl3, DMF, 70 °C; (b) cyclopentanone, NH4OAc, AcOH, 
reflux; (c) cyclohexanone, NH4OAc, AcOH, reflux; (d) α-tetralone, NH4OAc, AcOH, reflux. 
 
By employing 3-acetyl coumarin derivative 378 as the starting material, Tamam 
developed a concise synthetic route for pyrido[3,2-c]coumarin analogues 
(Scheme 2.7).134 Refluxing 3-acetylcoumarin 378 and 3-iminobutyronitrile 379 in the 
presence of acetic acid in dry benzene furnished the substituted pyrido[3,2-c]coumarin 
380 in 50% yield. The nucleophilic addition of the highly reactive methylene in 
3-iminobutyronitrile 379 to the 3-acetyl group to produces the cyclisation precursor, 
which undergoes the intramolecular Michael addition of the amino group and 
subsequent aromatisation, affording the pyrido[3,2-c]coumarin 380.  The major 
advantage of this protocol is the conciseness of the synthetic route. However, the need 





Scheme 2.7 Reagents and conditions: (a) AcOH, benzene, reflux, Dean-Stark apparatus. 
 
 
2.2.2 Cyclisation of Substituted Arylpyridines 
 
Recently, a novel method based on the Cu(I)-mediated carbon-oxygen bond formation 
was reported by Nealmongkol (Scheme 2.8).135 The Suzuki cross-coupling between 
2-iodonicotinate 381 and 2-chlorophenlboronic acid 382 gave cyclisation precursor 383. 
The lactonisation was accomplished in the presence of caesium carbonate, 
copper(I)-thiophene-2-carboxylate (CuTC) and N,N,N’,N’-tetramethylethylenediamine 
(TMEDA) in deionised water at 300 °C under microwave irradiation. The desired 
pyrido[3,2-c]coumarin 164 was obtained in 66% yield.  
 
Scheme 2.8 Reagents and conditions: (a) Pd(PPh3)4, 10% Na2CO3 solution, toluene, EtOH, reflux; 
(b)CuTC, Cs2CO3. TMEDA, deionised water, microwave irradiation, 300 °C. 
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The Suzuki cross-coupling of aldehyde 386 with boronic acids 387-389 furnished 
azabiaryls 390-392, which underwent oxidation by sodium chlorite to provide 
carboxylic acids 393-395. Treatment with boron tribromide achieved the cleavage of 
methoxy group, and simultaneous cyclisation finally afforded the 
pyrido[3,2-c]coumarins 396-398 in moderate to excellent yields (42-93%).136   
  
Scheme 2.9 Reagents and conditions: (a) Pd(PPh3)4, K2CO3, DMF, 80 °C; (b) NaClO2, NaH2PO4, 
THF, t-BuOH, H2O, rt; (c) BBr3, CH2Cl2, rt. 
 
2.2.3 Condensation of Phenols with Piperidones  
 
Eiden developed a synthetic route initiating from the condensation of piperidin-2-one 
and 2-hydroxybenzoic acid methyl ester (Scheme 2.10).137 The intramolecular 
nucleophilic addition of 401 yielded intermediate 402, which underwent a ring opening 
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followed by a second intramolecular nucleophilic addition to afford 404. The 
cyclisation product 404 was oxidised by DDQ to provide pyrido[3,2-c]coumarin 164. 




Scheme 2.10 Reagents and conditions: (a) NaH, dioxane, reflux, 18 h; (b) pyridine hydrochloride, 
blow lamp heating, 2 h; (c) DDQ, MeOH, reflux, 24 h. 
 
2.2.4 Condensation of Salicylic Aldehydes with Reactive Methylene Compounds in 
the Presence of Ammonia 
 
Readily available derivatives of salicylic aldehyde can be used to construct 
pyridocoumarin polycycles with [3,2-c] linkages. Condensation of salicylaldehyde 405 
and aminocrotonate 406 was performed in acetic acid at room temperature for 4 days, 




Scheme 2.11 Reagents and conditions: (a) CH3COOH, rt, 4 d. 
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A recent improved procedure of this protocol was developed by Navarrete-Encina by 
raising the reaction temperature to 60 °C (Scheme 2.12). Although the time for the 
reaction was greatly shortened to 5 hours, the yield was still poor 54%.139 
 
 
Scheme 2.12 Reagents and conditions: (a) CH3COOH, 60 ºC, 5 h. 
 
In the presence of ammonium acetate which acted as nitrogen source, condensation of 
2-hydroxy-3-methoxybenzaldehyde 408 with 4-hydroxy-6-methyl-2H-pyran-2-one 409 




Scheme 2.13 Reagents and conditions: (a) NH4OAc, AcOH, reflux 
 
In this process, pyranone 409 serves as the active methylene reactant. The Knoevenagel 
condensation of salicylic aldehyde derivative 408 with pyranone 409 gives intermediate 
411, whose pyranone moiety undergoes a ring opening reaction to yield 
acetoacetylcoumarin 412, which is then converted into enamine 413. Subsequent 
intramolecular Michael addition achieves cyclisation and constructing the tricyclic ring 
system. The final air oxidation and tautomerism provides target pyrido[3,2-c]coumarin 
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Figure 2.5 Formation of pyrido[3,2-c]coumarin 410. 
 
The survey of the literature reveals that most of the current methods for the synthesis of 
pyrido[3,2-c]coumarins have remarkable defects, such as lengthy synthetic routes, long 
reaction times, low overall yields or utilisation of toxic reagents. Compared with these 
methods, our protocol possesses significant advantages. Not only is our synthetic route 
more concise, but also the yield is improved. The reactants for this method are also 
widely commercially available and of low-toxicity. More importantly, the one-step 
reaction is conducted under milder reaction conditions. These milder conditions possess 
a high functional-group compatibility, affording an ideal means for the synthesis of 
pyrido[3,2-c]coumarin analogues with diverse groups, which could be further 
functionalised.  
 
The direct conversion of nitriles to the corresponding carboxylic esters is mainly 
Bronsted acid or Lewis acid catalysed alcoholysis. The Pinner reaction employing 
gaseous hydrogen chloride as catalyst exemplifies this conversion.141 Several improved 
methods for the Pinner reaction have been developed over the decades. Jiang reported a 
modified protocol, in which gaseous hydrogen chloride was replaced by ionic liquid 
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based on a sulfonic acid.142 1-Methyl-3-(3-sulphopropyl)-imidazolium hydrogen 
sulphate ([HSO3-pmim]HSO4) was proved to be an efficient catalyst for the 
esterification of nitriles with alcohols (Scheme 2.14). Nevertheless, this method is only 
applicable to primary aliphatic alcohols. The utilisation of secondary alcohol 417 




Scheme 2.14 Reagents and conditions: (a) [HSO3-pmim]HSO4, reflux; (b) H2O, rt. 
 
By utilising Lewis acid trimethylsilyl chloride, Luo developed a new method for the 
acid-catalysed esterification of nitriles (Scheme 2.15).145 Hydrogen chloride generated 
in situ from the reaction of trimethylsilyl chloride and ethanol serves as the catalyst for 
this modified Pinner reaction. This method avoids the direct use of gaseous hydrogen 




Scheme 2.15 Reagents and conditions: (a) TMSCl, EtOH, 50 ºC; (b) Na2CO3, H2O, CH2Cl2, rt.  
 
However, the base-catalysed conversions of nitriles to the corresponding carboxylic 
esters usually require harsh reaction conditions and are not frequently employed in 
organic synthesis. We’ve found two examples reported for the conversion of nitriles to 
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esters under basic conditions. Schaefer employed the strong base sodium methoxide to 
catalyse this reaction (Scheme 2.16).146 The treatment of terephthalonitrile 417 with 
sodium methoxide in methanol under reflux provided an imidate intermediate 418 after 
2.5 hours. Subsequent hydrolysis by 12 N hydrochloric acid gave the desired ester 419 
only in 61% yield, based on the recovered starting material. Unconverted substrate 417 
was recovered in a yield of 24%. The low yield of this esterification and harsh reaction 
conditions involving the utilisation of strong base and strong acid limits the wide 




Scheme 2.16 Reagents and conditions: (a) NaOMe, MeOH, reflux; (b) 12 N hydrochloric acid.  
In the synthesis of Vitamin B12, Zutter refluxed nitrile 420 in ethylene glycol and water 
at 110 °C for 75 h, in the presence of 18.75 equivalents of sodium hydroxide to 
hydrolyse the cyano groups into carboxyl groups (Scheme 2.17).147 Subsequent 
alkylation with methyl iodide in DMF yielded the desired ester 422. 
 
 
Scheme 2.17 Reagents and conditions: (a) NaOH, HOCH2CH2OH, H2O, 110 °C; (b) MeI, DMF, rt.  
 
Neither of the two methods described above is a one-step base-catalysed conversion. 
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Compared with these methods, our protocol requires far milder conditions. The 
esterification of nitriles under our reaction conditions has not been reported in the 
literature. Hence, it is of value to investigate this milder one-pot synthesis of 
pyrido[3,2-c]coumarins with nicotinonitriles as the starting core.  
 
 
2.3 One-pot Synthesis of Pyrido[3,2-c]coumarin Analogues under Thermal 
Conditions 
 
Initially the reaction conditions were optimised for 2-chloronicotinonitrile and 
2-hydroxyphenylboronic acid. These were subjected to the Suzuki cross 




Scheme 2.18 Reagents and conditions: (a) 0.1 equiv. Pd(PPh3)4, 2 M K2CO3 aq, solvent, 80 °C, 
18 h. 
 
As shown in Table 2.1, pyrido[3,2-c]coumarin 164 was afforded in high yields in polar 
aprotic solvents dimethoxyethane and tetrahydrofuran (Entry 1 and 2). Non-polar 
aprotic 1,4-dioxane was more efficient as the yield was raised to 89% (Entry 3). 
Nonetheless, the yield diminished in the case of N, N-dimethylformamide (Entry 4). 





Entry Solvent Yield (%) Dielectric Constant (ε) 
1 Dimethoxyethane 84 7.3 
2 Tetrahydrofuran 81 7.5 
3 1,4-Dioxane 89 2.2 
4 N, N-Dimethylformamide 70 38.3 
 
Table 2.1 Screening of different solvents for the one-pot reaction.  
 
As shown in Table 2.1, N, N-dimethylformamide possesses a much higher dielectric 
constant than 1,4-dioxane, tetrahydrofuran and dimethoxyethane.91 When the former 
three solvents were employed, the reactants were fully dissolved into two phases after 
the addition of potassium carbonate aqueous solution. However, due to the high 
dielectric constant of N, N-dimethylformamide, only one phase was formed after the 
aqueous solution of base was added, and some reactants precipitated. It could be the 
poor dissolution of the reactants that hindered the reaction.  
 
In the presence of tetrakis(triphenylphosphine)palladium(0) and potassium carbonate, 
the conversion was accomplished in 85% yield when the reaction time was decreased to 




Scheme 2.19 Reagents and conditions: (a) 0.1 equiv. Pd(PPh3)4, 2 M K2CO3 aq, 1,4-dioxane/H2O, 
80 °C, 12 h. 
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Sodium carbonate, a commonly employed base in Suzuki cross-coupling reactions, was 
also examined. It was demonstrated sodium carbonate solution was similarly efficient 





Scheme 2.20 Reagents and conditions: (a) 0.1 equiv. Pd(PPh3)4, 2 M Na2CO3 aq, 1,4-dioxane/H2O, 
80 °C, 12 h. 
 
To investigate the effect exerted by the quantity of the palladium catalyst on the 
reaction, another comparative study utilising different equivalents of 
tetrakis(triphenylphosphine)palladium(0) was conducted. As shown in Table 2.2, no 
enhancement of yield was observed when the quantity of palladium reagent was raised 
to 0.2 equivalents (Entry 2). Nevertheless, when the amount of palladium reagent was 
reduced to 0.03 equivalents, the Suzuki cross coupling-lactonisation was remarkably 
retarded, requiring more than 48 hours to reach completion (Entry 3).  
 
Entry 
Quantity of Pd(PPh3)4  
(equiv.) 
Reaction Time (h) Yield (%) 
1 0.1 12 85 
2 0.2 12 84 
3 0.03 48.5 79 
 
Table 2.2 Screening of different quantity of Pd(PPh3)4. 
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Consequently, the optimised conditions for this one-pot Suzuki cross 
coupling-lactonisation are the utilisation of 0.1 equivalent of 
tetrakis(triphenylphosphine)palladium(0) in the presence of potassium carbonate in 
1,4-dioxane and water at 80 °C for 12 hours.    
 
After determining these optimised parameters, a large scale Suzuki cross 
coupling-lactonisation was attempted using 1 g 2-chloronicotinonitrile. The high yield 
(88%) for this reaction confirmed the applicability of the method to the large scale 
synthesis of pyrido[3,2-c]coumarins. 
 
To investigate the scope of this protocol, a series of commercially available substrates 
were subjected to the Suzuki cross coupling-lactonisation reactions. A range of 
nicotinonitriles bearing electron-withdrawing or electron-donating functional groups at 
different positions and diverse arylboronic acid bearing electron-withdrawing or 
electron-donating functional groups were explored. Under the optimal conditions, the 
anticipated pyrido[3,2-c]coumarins were afforded in moderate to excellent yields 
(Table 2.3), demonstrating the versatility of the protocol. The results indicate that 
electronic effects influence the one-pot synthesis significantly. In Table 2.3, 
electron-withdrawing groups are labelled red and electron-donating groups are labelled 
green. In general, electron-withdrawing groups in the nicotinonitrile substrate promote 
the reaction (i.e. Entry 5 versus Entry 2), while electron-donating groups in the 
nicotinonitrile render the reaction less efficient (i.e. Entry 21 versus Entry 3). In 
contrast, the electron-withdrawing groups present in the arylboronic acids bring about 





Entry R1 R2 R3 R4 R5 Product 
Yield 
(%) 
1 H H H H H 164 85 
2 H H H Cl H 432 75 
3 H H H F H 433 77 
4 CF3 H H H H 434 90 
5 CF3 H H Cl H 435 81 
6 CF3 H H F H 436 78 
7 Me H H H H 437 78 
8 Me H H Cl H 438 71 
9 Me H H F H 439 70 
10 H H H H MeO 440 76 
11 CF3 H H H MeO 441 80 
12 Me H H H MeO 442 72 
13 H Me H H H 443 81 
14 H Me H Cl H 444 70 
15 H Me H F H 445 74 
16 H H Me H H 159 76 
17 H H Me Cl H 446 69 
18 H H Me F H 447 62 
19 H H MeO H H 448 72 
20 H H MeO Cl H 449 66 
21 H H MeO F H 450 60 
22 4-F-Ph H H H H 451 80 
23 4-F-Ph H H Cl H 452 75 
24 4-F-Ph H H F H 453 72 
Table 2.3 Synthesis of a library of pyrido[3,2-c]coumarins. 
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These results can be explained by considering the electronic effects exerted by the 
different groups on the Suzuki cross-coupling catalytic cycle.58 The oxidative addition 
of the nicotinonitrile 454 forms a σ-aryl-Pd(II)-Cl species 456 (Figure 2.6). Similar to 
nucleophilic aromatic substitution reactions, the nucleophilic attack of the palladium 
reagent affords intermediate 455 with a negative charge on the aromatic ring, which 
collapses to afford the oxidative addition product 456.146 In this process, the presence of 
electron-withdrawing groups in the halogenated substrate 454 decrease the electron 
density of the aromatic ring and enhance the electrophilicity, rendering it more 
vulnerable to nucleophilic attack from the palladium reagent. In addition, the 
electron-withdrawing groups could stabilise intermediate 455 with a negative charge, 
significantly facilitating the oxidative addition process (Figure 2.6). Conversely, 
electron-donating groups present in the halogenated substrate 454 bring about the 
opposite effects, retarding the oxidative addition.  
 
 
Figure 2.6 Oxidative addition of nicotinonitrile 454. 
 
In the transmetallation process, the aryl group in boronic acid 458, serving as a 
nucleophile, is transferred to the palladium-substrate complex 457.58 
Electron-withdrawing groups in arylboronic acid 458 diminish its electron density and 
reduce the nucleophilicity of the aryl group. As a consequence, this nucleophilic 
transfer of the aryl group is obstructed and the Suzuki cross coupling-lactonisation is 




Figure 2.7 Transmetallation in the Suzuki cross-coupling catalytic cycle. 
 
It is noteworthy that in the case of the arylboronic acid substituted with methoxy group 
which is an electron-donating group, the yields of the reactions were decreased, 
compared with the corresponding substrates without methoxy group (Entry 10 versus 
Entry 1). This outcome should arise from the unfavourable steric effect of the methoxy 
group during the subsequent lactonisation.  
 
Chromeno-quinolines, comprising both coumarin and quinoline moieties, have been 
shown to possess significant biological activity, such as antibacterial activity against 
Staphylococcus aureus.147 Consequently, it was attempted to prepare 
6H-chromeno[4,3-b]quinolin-6-one analogues using this one-pot strategy 
(Scheme 2.21). When 2-chloroquinoline-3-carbonitrile substrates were subjected to the 
optimised reaction conditions, the target products were afforded in moderate to good 
yields (Table 2.4). The yields obtained for the reactions with quinoline-3-carbonitrile 
substrates are lower than the reactions of the corresponding nicotinonitrile substrates, 
which can be attributed to the relative electron richness of the quinoline ring as well as 




Scheme 2.21 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, 1,4-dioxane/H2O, 80 °C. 
 
Entry R Product Yiled (%) 
1 H 461 75 
2 Cl 462 67 
3 F 463 62 
 
Table 2.4 Preparation of 6H-chromeno[4,3-b]quinolin-6-one analogues. 
 
During the course of these investigations, we became aware of a report for the 
microwave-promoted synthesis of dibenzopyranones.148 By utilising bromophenyl 
carboxylates 464 and hydroxyarylboronic acids 465, with caesium carbonate as the 
base, a series of dibenzopyranones were prepared in moderate to excellent yields under 




Scheme 2.22 Reagents and conditions: (a) Pd(PPh3)4, Cs2CO3, DME/H2O, MW 125 °C. 
 
Two bromonicotinate substrates were also examined under these conditions 





Scheme 2.23 Reagents and conditions: (a) Pd(PPh3)4, Cs2CO3, DME/H2O, MW 125 °C, 
 
Within comparison to this method, our protocol utilises chloronicotinonitriles instead of 
the bromonicotinate substrates. Chlorinated substrates in the Suzuki cross-coupling 
reactions are much less reactive than the corresponding brominated substrates,58 while 
the chlorinated substrates are far more widely available and much lower in cost than the 
corresponding brominated substrates. Our research has proved that the less reactive and 




2.4 One-pot Synthesis of Pyrido[3,2-c]coumarin Analogues under 
Microwave-irradiated Conditions 
 
Initially, 2-chloronicotinonitrile and 2-hydroxyphenylboronic acid were subjected to the 
microwave-heating conditions (Scheme 2.24). In the presence of 0.1 equivalent of 
tetrakis(triphenylphosphine)palladium(0) and 2 M potassium carbonate solution, 
pyrido[3,2-c]coumarin 164 was afforded in a yield of 79% after microwave heating at 
125 °C for 30 min. This demonstrates that the one-pot Suzuki cross 
coupling-lactonisation of the nicotinonitrile substrate can also be achieved under the 
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Scheme 2.24 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, 1,4-dioxane/H2O, 
MW 125 °C, 30 min. 
 
It was observed that the yield of this reaction under microwave-heating conditions was 
lower than the one under thermal conditions. Taking the difficulty of the base-catalysed 
alcoholysis of nitriles into account, longer reaction times for the lactonisation of 
nicotinonitriles under microwave-irradiated conditions may be required. Accordingly, 
2-chloronicotinonitrile and 2-hydroxyphenylboronic acid were subjected to the 
microwave irradiation for 1 hour, resulting in a comparable yield of 80%.  
 
The scope of the microwave-assisted reaction was investigated using a range of 
nicotinonitriles and arylboronic acids containing electron-withdrawing or 
electron-donating groups (Scheme 2.25). The target pyrido[3,2-c]coumarin analogues 
were obtained in moderate yields (Table 2.5).   
 
Scheme 2.25 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, 1,4-dioxane/H2O, 
MW 125 °C, 30 min. 
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Entry R1 R2 Product Yield (%) 
1 H H 164 79 
2 H Cl 432 76 
3 H F 433 66 
4 CF3 H 434 80 
5 CF3 Cl 435 75 
6 CF3 F 436 72 
7 Me H 437 74 
8 Me Cl 438 63 
9 Me F 439 69 
  
Table 2.5 Synthesis of pyrido[3,2-c]coumarins under microwave-irradiated conditions  
 
 
The results from the microwave-assisted reactions are generally consistent with the 
results under thermal heating conditions. The electron-withdrawing group present in the 
nicotinonitrile promoted the microwave-assisted one-pot reaction (Entry 6 versus Entry 
3) and the electron-donating group retarded the reaction (Entry 8 versus Entry 2). 
Conversely, the electron-withdrawing group in the arylboronic acid substrate rendered 
the yield decreased (Entry 3 versus Entry 1).  
 
 
2.5 Mechanistic Considerations  
 
Since the conversion of nitriles to the corresponding carboxylic esters are 
predominately acid catalysed, we set out to probe the mechanism of this unusual 
one-pot synthesis of pyrido[3,2-c]coumarins. The key question to be answered is 
whether this reaction proceeds via an amide intermediate.  
 
Under the identical thermal reaction conditions developed for the preparation of 
pyrido[3,2-c]coumarins, the treatment of 2-chloronicotinonitrile with phenylboronic 
 155 
acid afforded the cross-coupling product 470 in an excellent yield (Scheme 2.26). 
 
 
Scheme 2.26 Reagents and conditions: (a) Pd(PPh3)4, 2 M K2CO3 aq, 1,4-dioxane/H2O, 80 °C. 
 
The stability of 2-chloronicotinonitrile was investigated. Stirring in aqueous potassium 
carbonate solution and 1,4-dioxane at 80 °C resulted in a complete recovery of 
2-chloronicotinonitrile after 12 hours (Scheme 2.27) 
 
Scheme 2.27 Reagents and conditions: (a) 2 M K2CO3 aq, 1,4-dioxane/H2O, 80 °C. 
 
 
In addition, the potential reaction of 2-chloronicotinonitrile and phenol was investigated. 
In the presence of potassium carbonate solution, 2-chloronicotinonitrile and phenol in 
1,4-dioxane failed to afford the condensation product, with 2-chloronicotinonitrile 
substrate being completely recovered after 12 hours (Scheme 2.28).  
 
Scheme 2.28 Reagents and conditions: (a) 2 M K2CO3 aq, 1,4-dioxane/H2O, 80 °C. 
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These observations support the assertion that this one-pot reaction does not proceed via 
an amide intermediate, as the cyano group was not hydrolysed to an amide under these 
reaction conditions. The model reaction shown in Scheme 2.28 indicates that the 
intermolecular nucleophilic attack of phenol hydroxyl group to the cyano group cannot 
occur under the reaction conditions employed, suggesting that the Suzuki 
cross-coupling reaction occurs prior to the lactonisation. Only the arylpyridine structure 
derived from the cross-coupling can provide a favourable conformation facilitating the 
occurrence of intramolecular nucleophilic attack from phenol hydroxyl group to 
construct the tricyclic ring system. 
 
The proposed mechanism of the cross-coupling reactions is shown in Figure 2.7. 
Initially, the Suzuki-Miyaura cross-coupling of 163 and 155 yields azabiaryl 471. 
Under the basic condition, the phenol hydroxyl group in 471 is deprotonated to form 
the phenolate anion, whose nucleophilicity is much greater than the phenol. 
Intramolecular nucleophilic attack from the phenolate anion to the cyano group 
constructs the tricyclic ring system. Imidate anion 472 takes a proton from water and 
subsequently undergoes the nucleophilic attack of hydroxide ion, yielding tetrahedral 
intermediate 474. After the intramolecular proton transfer, intermediate 55 collapses to 









2.6  Summary and Conclusions 
 
An efficient one-pot method for the synthesis of pyrido[3,2-c]coumarin analogues has 
been developed. A range of different nicotinonitrile and arylboronic acid substrates 
have been investigated. Twenty seven pyrido[3,2-c]coumarin derivatives have been 
prepared in moderate to excellent yields under the optimised thermal conditions, which 
confirms the versatility of this protocol. It has been demonstrated that the electronic 
effects of the substrates is an important factor influencing the yield of this reaction. 
Electron-withdrawing groups present in the nicotinonitrile substrates promote this 
one-pot synthesis, while electron-donating groups in the nicotinonitrile substrates and 
electron-withdrawing groups in the arylboronic acid substrates retard this reaction. 
Moreover, microwave-assisted one-pot synthesis of pyrido[3,2-c]coumarins has also 
been investigated. Nine analogues of pyrido[3,2-c]coumarin have been prepared in 
moderate to good yields, confirming that this one-pot synthetic method is also efficient 
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under microwave-heating conditions. The good yields, concise synthetic route, wide 
availability of substrates and milder reaction conditions render this one-pot protocol 
superior to other commonly used methods and make it a feasible approach to the 
synthesis of pyrido[3,2-c]coumarins in gram quantities. 
 
In addition, the mechanism of this cross coupling-lactonisation has been explored. The 
model reactions performed support the perspective that the Suzuki reaction occurs prior 
to the lactonisation and this one-pot reaction does not proceed via an amide 
intermediate. A mechanism proposal for this one-pot synthesis of 












































3.1  General Experimental Procedures 
 
Infrared (IR) spectra were recorded using a Perkin Elmer FTIR spectrophotometer. Only 
significant absorptions (νmax) are reported and all absorptions are recorded in 
wavenumbers (cm-1). Melting points (mp) were measured on Barnstead Electrothermal 
9100 apparatus and are uncorrected. 
 
Proton magnetic resonance spectra (1H NMR) were recorded at 400 MHz using a Bruker 
spectrometer. Chemical shifts (δH) are quoted in parts per million (ppm) and are 
referenced to the residual protonated solvent peak. The order of citation in parentheses is 
(i) number of equivalent nuclei (by integration), (ii) multiplicity (s, singlet; d, doublet; t, 
triplet; q, quartet and m, multiplet), (iii) coupling constant (J) quoted in Hertz to the 
nearest 0.1 Hz, (iv) assignment. Carbon magnetic resonance spectra (13C NMR) were 
recorded at 100 MHz using a Bruker spectrometer. Chemical shifts (δC) are quoted in 
parts per million (ppm) and are referenced to the appropriate solvent peak. Fluorine 
magnetic resonance spectra (19F NMR) were recorded at 376 MHz using a Bruker 
spectrometer. Chemical shifts (δF) are quoted in parts per million (ppm) and are 
referenced to trifluoroacetic acid as external standard.  
 
Low resolution mass spectra (m/z) were recorded using LCQ DECA XP instrument by 
electrospray ionisation (ESI). Only molecular ions are reported. Accurate masses were 
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determined using a quadrupole time-of-fight mass (QTOF) spectrometer at King's 
College London or a Thermofisher LTQ Orbitrap XL instrument at the EPSRC National 
Mass Spectrometry Facility in Swansea by electrospray ionisation (ESI). 
 
Reactions were carried out under dry, oxygen free nitrogen and all reagents were used as 
received unless otherwise stated. Microwave-assisted reactions were performed on a 
Monowave 300 Microwave Synthesis Reactor from Anton Paar. The fractions of light 
petroleum ether boiling between 40 and 60 C are referred to as “hexanes”. Solvents 
were evaporated using a Büchi Rotavapor RE111. 
 
Flash Chromatography was carried out using silica gel (Sigma, 230-400 mesh) as the 
stationary phase. Thin Layer Chromatography was carried out on aluminium plates 
pre-coated with silica (Merck silica gel 60 F254 on aluminium) which was visualised by 
the quenching of ultraviolet fluorescence (λmax=254nm).  
 
The azafluorenones evaluated for the antiplasmodial activity were analysed by high 
performance liquid chromatography (HPLC) using three different linear gradients. The 
purity of the compounds was found to be over 95%. The HPLC analysis was conducted 
on a Hewlett-Packard 1050 system equipped with an autosampler, a reversed-phase 
HPLC column (Agilent Zorbax 300Å, C18, 5 μ M, 150  2 mm) and a diode array 
detector (DAD) set to monitor 210-280 nm. The column was developed using three 
linear gradients: 
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(i) 0-90% CH3CN in 0.1%(v/v) trifluoroacetic acid aqueous solution within 20 min 
(tR1); 
(ii) 0-90% CH3CN in 0.1%(v/v) trifluoroacetic acid aqueous solution within 30 min 
(tR2); 
(iii) 0-50% CH3CN in 0.1%(v/v) trifluoroacetic acid aqueous solution within 50 min 
(tR3). 
 
The in vitro β-haematin inhibition assays were carried out in Nunc clear, flat-bottom 
96-well plates. Centrifugations were carried out in a Beckman Coulter Allegra 25R 
rotor. The absorbance of the samples was measured at 400 nm or 405 nm on a BMG 
Labtech POLARstar Optima multiplate reader. Sigmoidal concentration-response 
curves and the IC50 values were acquired from the software of GraphPad Prism v5.0. 
 
 
3.2  Chemical Synthesis 
 




To a solution of ethyl 2-cyano-3-methylbut-2-enoate 138 (11.40 g, 74.42 mmol, 
1.0 equiv.) in absolute ethanol (70 mL), N,N-dimethylformamide dimethyl acetal (9.15 
mL, 74.42 mmol, 1.0 equiv.) was added dropwise. After addition, the solution was 
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heated at reflux for 6 h and then concentrated in vacuo to yield crude (2E,4E)-ethyl 
2-cyano-5-(dimethylamino)-3-methylpenta-2,4-dienoate 137. Crude 137 was dissolved 
in acetic acid (50.0 mL) and the mixture was heated at 40 ºC. A solution of 30% 
HBr-AcOH (91.0 mL) was added dropwise, then the mixture was heated to 55 ºC with 
stirring. After heating for 45 min, the solution was poured onto ice, neutralised with 
solid sodium carbonate, and extracted with dichloromethane (4  200 mL) and the 
combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
chromatography (10.5% ethyl acetate-hexane) afforded ethyl 
2-bromo-4-methylnicotinate 139 (10.58 g, 62% over two steps) as a colourless oil; 
Rf 0.31 (12.5% ethyl acetate-hexane); νmax (neat) 2982, 1728 (C=O), 1579, 1446, 1379, 
1273, 1118, 1065, 859 cm-1; δH (400 MHz, CDCl3) 8.19 (1H, d, J 5.2 Hz, H-6), 7.06 (1H, 
d, J 5.2 Hz, H-5), 4.39 (2H, q, J 7.2 Hz, O-CH2-CH3), 2.29 (s, 3H, 4-CH3), 1.36 (3H, t, 
J 7.2 Hz, O-CH2-CH3); δC (100 MHz, CDCl3) 165.0(C=O), 148.5 (C-6), 145.7 (C-4), 
137.0 (C-2), 131.9 (C-3), 123.0 (C-5), 60.8 (O-CH2-CH3), 17.9 (4-CH3), 12.6 









A mixture of 139 (488 mg, 2.00 mmol, 1.0 equiv.), phenylboronic acid 148 (268 mg, 
2.20 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (231 mg, 0.20 mmol, 
0.1 equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then sodium 
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carbonate solution (2 M aqueous solution; 3.0 mL, 6.00 mmol, 3.0 equiv.) was added 
and the resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(14.3% ethyl acetate-hexane) afforded ethyl 2-phenyl-4-methylnicotinate 149 (425 mg, 
88%) as a colourless oil; Rf 0.21 (16.7% ethyl acetate-hexane); νmax (neat) 2981, 
1722 (C=O), 1604, 1565, 1286, 1250, 775 cm-1; δH (400 MHz, CDCl3) 8.51 (1H, d, J 
5.2 Hz, H-6), 7.52-7.50 (2H, m, H-2’, H-6’), 7.37-7.32 (3H, m, H-3’, H-5’, H-4’), 7.08 
(1H, d, J 5.2 Hz, H-5), 4.06 (2H, q, J 7.2 Hz, O-CH2-CH3), 2.36 (s, 3H, 4-CH3), 0.94 (3H, 
t, J 7.2 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 166.5 (C=O), 154.5 (C-6), 147.4 (C-4), 
143.5 (C-2), 137.8 (C-1’), 127.1 (C-3), 126.4 (C-3’, C-5’), 126.1 (C-2’, C-4’), 
126.0 (C-6’), 121.5 (C-5), 59.2 (O-CH2-CH3), 17.2 (4-CH3), 11.4 (O-CH2-CH3). In 








A mixture of ethyl 2-phenyl-4-methylnicotinate 149 (100 mg, 0.68 mmol, 1.0 equiv.) 
and polyphosphoric acid (9 g, 4.5 mL) was heated at 140 ºC for 5.5 h. The mixture was 
 165 
poured on crushed ice, neutralised with solid potassium carbonate and partitioned 
between ethyl acetate (200 mL) and water (60 mL). The aqueous phase was extracted 
with ethyl acetate (3  200 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (25% ethyl acetate-hexane) 
afforded 1-methyl-4-azafluoren-9-one 107 (62 mg, 78%) as a yellow solid; 
Rf 0.22 (20% ethyl acetate-hexane); mp 127-129 °C; νmax (solid) 1702 (C=O), 1596, 
1564, 1448, 1371, 756 cm-1; δH (400 MHz, CDCl3) 8.35 (d, 1H, J 5.3 Hz, H-3), 7.78 (dd, 
1H, J 7.4, 1.2 Hz, H-5), 7.63 (dd, 1H, J 7.4, 1.2 Hz, H-8), 7.52 (td, 1H, J 7.4, 1.2 Hz, 
H-6), 7.36 (td, 1H, J 7.4, 1.2 Hz, H-7), 6.91 (d, 1H, J 5.3 Hz, H-2), 2.57 (s, 3H, 1-CH3); 
δc (100 MHz, CDCl3) 193.2 (C=O), 165.6 (C-4a), 153.7 (C-3), 147.9 (C-1), 143.9 
(C-4b), 135.7 (C-6), 135.5 (C-8a), 131.5 (C-7), 126.6 (C-2), 126.2 (C-9a), 123.9 (C-8), 











A mixture of 139 (244 mg, 1.00 mmol, 1.0 equiv.), 3-methoxyphenylboronic acid 
(167 mg, 1.10 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (116 mg, 
0.10 mmol, 0.1 equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then 
 166 
sodium carbonate solution (2 M aqueous solution; 1.5 mL, 3 mmol, 3.0 equiv.) was 
added and the resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(14.3% ethyl acetate-hexane) afforded ethyl 2-(3-methoxyphenyl)-4-methylnicotinate 
211 (258 mg, 95%) as a colourless oil; Rf 0.19 (16.7% ethyl acetate-hexane); νmax (neat) 
2984, 1718 (C=O), 1570, 1464, 1275, 1232, 1118, 1072 cm-1; δH (400 MHz, CDCl3) 
8.50 (1H, d, J 5.1 Hz, H-6), 7.25 (1H, t, J 8.0 Hz, H-6’), 7.09-7.06 (3H, m, H-5, H-2’, 
H-5’), 6.88 (1H, ddd, J 8.0, 2.4, 0.8 Hz, H-4’), 4.09 (2H, q, J 7.1 Hz, O-CH2-CH3), 3.77 
(s, 3H, O-CH3), 2.36 (s, 3H, 4-CH3), 0.98 (3H, t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, 
CDCl3) 167.6 (C=O), 158.6 (C-3’), 155.4 (C-6), 148.5 (C-2), 144.7 (C-4), 140.2 (C-1’), 
128.3 (C-5’), 122.7 (C-3), 122.4 (C-5), 119.7 (C-6’), 114.1 (C-4’), 112.2 (C-2’), 60.5 
(O-CH2-CH3), 54.3 (O-CH3), 18.2 (4-CH3), 12.7 (O-CH2-CH3); m/z (ESI) 272 [M+H]
+ 
















A mixture of ethyl 2-(3-methoxyphenyl)-4-methylnicotinate 211 (50 mg, 0.18 mmol, 
1.0 equiv.) and polyphosphoric acid (3 g, 1.5 mL) was heated at 140 ºC for 5.5 h. The 
mixture was poured on crushed ice, neutralised with solid potassium carbonate and 
partitioned between ethyl acetate (80 mL) and water. The aqueous phase was extracted 
with ethyl acetate (3  50 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (25% ethyl acetate-hexane) 
afforded 1-methyl-6-methoxy-4-azafluoren-9-one 108 (14 mg, 33%) as a yellow solid, 
1-methyl-8-methoxy-4-azafluoren-9-one 218 (11 mg, 28%) as a yellow solid and 
1-methyl-6-hydroxy-4-azafluoren-9-one 219 (10 mg, 24%) as a yellow solid.  
 
1-Methyl-6-methoxy-4-azafluoren-9-one 108. Rf 0.41 (40% ethyl acetate-hexane); 
mp 130-132 °C; νmax (solid) 1695 (C=O), 1610, 1570, 1470, 1435, 1360, 1265, 1225, 
1175, 1100, 895, 800 cm-1; 8.35 (d, 1H, J 5.2 Hz, H-3), 7.59 (d, 1H, J 8.2 Hz, H-8), 7.39 
(d, 1H, J 2.4 Hz, H-5), 6.97 (d, 1H, J 5.2 Hz, H-2), 6.84 (dd, 1H, J 8.2, 2.4 Hz, H-7), 
3.88 (s, 3H, O-CH3), 2.59 (s, 3H, Ar-CH3); δc (100 MHz, CDCl3) 193.7 (C=O), 165.7 
(C-4a), 165.3 (C-6), 164.9 (C-3), 164.8 (C-1), 148.5 (C-4b), 127.8 (C-9a), 127.5 (C-8a), 
126.6 (C-8), 126.0 (C-2), 120.1 (C-7), 106.8 (C-5), 53.4 (O-CH3), 17.4 (1-CH3); m/z 
(ESI) 226 [M+H]+ (Found: [M+H]+, 226.0864. C14H11NO2 requires [M+H]
+, 226.0868); 
 168 
HPLC analysis: tR1 = 17.327 min, tR2 = 21.506 min, tR3 = 41.837 min. 
 
1-Methyl-8-methoxy-4-azafluoren-9-one 218. Rf 0.37 (40% ethyl acetate-hexane); 
mp 125-127 °C; νmax (solid) 1700 (C=O), 1585, 1565, 1480, 1275, 1150, 1045, 920, 800 
cm-1; δH (400 MHz, CDCl3) 8.34 (d, 1H, J 5.2 Hz, H-3), 7.49 (dd, 1H, J 8.4, 7.2 Hz, 
H-6), 7.43 (dd, 1H, J 7.2, 0.7 Hz, H-5), 6.93-6.82 (m, 2H, H-2, H-7), 3.94 (s, 3H, 
O-CH3), 2.57 (s, 3H, Ar-CH3); δc (100 MHz, CDCl3) 188.3 (C=O), 166.3 (C-4a), 157.1 
(C-8), 152.5 (C-3), 147.3 (C-1), 141.7 (C-4b), 136.4 (C-6), 126.1 (C-9a), 125.3 (C-2), 
119.7 (C-8a), 114.1 (C-5), 112.9 (C-7), 55.0 (O-CH3), 16.3 (1-CH3); m/z (ESI) 226 




1-Methyl-6-hydroxy-4-azafluoren-9-one 219. Rf 0.26 (40% ethyl acetate-hexane); 
mp 240-241 °C; νmax (solid) 2900, 1710 (C=O), 1605, 1570, 1460, 1370, 1320, 1265, 
1240, 895, 840 cm-1; δH (400 MHz, CDCl3) 8.36 (d, 1H, J 5.2 Hz, H-3), 7.39 (d, 1H, 
J 8.4 Hz, H-8), 7.30 (d, 1H, J 2.4 Hz, H-5), 6.91 (d, 1H, J 5.2 Hz, H-2), 6.83 (dd, 1H, J 
8.4, 2.4 Hz, H-7), 2.56 (s, 3H, Ar-CH3); δc (100 MHz, CDCl3) 194.6 (C=O), 170.3 
(C-4a), 161.7 (C-6), 155.2 (C-3), 148.5(C-1), 148.1 (C-4b), 137.0 (C-8), 129.6 (C-9a), 
129.4 (C-8a), 125.5 (C-2), 116.9 (C-7), 111.9 (C-5), 16.4 (1-CH3); m/z (ESI) 
212 [M+H]+ (Found: [M+H]+, 212.0706. C13H9NO2 requires [M+H]
+, 212.0706); HPLC 















A mixture of 139 (244 mg, 1.00 mmol, 1.0 equiv.), 2-fluorophenylboronic acid (154 mg, 
1.10 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.10 mmol, 
0.1 equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then sodium 
carbonate solution (2 M aqueous solution; 1.5 mL, 3 mmol, 3.0 equiv.) was added and 
the resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(16.7% ethyl acetate-hexane) afforded ethyl 2-(2-fluorophenyl)-4-methylnicotinate 212 
(185 mg, 72%) as a colourless oil; Rf 0.28 (25% ethyl acetate-hexane); νmax (neat) 2976, 
1721 (C=O), 1582, 1445, 1368, 1239, 1116, 1069, 816 cm-1; δH (400 MHz, CDCl3) 8.54 
(1H, d, J 5.0 Hz, H-6), 7.43-7.39 (1H, m, H-6’), 7.13-7.06 (1H, m, H-4’), 7.17-7.13 (2H, 
m, H-3’, H-5), 7.07-7.01 (1H, m, H-5’), 4.06 (2H, q, J 7.1 Hz, O-CH2-CH3), 2.43 (s, 3H, 
4-CH3), 0.94 (3H, t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 166.5 (C=O), 158.7 
(d, 1JCF 247.7 Hz, C-2’), 151.7 (C-6), 148.9 (C-2), 145.4 (C-4), 130.0 (d, 3JCF 6.8 Hz, 
C-6’), 129.3 (d, 3JCF 8.1 Hz, C-4’), 128.9 (C-3), 127.0 (d, 2JCF 20.8 Hz, C-1’), 123.6 
(C-5), 123.1 (d, 4JCF 3.6 Hz, C-5’), 114.4 (d, 2JCF 21.9 Hz, C-3’), 60.3 (O-CH2-CH3), 
19.0 (4-CH3), 12.6 (O-CH2-CH3); δF (376 MHz, CDCl3) -116.7 (s); m/z (ESI) 









A mixture of ethyl 2-(2-fluorophenyl)-4-methylnicotinate 212 (60 mg, 0.23 mmol, 1.0 
equiv.) and polyphosphoric acid (4 g, 2 mL) was heated at 140 ºC for 5.5 h. The 
mixture was poured on crushed ice, neutralised with solid potassium carbonate and 
partitioned between ethyl acetate (80 mL) and water. The aqueous phase was extracted 
with ethyl acetate (3  50 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography 
(1% dichloromethane-methanol) afforded 1-methyl-5-fluoro-4-azafluoren-9-one 110 
(15 mg, 31%) as a yellow solid, with 212 (30 mg, 54%) recovered; 
Rf 0.19 (10% hexane-acetone); mp 180-181 °C; νmax  (solid) 1730 (C=O), 1551, 1523, 
1341, 1292, 1224, 826 cm-1; δH (400 MHz, CDCl3) 8.46 (d, 1H, J 5.3 Hz, H-3), 7.47 (dd, 
1H, J 7.2, 0.6 Hz, H-8), 7.37-7.32 (m, 1H, H-7), 7.25-7.23 (m, 1H, H-6), 6.94 (d, 1H, J 
5.3 Hz, H-2), 2.58 (s, 3H, 1-CH3); δc (100 MHz, CDCl3) 191.2 (C=O), 162.8 (C-4a), 
156.5 (d, 1JCF 259.6 Hz, C-5), 152.6 (C-3), 147.1 (C-1), 131.9 (d, 
3JCF 7.0 Hz, C-7), 
127.5 (d, 3JCF 7.0 Hz, C-8a), 124.9 (C-2), 123.4 (C-9a), 122.7 (d, 
2JCF 21.1 Hz, C-6), 
119.0 (d, 4JCF 3.3 Hz, C-8), 114.6 (d, 
2JCF 21.1 Hz, C-4b), 16.6 (1-CH3); δF (376 MHz, 
CDCl3) -111.1 (s); m/z (ESI) 214 [M+H]
+ (Found: [M+H]+, 214.0666. C13H8NOF 
requires [M+H]+, 214.0668); HPLC analysis: tR1 = 17.428 min, tR2 = 21.810 min, 









A mixture of 139 (244 mg, 1.00 mmol, 1.0 equiv.), 2-methylphenylboronic acid 
(150 mg, 1.10 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 
mmol, 0.1 equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then sodium 
carbonate solution (2 M aqueous solution; 1.5 mL, 3 mmol, 3.0 equiv.) was added and 
the resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(14.3% ethyl acetate-hexane) afforded ethyl 2-(2-methylphenyl)-4-methylnicotinate 213 
(230 mg, 91%) as a colourless oil; Rf 0.34 (16.7% ethyl acetate-hexane); νmax (neat) 
2981, 1725 (C=O), 1579, 1442, 1236, 1131, 1061, 812 cm-1; δH (400 MHz, CDCl3) 
8.49 (1H, d, J 5.1 Hz, H-6), 7.19-7.14 (2H, m, H-5’, H-6’), 7.13-7.06 (3H, m, H-4’, 
H-3’, H-5), 3.92 (2H, q, J 7.1 Hz, O-CH2-CH3), 2.37 (s, 3H, 2’-CH3), 2.11 (s, 3H, 
4-CH3), 0.80 (3H, t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 167.9 (C=O), 157.9 
(C-6), 149.3 (C-2), 145.4 (C-4), 139.5 (C-2’), 136.2 (C-1’), 130.2 (C-3’), 130.1 (C-4’), 
128.5 (C-5’), 128.3 (C-3), 125.2 (C-5), 123.7 (C-6’), 61.1 (O-CH2-CH3), 19.6 (4-CH3), 











A mixture of ethyl 2-(2-methylphenyl)-4-methylnicotinate 213 (60 mg, 0.24 mmol, 1.0 
equiv.) and polyphosphoric acid (4 g, 2 mL) was heated at 140 ºC for 5.5 h. The 
mixture was poured on crushed ice, neutralised with solid potassium carbonate and 
partitioned between ethyl acetate (80 mL) and water. The aqueous phase was extracted 
with ethyl acetate (3  50 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 1-methyl-5-methyl-4-azafluoren-9-one 111 (41 mg, 80%) as a yellow solid; 
Rf 0.61 (16.7% ethyl acetate-hexane); νmax (solid) 2917, 1707 (C=O), 1595, 1560, 1377, 
1272, 1224, 948, 829, 759 cm-1; δH (400 MHz, CDCl3) 8.36 (d, 1H, J 5.3 Hz, H-3), 7.46 
(dd, 1H, J 7.1, 0.6 Hz, H-8), 7.26 (dd, 1H, J 7.6, 0.6 Hz, H-6), 7.21 (d, 1H, J 7.3 Hz, 
H-7), 6.84 (d, 1H, J 5.3 Hz, H-2), 2.73 (s, 3H, 1-CH3), 2.56 (s, 3H, O-CH3); δc 
(100 MHz, CDCl3) 192.7 (C-9), 166.2 (C-4a), 151.3 (C-3), 146.1 (C-1), 138.8 (C-4b), 
136.6 (C-5), 134.5 (C-8a), 134.3 (C-6), 129.1 (C-9a), 125.1 (C-7), 123.9 (C-2), 120.2 
(C-8), 18.0 (1-CH3), 16.4 (5-CH3); m/z (ESI) 210 [M+H]













A mixture of 139 (244 mg, 1 mmol, 1.0 equiv.), 4-fluorophenylboronic acid (154 mg, 
1.1 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 mmol, 0.1 
equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then sodium carbonate 
solution (2 M aqueous solution; 1.5 mL, 3 mmol, 3.0 equiv.) was added and the 
resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(16.7% ethyl acetate-hexane) afforded ethyl 2-(4-fluorophenyl)-4-methylnicotinate 214 
(201 mg, 78%) as a colourless oil; Rf 0.33 (20% ethyl acetate-hexane); νmax (neat) 2985, 
1710 (C=O), 1581, 1486, 1375, 1250, 1172, 1083, 837 cm-1; δH (400 MHz, CDCl3) 8.48 
(1H, d, J 5.1 Hz, H-6), 7.51 (dd, 2H, J 8.8, 5.4 Hz, H-2’, H-6’), 7.10-7.00 (3H, m, H-3’, 
H-5’, H-5), 4.09 (2H, q, J 7.1 Hz, O-CH2-CH3), 2.35 (s, 3H, 4-CH3), 1.00 (3H, t, 
J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 167.6 (C=O), 162.1 (d, 1JCF 248.2 Hz, 
C-4’), 154.5 (C-6), 148.6 (C-2), 144.7 (C-4), 135.1 (d, 4JCF 3.3 Hz, C-1’), 129.2 (d, 3JCF 
8.4 Hz, C-2’, C-6’), 128.2 (C-3), 122.7(C-5), 114.3 (d, 2JCF 21.6 Hz, C-3’, C-5’), 60.5 
(O-CH2-CH3), 18.4 (4-CH3), 12.7 (O-CH2-CH3); δF (376 MHz, CDCl3) -113.1 (s); m/z 










A mixture of ethyl 2-(4-fluorophenyl)-4-methylnicotinate 214 (60 mg, 0.23 mmol, 
1.0 equiv.) and polyphosphoric acid (4 g, 2 mL) was heated at 140 ºC for 5.5 h. The 
mixture was poured on crushed ice, neutralised with solid potassium carbonate and 
partitioned between ethyl acetate (80 mL) and water. The aqueous phase was extracted 
with ethyl acetate (3  50 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (33.3% ethyl acetate-hexane) 
afforded 1-methyl-7-fluoro-4-azafluoren-9-one 112 (13 mg, 26%) as a yellow solid, 
with 214 (35 mg, 58%) recovered; Rf 0.54 (1.2% methanol-dichloromethane); mp 
160-162 °C; νmax (solid) 1725 (C=O), 1610, 1583, 1310, 1264, 1233, 875 cm-1; δH 
(400 MHz, CDCl3) δH (400 MHz, CDCl3) 8.34 (d, 1H, J 5.3 Hz, H-3), 7.74 (dd, 1H, J 
7.6, 4.6 Hz, H-5), 7.31 (dd, 1H, J 7.6, 2.4 Hz, H-8), 7.21 (td, 1H, J 7.6, 2.4 Hz, H-6), 
6.90 (d, 1H, J 5.3 Hz, H-2), 2.56 (s, 3H, 1-CH3); δc (100 MHz, CDCl3) 190.7 (C-9), 
163.7 (d, 1JCF 252.3 Hz, C-7), 163.6 (C-4a), 151.9 (C-3), 147.0 (C-1), 137.8 (C-9a), 
136.2 (d, 3JCF 7.6 Hz, C-8a), 125.2 (d, 
4JCF 2.5 Hz, C-4b), 124.6 (C-2), 121.6 (d, 
3JCF 7.6 
Hz, C-5), 120.4 (d, 2JCF 23.4 Hz, C-6), 110.4 (d, 
2JCF 23.9 Hz, C-8), 16.4 (1-CH3); δF 
(376 MHz, CDCl3) -108.5 (s); m/z (ESI+) 214 [M+H]












A mixture of 139 (244 mg, 1 mmol, 1.0 equiv.), 4-methylphenylboronic acid (150 mg, 
1.1 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 mmol, 0.1 
equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then sodium carbonate 
solution (2 M aqueous solution; 1.5 mL, 3 mmol, 3.0 equiv.) was added and the 
resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(16.7% ethyl acetate-hexane) afforded ethyl 2-(4-methylphenyl)-4-methylnicotinate 215 
(225 mg, 89%) as a colourless oil; Rf 0.35 (20% ethyl acetate-hexane); νmax (neat) 2981, 
1723 (C=O), 1582, 1446, 1239, 1131, 1066, 826 cm-1; δH (400 MHz, CDCl3) 8.48 (1H, 
d, J 5.0 Hz, H-6), 7.41 (d, 2H, J 8.1, H-2’, H-6’), 7.15 (d, 2H, J 8.1, H-3’, H-5’), 7.04 
(1H, d, J 5.0 Hz, H-5), 4.09 (2H, q, J 7.1 Hz, O-CH2-CH3), 2.34 (s, 3H, 2’-CH3), 2.31 (s, 
3H, 4-CH3),1.00 (3H, t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 167.2 (C=O), 
154.9 (C-6), 147.9 (C-2), 143.8 (C-4), 136.9 (C-1’), 135.5 (C-4’), 127.5 (C-3’, C-5’), 
127.4 (C-2’, C-6’), 126.5 (C-3), 121.6 (C-5), 59.8 (O-CH2-CH3), 19.6 (4’-CH3), 17.8 
(4-CH3), 12.1 (O-CH2-CH3); m/z (ESI) 256 [M+H]












A mixture of ethyl 2-(4-methylphenyl)-4-methylnicotinate 215 (60 mg, 0.24 mmol, 1.0 
equiv.) and polyphosphoric acid (4 g, 2 mL) was heated at 140 ºC for 5.5 h. The 
mixture was poured on crushed ice, neutralised with solid potassium carbonate and 
partitioned between ethyl acetate (80 mL) and water. The aqueous phase was extracted 
with ethyl acetate (3  50 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (20% ethyl acetate-hexane) 
afforded 1-methyl-7-methyl-4-azafluoren-9-one 113 (37 mg, 75%) as a yellow solid; 
Rf 0.31 (20% ethyl acetate-hexane); mp 151-153 °C; νmax (solid) 1715 (C=O), 1599, 
1568, 1379, 1280, 1246, 830 cm-1; δH (400 MHz, CDCl3) 8.31 (d, 1H, J 5.3 Hz, H-3), 
7.65 (d, 1H, J 7.6 Hz, H-5), 7.43 (d, 1H, J 0.8 Hz, H-8), 7.31 (dd, 1H, J 7.6, 0.8 Hz, 
H-6), 6.86 (d, 1H, J 5.3 Hz, H-2), 2.55 (s, 3H, 1-CH3), 2.35 (s, 3H, 7-CH3); δc (100 MHz, 
CDCl3) 192.2 (C-9), 164.1 (C-4a), 151.3 (C-3), 146.1 (C-1), 140.0 (C-4b), 139.1 (C-7), 
134.2 (C-8a), 133.9 (C-6), 124.7 (C-8), 124.2 (C-9a), 123.0 (C-5), 119.3 (C-2), 20.3 
(7-CH3), 16.0 (1-CH3); m/z (ESI) 210 [M+H]
+ (Found: [M+H]+, 210.0909. C14H11NO 










A mixture of 139 (100 mg, 0.41 mmol, 1.0 equiv.), 2-hydroxyphenylboronic acid 
(62 mg, 0.45 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) (47 mg, 
0.04 mmol, 0.1 equiv.) and tetrahydrofuran (20 mL) was stirred at 80 ºC for 1 h, then 
sodium carbonate solution (2 M aqueous solution; 0.62 mL, 1.23 mmol, 3.0 equiv.) was 
added and the resulting mixture stirred at 80 ºC for 18 h. The mixture was diluted with 
dichloromethane (100 mL) and water (20 mL). The layers were separated and the 
organic phase washed with water (20 mL) and brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  100 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(6.7% ethyl acetate-hexane) afforded 4-methylpyrido[3,2-c]coumarin 159 (82 mg, 92%) 
as a white solid. Rf 0.58 (25% ethyl acetate-hexane); mp 156-158 °C; νmax (solid) 2957, 
1731 (C=O), 1580, 1506, 1472, 762 cm-1; δH (400 MHz, CDCl3) 8.74 (d, 1H, J 4.9 Hz, 
H-2), 8.53 (dd, 1H, J 7.4, 1.2 Hz, H-10), 7.50 (td, 1H, J 7.4, 1.2 Hz, H-8), 7.33-7.27 (m, 
2H, H-7, H-9), 7.24 (d, 1H, J 4.9 Hz, H-3), 2.84 (s, 3H, 4-CH3); δc (100 MHz, CDCl3) 
159.5 (C=O), 153.2 (C-2), 152.5 (C-6a), 152.0 (C-10b), 151.4 (C-4), 131.1 (C-10a), 
125.7 (C-8a), 124.3 (C-10), 123.6 (C-8), 118.5 (C-9), 115.7 (C-3), 115.5 (C-7), 22.0 
(4-CH3); m/z (ESI) 212 [M+H]
+ (Found: [M+H]+, 212.0704. C13H9NO2 requires [M+H]
+, 













To a solution of 2-bromo-6-methoxyphenol 173 (1.50 g, 7.39 mmol, 1.0 equiv.) in 
dichloromethane (20 mL) was added triethylamine (2.05 mL, 14.78 mmol, 2.0 equiv.) 
and methanesulfonyl chloride (694 µL, 8.87 mmol, 1.2 equiv.) at 0 ºC. The mixture was 
stirred for 6 h at rt. The mixture was partitioned between dichloromethane (200 mL) 
and water (50 mL). The aqueous phase was extracted with dichloromethane 
(3  200 mL) and the combined organic phases dried (Na2SO4). Concentration under 
reduced pressure and chromatography (20% ethyl acetate-hexane) afforded 
2-bromo-6-methoxyphenyl methanesulfonate 174 (1.84 g, 89%) as a white solid; 
Rf 0.27 (25% ethyl acetate-hexane); mp 71-72 °C; νmax (solid) 2920, 1469, 1366, 1275, 
1252, 1161, 1029, 965, 800 cm-1; δH (400 MHz, CDCl3) 7.14 (1H, dd, J 8.2, 1.2 Hz, 
H-3), 7.05 (1H, t, J 8.2 Hz, H-4), 6.88 (1H, dd, J 8.4, 1.2 Hz, H-5), 3.84 (s, 3H, O-CH3), 
3.33 (s, 3H, SO2-CH3); δC (100 MHz, CDCl3) 153.8 (C-6), 139.5 (C-1), 131.3 (C-3), 
123.7 (C-4), 121.5 (C-2), 113.3 (C-5), 56.8 (O-CH3), 40.7 (SO2 -CH3); m/z (ESI) 








2-Methoxy-6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl methanesulfonate  
 
 
A mixture of 2-bromo-6-methoxyphenyl methanesulfonate 174 (140 mg, 0.50 mmol, 1.0 
equiv.), bis(neopentyl glycolato)diboron (136 mg, 0.60 mmol, 1.2 equiv.), potassium 
acetate (147 mg, 1.50 mmol, 3.0 equiv.),    
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.025 mmol, 0.05 
equiv.) and dimethyl sulfoxide (5.0 mL) was stirred at 80 ºC for 12 h. The reaction 
solution was cooled to rt and poured into ice water. The mixture was partitioned 
between ethyl acetate (200 mL) and water (40 mL). The aqueous phase was extracted 
with ethyl acetate (3  200 mL) and the combined organic phases dried (Na2SO4).            
Concentration under reduced pressure and chromatography (dichloromethane: methanol: 
triethylamine = 80:2:1) gave 
2-methoxy-6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl methanesulfonate 175 
(11 mg, 7%) as a colourless oil and 2,2'-methanesulfonyloxy-3,3'-dimethoxybiphenyl 
176 (72 mg, 36%) as a colourless oil. 
2-Methoxy-6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl methanesulfonate 175. 
Rf 0.26 (dichloromethane: methanol: triethylamine = 80:2:1); νmax (neat) 2891, 1561, 
1408, 1364, 1225, 1162, 1042, 902, 793 cm-1; δH (400 MHz, CDCl3) 7.25 (1H, dd, J 7.6, 
1.6 Hz, H-5), 7.16 (1H, t, J 7.6 Hz, H-4), 6.98 (1H, dd, J 7.6, 1.6 Hz, H-3), 3.81 (s, 3H, 
O-CH3), 3.72 (4H, s, O-CH2-), 3.11 (s, 3H, SO2-CH3), 0.98 (6H, s, C-(CH3)2); 
δC (100 MHz, CDCl3) 150.2 (C-6), 141.2 (C-1), 126.4 (C-3), 126.0 (C-4), 113.9 (C-5), 
112.7 (C-2), 71.3 (O-CH2-), 55.1 (O-CH3), 37.9 (SO2 -CH3), 30.8 (C-(CH3)2), 30.0 
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(C-(CH3)2); m/z (ESI) 315 [M+H]
+ (Found: [M+H]+, 315.1082. C13H19O6SB requires 
[M+H]+, 315.1074). 
 
2,2'-Methanesulfonyloxy-3,3'-dimethoxybiphenyl 176. Rf 0.72 (dichloromethane: 
methanol: triethylamine = 80:2:1); νmax (neat) 2870, 1621, 1534, 1368, 1273, 1246, 
1168, 1035, 954, 785 cm-1; δH (400 MHz, CDCl3) 7.25 (2H, t, J 8.4 Hz, H-5, H-5’), 
7.00-6.96 (4H, m, H-4, H-4’, H-6, H-6’), 3.88 (6H, s, O-CH3  2), 2.70 (6H, s, SO2-CH3  
2); δC (100 MHz, CDCl3) 151.5 (C-3, C-3’), 135.7 (C-2, C-2’), 130.4 (C-1, C-1’), 126.1 
(C-6, C-6’), 122.2 (C-5, C-5’), 111.4 (C-4, C-4’), 55.2 (O-CH3), 38.1 (SO2 -CH3); m/z 









To a mixture of 2-fluoro-3-methoxyphenylboronic acid 243 (2.50 g, 14.71 mmol, 1.0 
equiv.), 139 (3.95 g, 16.18 mmol, 1.1 equiv.), tetrakis(triphenylphosphine)palladium(0) 
(1.87 g, 1.618 mmol, 0.11 equiv.) was added tetrahydrofuran (80 mL). The mixture was 
stirred at 80 ºC for 1 h, then sodium carbonate solution (2 M aqueous solution; 18.4 mL, 
36.8 mmol, 2.5 equiv.) was added and the resulting mixture stirred at 80 ºC for 20 h. 
The reaction solution was cooled to rt and diluted with dichloromethane (1 L) and water 
(100 mL). The layers were separated and the organic phase washed with brine (50 mL). 
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The combined aqueous phases were extracted with dichloromethane (3  500 mL) and 
the combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
chromatography (33.3% ethyl acetate-hexane) afforded ethyl 
2-(2-fluoro-3-methoxyphenyl)-4-methylnicotinate 244 (3.99 g, 94%) as a colourless oil; 
Rf 0.33 (25% ethyl acetate-hexane); νmax (neat) 2970, 1721 (C=O), 1442, 1366, 1268, 
1217, 1121, 1054, 785 cm-1; δH (400 MHz, CDCl3) 8.58 (1H, d, J 5.1 Hz, H-6), 7.19 
(1H, d, J 5.1 Hz, H-5), 7.12 (1H, td, J 8.1, 1.2 Hz, H-6’), 7.03-6.98 (2H, m, H-4’, H-5’), 
4.14 (2H, q, J 7.1 Hz, O-CH2-CH3), 3.89 (s, 3H, O-CH3), 2.47 (s, 3H, 1-CH3), 1.03 (3H, 
t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 167.5 (C=O), 152.5 (C-6), 149.9 (C-2), 
149.8 (d, 1JCF 246.4 Hz, C-2’), 147.8 (d, 2JCF 10.9 Hz, C-3’), 146.5 (C-4), 130.1 (C-3), 
128.8 (d, 2JCF 12.7 Hz, C-1’), 124.8 (C-5), 124.0 (d, 3JCF 4.7 Hz, C-6’), 122.3 (d, 4JCF 
2.0 Hz, C-5’), 129.3 (d, 3JCF 1.9 Hz, C-4’), 61.4 (O-CH2-CH3), 56.6 (O-CH3), 20.2 
(4-CH3), 13.7 (O-CH2-CH3); δF (376 MHz, CDCl3) -139.0 (s); m/z (ESI) 290 [M+H]+ 









A mixture of ethyl 2-(2-fluoro-3-methoxyphenyl)-4-methylnicotinate 244 (2.07 g, 7.16 
mmol, 1.0 equiv.) and polyphosphoric acid (36.8 g, 17.9 mL) was stirred at 130 ºC for 
10.5 h. The mixture was poured on crushed ice, neutralised with saturated potassium 
hydroxide solution and partitioned between chloroform (1 L) and water. The aqueous 
phase was extracted with chloroform (3  1 L) and the combined organic phases dried 
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(Na2SO4). Concentration under reduced pressure and chromatography (1% 
methanol-dichloromethane) afforded 1-methyl-5-fluoro-6-methoxy-4-azafluoren-9-one 
106 (930 mg, 53%) as a yellow solid and 
1-methyl-5-fluoro-6-hydroxy-4-azafluoren-9-one 245 (219 mg, 13%) as a yellow solid. 
1-Methyl-5-fluoro-6-methoxy-4-azafluoren-9-one 106. Rf 0.25 (1% methanol- 
dichloromethane); mp 189-190 °C; νmax (solid) 3022, 1699 (C=O), 1569, 1496, 1271, 
1238, 1084, 992, 796, 776 cm-1; δH (400 MHz, CDCl3) 8.52 (d, 1H, J 5.3 Hz, H-3), 7.50 
(d, 1H, J 8.1 Hz, H-8), 7.00 (d, 1H, J 5.3 Hz, H-2), 6.97 (dd, 1H, J 7.9, 7.2 Hz, H-7), 
3.98 (s, 3H, O-CH3), 2.64 (s, 3H, 1-CH3); δc (100 MHz, CDCl3) 191.1 (C=O), 162.8 
(C-4a), 154.7 (d, 2JCF 10.2 Hz, C-6), 153.0 (C-3), 147.8 (C-1), 147.1 (d, 
1JCF 260.4 Hz, 
C-5), 132.2 (d, 2JCF 10.0 Hz, C-4b), 129.0 (d, 
3JCF 9.0 Hz, C-8a), 128.7 (d, 
3JCF 12.2 Hz, 
C-7), 127.1 (C-9a), 126.1 (C-2), 121.1 (d, 4JCF 3.5 Hz, C-8), 56.9 (O-CH3), 
17.5 (1-CH3); δF (376 MHz, CDCl3) -137.7 (s); m/z (ESI) 244 [M+H]+ (Found: [M+H]+, 
244.0766. C14H10NO2F requires [M+H]
+, 244.0768); HPLC analysis: tR1 = 16.688 min, 
tR2 = 20.580 min, tR3 = 39.533 min.    
 
1-Methyl-5-fluoro-6-hydroxy-4-azafluoren-9-one 245. Rf 0.07 (1% methanol- 
dichloromethane); mp 237-238 °C; νmax (solid) 3080, 1712 (C=O), 1574, 1511, 1277, 
1263, 1238, 990, 818, 797, 770, 668 cm-1; δH (400 MHz, CDCl3) 8.43 (d, 1H, J 5.3 Hz, 
H-3), 7.38 (d, 1H, J 8.0 Hz, H-8), 7.00 (d, 1H, J 5.3 Hz, H-2), 6.96 (t, 1H, J 7.6 Hz, 
H-7), 2.66 (s, 3H, 1-CH3); δc (100 MHz, CDCl3) 190.8 (C=O), 162.1 (C-4a), 152.9 (d, 
2JCF 12.8 Hz, C-6), 151.3 (C-3), 148.5 (C-1), 146.1 (d, 
1JCF 255.5 Hz, C-5), 128.6 (d, 
2JCF 9.7 Hz, C-4b), 127.2 (C-9a), 127.0 (d, 
3JCF 4.7 Hz, C-8a), 126.2 (C-2), 121.6 (d, 
4JCF 2.8 Hz, C-8), 119.6 (d, 
3JCF 2.8 Hz, C-7), 17.1 (1-CH3); δF (376 MHz, CDCl3) 
-136.2 (s); m/z (ESI) 230 [M+H]+ (Found: [M+H]+, 230.0611. C13H8NO2F requires 
[M+H]+, 230.0617); HPLC analysis: tR1 = 14.884 min, tR2 = 17.845 min, 








To a solution of 1-methyl-5-fluoro-6-methoxy-4-azafluoren-9-one 106 (897 mg, 3.68 
mmol) in acetic acid (68 mL), 30% H2O2 (6.8 mL) was added at rt. The mixture was 
stirred at 80 ºC for 9 h. Then the reaction solution was cooled to rt and neutralised with 
sodium carbonate solid in the ice bath. The mixture was partitioned between 
chloroform (500 mL) and water (40 mL). The aqueous phase was extracted with 
chloroform (3  500 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (2.5% 
methanol-dichloromethane) afforded 1-methyl-5-fluoro-6-methoxy-4-azafluoren-9-one 
N-oxide 246 (582 mg, 61%) as an orange solid; Rf 0.31 (50% acetone-hexane); mp 
236-238 °C; νmax (solid) 3031, 1708(C=O), 1583, 1442, 1268, 1225, 1076, 898, 787, 
769 cm-1; δH (400 MHz, CDCl3) 8.14 (d, 1H, J 4.3 Hz, H-3), 7.52 (d, 1H, J 8.1 Hz, H-8), 
7.01 (d, 1H, J 4.4 Hz, H-2), 6.93 (t, 1H, J 7.1 Hz, H-7), 3.93 (s, 3H, O-CH3), 2.60 (s, 
3H, 1-CH3); δc (100 MHz, CDCl3 + CD3OD) 187.7 (C=O), 156.0 (d, 2JCF 12.2 Hz, C-6), 
149.4 (C-4a), 146.7 (d, 1JCF 270.1 Hz, C-5), 143.9 (C-3), 139.2 (C-1), 129.3 (C-2), 
127.6 (C-9a), 124.2 (d, 3JCF 3.3 Hz, C-8a), 121.9 (d, 
3JCF 12.2 Hz, C-7), 119.4 (d, 
2JCF 
13.6 Hz, C-4b), 114.3 (d, 4JCF 1.5 Hz, C-8), 56.7 (O-CH3), 16.3 (1-CH3); δF (376 MHz, 











A mixture of 1-methyl-5-fluoro-6-methoxy-4-azafluoren-9-one N-oxide 246 (141 mg, 
0.55 mmol) and phosphoric trichloride (11.0 mL) was stirred at 100 ºC for 1 h. Then 
the reaction solution was cooled to rt. Ice water was added and the mixture neutralised 
with sodium carbonate solid. The resulting mixture was partitioned between 
dichloromethane (500 mL) and water. The aqueous phase was extracted with 
dichloromethane (3  250 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (33.3% 
dichloromethane-hexane) afforded 
1-methyl-3-chloro-5-fluoro-6-methoxy-4-azafluoren-9-one 115 (51 mg, 34%) as a 
yellow solid, 1-methyl-2-chloro-5-fluoro-6-methoxy-4-azafluoren-9-one 247 (26 mg, 
17%) as a yellow solid and 1-chloromethyl-5-fluoro-6-methoxy-4-azafluoren-9-one 248 
(28 mg, 18%) as a yellow solid. 
 
1-Methyl-3-chloro-5-fluoro-6-methoxy-4-azafluoren-9-one 115. Rf 0.43 
(dichloromethane); mp 202-204 °C; νmax (solid) 2926, 1710 (C=O), 1561, 1500, 1372, 
1281, 1240, 898, 791 cm-1; δH (400 MHz, CDCl3) 7.50 (d, 1H, J 8.1 Hz, H-8), 7.06 (s, 
1H, H-2), 6.93 (dd, 1H, J 8.0, 7.0 Hz, H-7), 3.99 (s, 3H, O-CH3), 2.62 (s, 3H, 1-CH3); 
δc (100 MHz, CDCl3) 189.9 (C=O), 163.8 (C-4a), 155.8 (C-3), 154.8 (d, 2JCF 10.0 Hz, 
C-6), 149.8 (C-1), 147.1 (d, 1JCF 264.1 Hz, C-5), 128.6 (d, 
3JCF 4.4 Hz, C-8a), 128.2 (d, 
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2JCF 22.9 Hz, C-4b), 125.8 (d, 
3JCF 8.2 Hz, C-7), 125.7 (C-9a), 121.2 (d, 
4JCF 3.5 Hz, 
C-8), 114.3 (C-2), 57.0 (O-CH3), 17.3 (1-CH3); δF (376 MHz, CDCl3) -135.7 (s); m/z 




1-Methyl-2-chloro-5-fluoro-6-methoxy-4-azafluoren-9-one 247. Rf 0.37 
(dichloromethane); mp 170-172 °C; νmax (solid) 2938, 1709 (C=O),  1565, 1487, 1374, 
1269, 1136, 1061, 789 cm-1; δH (400 MHz, CDCl3) 8.57 (s, 1H, H-3), 7.51 (dd, 1H, J 
8.0, 0.4 Hz, H-8), 6.97 (dd, 1H, J 8.0, 7.1 Hz, H-7), 3.99 (s, 3H, O-CH3), 2.70 (s, 3H, 
1-CH3); δc (100 MHz, CDCl3) 190.0 (C=O), 160.9 (C-4a), 154.9 (d, 2JCF 10.1 Hz, C-6), 
152.2 (d, 1JCF 227.6 Hz, C-5), 152.1 (C-3), 145.8 (C-1), 133.9 (C-2), 128.4 (d, 
2JCF 24.5 
Hz, C-4b), 127.8 (C-9a), 124.9 (d, 3JCF 4.9 Hz, C-7), 124.1 (d, 
3JCF 4.6 Hz, C-8a), 121.5 
(d, 4JCF 3.6 Hz, C-8), 56.9 (O-CH3), 13.9 (1-CH3); δF (376 MHz, CDCl3) -137.6 (s); m/z 




1-Chloromethyl-5-fluoro-6-methoxy-4-azafluoren-9-one 248. Rf 0.30 
(dichloromethane); mp 176-178 °C; νmax (solid) 2960, 1707 (C=O), 1568, 1508, 1373, 
1264, 1226, 1048, 794, 730 cm-1; δH (400 MHz, CDCl3) 8.64 (d, 1H, J 5.4 Hz, H-3), 
7.47 (d, 1H, J 8.1 Hz, H-8), 7.33 (d, 1H, J 5.4 Hz, H-2), 6.88 (dd, 1H, J 7.9, 7.1 Hz, 
H-7), 4.99 (2H, s, 1-ClCH2), 3.99 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 189.0 (C=O), 
161.6 (C-4a), 153.9 (d, 2JCF 10.0 Hz, C-6), 153.3 (C-3), 146.0 (d, 
1JCF 262.7 Hz, C-5), 
144.3 (C-1), 128.0 (d, 2JCF 9.1 Hz, C-4b), 127.0 (d, 
3JCF 6.2 Hz, C-8a), 124.4 (C-9a), 
122.2 (C-2), 120.5 (d, 3JCF 3.6 Hz, C-7), 112.9 (d, 
4JCF 1.4 Hz, C-8), 55.7 (O-CH3), 
38.5 (1-CH2); δF (376 MHz, CDCl3) -137.2 (s); m/z (ESI) 278 [M+H]+ (Found: [M+H]+, 












To a mixture of 1-methyl-3-chloro-5-fluoro-6-methoxy-4-azafluoren-9-one 115 (42 mg, 
0.15 mmol, 1.0 equiv.), sodium methoxide (123 mg, 2.27 mmol, 15.0 equiv.), 
anhydrous methanol (5.0 mL) was added at rt. The resulting solution was refluxed for 4 
h, then cooled to rt and water (25 mL) was added. The mixture was extracted with 
dichloromethane (3  250 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography  (14.3%  acetone-hexane) 
afforded 1-methyl-3-methoxy-5-fluoro-6-methoxy-4- azafluoren-9-one 116 (21 mg, 
51%) as a yellow solid; Rf 0.30 (14.3% acetone-hexane); mp 220-221 °C; νmax (solid) 
2926, 1693 (C=O), 1560, 1500, 1364, 1280, 1066, 790, 778 cm-1; δH (400 MHz, CDCl3) 
7.41 (d, 1H, J 8.0 Hz, H-8), 6.95 (dd, 1H, J 8.0, 7.1 Hz, H-7), 6.38 (s, 1H, H-2), 4.01 (s, 
3H, 6-O-CH3), 3.96 (s, 3H, 3-O-CH3), 2.55 (s, 3H, 1-CH3); δc (100 MHz, CDCl3) 190.6 
(C=O), 168.1 (C-3), 163.8 (C-4a), 154.1 (d, 2JCF 10.1 Hz, C-6), 149.8 (C-1), 146.8 (d, 
1JCF 262.0 Hz, C-5), 129.3 (d, 
3JCF 7.1 Hz, C-8a), 128.4 (d, 
2JCF 9.0 Hz, C-4b), 121.4 
(C-9a), 120.2 (d, 4JCF 3.5 Hz, C-8), 113.2 (d, 
3JCF 4.2 Hz, C-7), 111.0 (C-2), 56.8 
(6-O-CH3), 54.4 (3-O-CH3), 17.8 (1-CH3); δF (376 MHz, CDCl3) -138.4 (s); m/z (ESI) 
274 [M+H]+ (Found: [M+H]+, 274.0874. C13H8NO3F requires [M+H]
+, 274.0874); 










To a mixture of 2-fluoro-3-methoxyphenylboronic acid 243 (765 mg, 4.50 mmol, 1.1 
equiv.), 260 (940 mg, 4.09 mmol, 1.0 equiv.), tetrakis(triphenylphosphine)palladium(0) 
(473 mg, 0.41 mmol, 0.1 equiv.) was added tetrahydrofuran (20 mL). The mixture was 
stirred at 80 ºC for 1 h, then potassium carbonate solution (2 M aqueous solution; 
5.12 mL, 10.24 mmol, 2.5 equiv.) was added and the resulting mixture stirred at 80 ºC 
for 25 h. The reaction solution was cooled to rt and diluted with dichloromethane 
(500 mL) and water (50 mL). The layers were separated and the organic phase washed 
with brine (50 mL). The combined aqueous phases were extracted with dichloromethane 
(3  500 mL) and the combined organic phases dried (Na2SO4). Concentration under 
reduced pressure and chromatography (44.4% ethyl acetate-hexane) afforded ethyl 
2-(2-fluoro-3-methoxyphenyl)-4-methoxy-6-methylnicotinate 261 (1.13 g, 86%) as a 
colourless oil; Rf 0.24 (44.4% ethyl acetate-hexane); νmax (neat) 2943, 1720 (C=O), 
1575, 1484, 1351, 1274, 1207, 1040, 790, 765 cm-1; δH (400 MHz, CDCl3) 7.11-7.05 
(1H, m, H-6’), 6.99-6.94 (2H, m, H-4’, H-5’), 6.74 (1H, s, H-5), 4.10 (2H, q, J 7.1 Hz, 
O-CH2-CH3), 3.90 (s, 3H, 3’-O-CH3), 3.87 (s, 3H, 4-O-CH3), 2.58 (s, 3H, 6-CH3), 0.99 
(3H, t, J 7.1 Hz, O-CH2-CH3); δc (100 MHz, CDCl3) 166.8 (C=O), 166.0 (C-4), 163.8 
(C-6), 161.5 (d, 2JCF 14.5 Hz, C-3’), 153.0 (C-2), 149.8 (d, 1JCF 248.2 Hz, C-2’), 128.3 
(d, 3JCF 12.7 Hz, C-6’), 123.9 (d, 3JCF 11.3 Hz, C-4’), 122.2 (d, 4JCF 1.9 Hz, C-5’), 117.7 
(d, 2JCF 23.1 Hz, C-1’), 113.9 (C-5), 105.2 (C-3), 61.3 (O-CH2-CH3), 56.5 (3’-O-CH3), 
56.0 (4’-O-CH3), 25.3 (6-CH3), 13.7 (O-CH2-CH3); δF (376 MHz, CDCl3) -138.9 (s); 












To a solution of 2-chloro-6-methylnicotinic acid 256 (5.67 g, 33.0 mmol, 1.0 equiv.) in 
dry N,N-dimethylformamide (49 mL) was added anhydrous potassium carbonate (6.80 
g, 49.6 mmol, 1.5 equiv.) and iodomethane (3.1 mL, 49.6 mmol, 1.5 equiv.) at 0 ºC. The 
mixture was stirred at rt for 18 h. After removal of the solvent in vacuo, the residue was 
partitioned between dichloromethane (450 mL) and water (50 mL). The aqueous phase 
was extracted with dichloromethane (2  450 mL). The combined organic phases were 
dried (Na2SO4). Concentration under reduced pressure and chromatography (11.8% ethyl 
acetate-hexane) afforded 2-chloro-6-methylnicotinate (6.02 g, 98%) as a white solid; 
Rf 0.36 (16.7% ethyl acetate-hexane); mp 138-140 °C; νmax (solid) 2974, 1733 
(C=O), 1561, 1354, 1280, 1109, 1058, 867 cm-1; δH (400 MHz, CDCl3) 8.09 (1H, d, J 
7.9 Hz, H-4), 7.16 (1H, d, J 7.9 Hz, H-5), 3.94 (3H, s, O-CH3), 2.59 (s, 3H, 6-CH3); δc 
(100 MHz, CDCl3) 165.1 (C=O), 162.6 (C-6), 149.6 (C-2), 140.9 (C-4), 123.6 (C-3), 
121.8 (C-5), 52.8 (O-CH3), 24.5 (6-CH3); m/z (ESI) 186 [M+H]













A mixture of ethyl 2-(2-fluoro-3-methoxyphenyl)-4-methoxy-6-methylnicotinate 261 
(741 mg, 2.32 mmol, 1.0 equiv.) and polyphosphoric acid (11.6 g, 5.8 mL) was stirred 
at 130 ºC for 11 h. The mixture was poured on crushed ice, neutralised with saturated 
potassium hydroxide solution and partitioned between chloroform (1 L) and water. The 
aqueous phase was extracted with chloroform (3  1 L) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography (1% 
methanol-dichloromethane) afforded 
1-methoxy-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 118 (173 mg, 27%) as a 
yellow solid and 1-methoxy-3-methyl-5-fluoro-6-hydroxy-4-azafluoren-9-one 262 (211 
mg, 35%) as a yellow solid. 
 
1-Methoxy-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 118. Rf 0.52 (3.2% 
methanol-dichloromethane); mp 212-213 °C; νmax (solid) 2948, 1701 (C=O), 1577, 
1504, 1375, 1276, 1213, 1033, 858, 790, 772 cm-1; δH (400 MHz, CDCl3) 7.00 (d, 1H, J 
8.0 Hz, H-8), 6.97 (t, 1H, J 8.0 Hz, H-7), 6.61 (s, 1H, H-2), 4.00 (s, 3H, 6-O-CH3), 3.96 
(s, 3H, 1-O-CH3), 2.64 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 188.3 (C=O), 167.2 (C-1), 
165.0 (C-4a), 163.4 (C-3), 154.2 (d, 2JCF 10.3 Hz, C-6), 147.0 (d, 
1JCF 262.0 Hz, C-5), 
128.8 (d, 2JCF 8.8 Hz, C-4b), 128.7 (d, 
3JCF 7.3 Hz, C-8a), 120.7 (d, 
3JCF 3.5 Hz, C-7), 
114.4 (C-9a), 113.6 (d, 4JCF 1.0 Hz, C-8), 106.9 (C-2), 56.9 (6-O-CH3), 56.1 (1-O-CH3), 
25.8 (1-CH3); δF (376 MHz, CDCl3) -137.4 (s); m/z (ESI) 274 [M+H]+ (Found: [M+H]+, 
274.0874. C15H12NO3F requires [M+H]
+, 274.0880); HPLC analysis: tR1 = 15.559 min, 
tR2 = 18.884 min, tR3 = 34.308 min.  
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1-Methoxy-3-methyl-5-fluoro-6-hydroxy-4-azafluoren-9-one 262. Rf 0.12 (3.2% 
methanol-dichloromethane); mp 282-283 °C; νmax (solid) 3289, 2923, 1691 (C=O), 
1579, 1378, 1237, 1210, 996, 846, 792 cm-1; δH (400 MHz, DMSO-d6) 7.21 (d, 1H, 
J 7.9 Hz, H-8), 6.92-6.82 (m, 2H, H-7, H-2), 3.86 (s, 3H, 3-O-CH3), 2.44 (s, 3H, 
1-CH3); δc (100 MHz, DMSO-d6) 187.1 (C=O), 166.3 (C-1), 163.8 (C-4a), 162.8 
(C-3),152.4 (d, 2JCF 11.3 Hz, C-6), 147.0 (d, 
1JCF 257.8 Hz, C-5), 128.6 (d, 
2JCF 8.7 Hz, 
C-4b), 126.5 (d, 3JCF 3.8 Hz, C-8a), 120.6 (d, 
3JCF 2.1 Hz, C-7), 118.4 (d, 
4JCF 1.5 Hz, 
C-8), 113.1 (C-9a), 107.7 (C-2), 56.0 (1-O-CH3), 24.9 (1-CH3); δF (376 MHz, DMSO-d6) 
-139.3 (s); m/z (ESI) 260 [M+H]+ (Found: [M+H]+, 260.0716. C14H10NO3F requires 
[M+H]+, 260.0723); HPLC analysis: tR1 = 14.278 min, tR2 = 16.881 min, 












To a mixture of 2-fluoro-3-methoxyphenylboronic acid 243 (767 mg, 4.51 mmol, 1.1 
equiv.), 257 (761 mg, 4.10 mmol, 1.0 equiv.), tetrakis(triphenylphosphine)palladium(0) 
(473.8 mg, 0.41 mmol, 0.1 equiv.) was added tetrahydrofuran (20 mL). The mixture 
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was stirred at 80 ºC for 1 h, then potassium carbonate solution (2 M aqueous solution; 
5.12 mL, 10.24 mmol, 2.5 equiv.) was added and the resulting mixture stirred at 80 ºC 
for 24 h. The reaction solution was cooled to rt and diluted with dichloromethane 
(500 mL) and water (50 mL). The layers were separated and the organic phase washed 
with brine (50 mL). The combined aqueous phases were extracted with dichloromethane 
(3  500 mL) and the combined organic phases dried (Na2SO4). Concentration under 
reduced pressure and chromatography (16.7% ethyl acetate-hexane) afforded ethyl 
2-(2-fluoro-3-methoxyphenyl)-6-methylnicotinate 258 (974 mg, 86%) as a colourless 
oil; Rf 0.28 (16.7% ethyl acetate-hexane); νmax (neat) 2959, 1727 (C=O), 1580, 1432, 
1269, 1136, 1082, 1042, 777, 730 cm-1; δH (400 MHz, CDCl3) 8.12 (1H, d, J 8.0 Hz, 
H-6), 7.20 (1H, d, J 8.0 Hz, H-5), 7.17-7.07 (2H, m, H-4’, H-5’), 7.00 (1H, td, J 8.0, 
1.6 Hz, H-5’), 3.87 (s, 3H, COOCH3), 3.72 (s, 3H, 3’-O-CH3), 2.62 (s, 3H, 6-CH3); 
δc (100 MHz, CDCl3) 166.8 (C=O), 161.7 (C-6), 153.5 (C-2), 149.7 (d, 1JCF 246.3 Hz, 
C-2’), 147.3 (d, 2JCF 11.1 Hz, C-3’), 138.3 (C-4), 129.3 (d, 2JCF 12.6 Hz, C-1’), 124.5 
(C-3), 124.0 (d, 3JCF 4.6 Hz, C-6’), 122.1 (C-5), 122.0 (d, 4JCF 2.2 Hz, C-5’), 113.7 (d, 
3JCF 2.0 Hz, C-4’), 56.4 (3’-O-CH3), 52.2 (COOCH3), 24.8 (6-CH3); δF (376 MHz, 
CDCl3) -140.0 (s); m/z (ESI) 276 [M+H]
+ (Found: [M+H]+, 276.1028. C15H14NO3F 


















A mixture of ethyl 2-(2-fluoro-3-methoxyphenyl)-6-methylnicotinate 258 (694 mg, 
2.52 mmol, 1.0 equiv.) and polyphosphoric acid (12.6 g, 6.3 mL) was stirred at 130 ºC 
for 11 h. The mixture was poured on crushed ice, neutralised with saturated potassium 
hydroxide solution and partitioned between chloroform (1 L) and water. The aqueous 
phase was extracted with chloroform (3  1 L) and the combined organic phases dried 
(Na2SO4). Concentration under reduced pressure and chromatography (0.66% 
methanol-dichloromethane) afforded 5-fluoro-3-methyl-6-methoxy-4- azafluoren-9-one 
114 (178 mg, 29%) as a yellow solid and 
5-fluoro-3-methyl-6-hydroxy-4-azafluoren-9-one 259 (141 mg, 24%) as a yellow solid.  
 
5-Fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 114. Rf 0.68 (2.4% methanol- 
dichloromethane); mp 159-160 °C; νmax (solid) 2958, 1716 (C=O), 1577, 1502, 1394, 
1279, 1117, 846, 790, 769, 693 cm-1; δH (400 MHz, CDCl3) 7.78 (d, 1H, J 7.7 Hz, H-1), 
7.49 (d, 1H, J 8.1 Hz, H-8), 7.08 (d, 1H, J 7.7 Hz, H-2), 6.97 (t, 1H, J 8.0 Hz, H-7), 
3.97 (s, 3H, O-CH3), 2.67 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 189.8 (C=O), 165.0 
(C-4a), 161.8 (C-3), 154.8 (d, 2JCF 10.2 Hz, C-6), 149.9 (d, 
1JCF 246.4 Hz, C-5), 138.6 
(d, 2JCF 20.8 Hz, C-4b), 132.2 (d, 
3JCF 10.0 Hz, C-8a), 131.6 (C-1), 128.7 (d, 
3JCF 8.2 Hz, 
C-7), 127.1 (C-9a), 122.9 (C-2), 121.3 (d, 4JCF 3.5 Hz, C-8), 25.4 (3-CH3); δF (376 MHz, 
CDCl3) -137.2 (s); m/z (ESI) 244 [M+H]
+ (Found: [M+H]+, 244.0769. C14H10NO2F 




5-Fluoro-3-methyl-6-hydroxy-4-azafluoren-9-one 259. Rf 0.17 (2.4% methanol- 
dichloromethane); mp 212-213 °C; νmax (solid) 3237, 1719 (C=O), 1579, 1478, 1385, 
1269, 1070, 972, 786, 726, 683 cm-1; δH (400 MHz, CDCl3 + CD3OD) 7.94 (d, 1H, J 
8.0 Hz, H-1), 7.55 (d, 1H, J 7.7 Hz, H-8), 6.90 (d, 1H, J 7.7 Hz, H-2), 6.73 (t, 1H, J 7.7 
Hz, H-7), 2.40 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 186.8 (C=O), 165.3 (C-3), 164.1 
(C-4a), 154.7 (d, 2JCF 10.0 Hz, C-6), 147.1 (d, 
1JCF 263.3 Hz, C-5), 141.6 (C-1), 128.5 
(d, 3JCF 4.8 Hz, C-8a), 128.2 (d, 
2JCF 8.9 Hz, C-4b), 124.2 (C-2), 123.3 (C-9a), 121.4 (d, 
3JCF 3.6 Hz, C-7), 114.2 (d, 
4JCF 1.2 Hz, C-8), 56.9 (O-CH3), 25.0 (3-CH3); δF (376 MHz, 
CDCl3) -136.5 (s); m/z (ESI) 230 [M+H]
+ (Found: [M+H]+, 230.0611. C13H8NO2F 









To a mixture of 243 (8.00 g, 34.07 mmol, 1.0 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (1.77 g, 1.54 mmol, 0.045 equiv.) and cesium 
carbonate (19.99 g, 61.38 mmol, 1.8 equiv.) was added acetonitrile (110 mL) and water 
(22 mL). The mixture was stirred at rt for 10 min, then 
2-fluoro-3-methoxyphenylboronic acid 243 (6.37 g, 37.48 mmol, 1.1 equiv.) in 
dimethoxyethane (110 mL) was added and the resulting mixture stirred at 80 ºC for 
16 h. The reaction solution was cooled to rt and diluted with dichloromethane (1 L) and 
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water (100 mL). The layers were separated and the organic phase washed with brine 
(50 mL). The combined aqueous phases were extracted with dichloromethane 
(3  500 mL) and the combined organic phases dried (Na2SO4). Concentration under 
reduced pressure and chromatography (14.3% acetone-hexane) afforded ethyl 
4-chloro-2-(2-fluoro-3-methoxyphenyl)-6-methylnicotinate 264 (9.15 g, 83%) as a 
white solid; Rf 0.30 (14.3% acetone-hexane); mp 95-96 °C; νmax (solid) 2972, 1732 
(C=O), 1570, 1488, 1370, 1273, 1146, 1078, 859, 785, 753 cm-1; δH (400 MHz, CDCl3) 
7.29 (1H, s, H-5), 7.14-7.11 (1H, m, H-6’), 7.05-6.97 (2H, m, H-4’, H-5’), 4.19 (2H, q, 
J 7.1 Hz, O-CH2-CH3), 3.90 (s, 3H, O-CH3), 2.62 (s, 3H, CH3), 1.09 (3H, t, J 7.1 Hz, 
O-CH2-CH3); δc (100 MHz, CDCl3) 165.3 (C=O), 160.4 (C-6), 153.2 (C-2), 149.8 (d, 
1JCF 248.8 Hz, C-2’), 147.9 (d, 2JCF 10.7 Hz, C-3’), 142.1 (C-4), 127.7 (d, 2JCF 12.6 Hz, 
C-1’), 127.3 (C-3), 124.0 (d, 3JCF 4.8 Hz, C-6’), 123.3 (C-5), 122.1 (d, 4JCF 1.6 Hz, 
C-5’), 114.2 (d, 3JCF 1.9 Hz, C-4’), 61.9 (O-CH2-CH3), 56.5 (O-CH3), 24.5 (6-CH3), 
13.7 (O-CH2-CH3); δF (376 MHz, CDCl3) -138.3 (s); m/z (ESI) 324 [M+H]+ (Found: 










A mixture of ethyl 4-chloro-2-(2-fluoro-3-methoxyphenyl)-6-methylnicotinate 164 
(3.00 g, 10.8 mmol) and Eaton’s reagent (21 mL) was stirred at 110 ºC for 30 h. Then 
reaction mixture was cooled to rt and crushed ice was added. The resulting mixture was 
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neutralised with saturated potassium hydroxide solution and partitioned between 
chloroform (1 L) and water. The aqueous phase was extracted with chloroform and 
tetrahydrofuran (3:1, 3  1 L) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (13.3% acetone-hexane) 
afforded 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (1.42 g, 55%) 
as a yellow solid; Rf 0.36 (14.3% acetone-hexane); mp 204-205 °C; νmax (solid) 2954, 
1712 (C=O), 1575, 1505, 1373, 1286, 1242, 1056, 835, 789, 760 cm-1; δH (400 MHz, 
CDCl3) 7.51 (dd, 1H, J 8.0, 0.4 Hz, H-8), 7.03 (s, 1H, H-2), 6.93 (dd, 1H, J 8.0, 7.1 Hz, 
H-7), 3.98 (s, 3H, O-CH3), 2.64 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 186.8 (C=O), 
165.3 (C-3), 164.1 (C-4a), 154.7 (d, 2JCF 10.0 Hz, C-6), 147.1 (d, 
1JCF 263.3 Hz, C-5), 
141.6 (C-1), 128.5 (d, 3JCF 4.8 Hz, C-8a), 128.2 (d, 
2JCF 8.9 Hz, C-4b), 124.2 (C-2), 
123.3 (C-9a), 121.4 (d, 3JCF 3.6 Hz, C-7), 114.2 (d, 
4JCF 1.2 Hz, C-8), 56.9 (O-CH3), 
25.0 (3-CH3); δF (376 MHz, CDCl3) -136.4 (s); m/z (ESI) 278 [M+H]+ (Found: [M+H]+, 
278.0381. C14H9NO2FCl requires [M+H]
+, 278.0379); HPLC analysis: tR1 = 16.120 min, 











A mixture of 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (100 mg, 
0.36 mmol, 1.0 equiv.), 295 (418 µL, 2.16 mmol, 6.0 equiv.), phenol (203 mg, 
2.16 mmol, 6.0 equiv.) and sodium iodide (10 mg) was stirred at 160 ºC for 2 h. After 
being cooled to rt, sodium hydroxide solution (1 M, 20 mL) was added to the reaction 
mixture. The mixture was extracted with chloroform (3  250 mL) and the combined 
organic phases dried (Na2SO4). Concentration under reduced pressure and aluminium 
oxide column chromatography (0.5% methanol-dichloromethane) afforded 
1-(4-diethylamino-1-methyl-butylamino)-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-
one 122 (48 mg, 33%) as a yellow oil;  Rf 0.19 (0.25% methanol-dichloromethane, 
aluminium oxide TLC plate); νmax (neat) 3358, 2968, 1680 (C=O), 1598, 1582, 1495, 
1371, 1277, 1238, 1033, 790, 775 cm-1; δH (400 MHz, CDCl3) 7.36 (d, 1H, J 8.0 Hz, 
H-8), 6.84-6.76 (m, 2H, H-7, NH), 6.28 (s, 1H, H-2), 3.94 (s, 3H, O-CH3), 3.71-3.62 (m, 
1H, H-1’), 2.59 (4H, q, J 7.2 Hz, N-(CH2-CH3)2), 2.52-2.44 (m, 5H, H-4’, 3-CH3), 
1.63-1.57 (m, 4H, H-2’, H-3’), 1.26 (d, 3H, J 6.4 Hz, 1’-CH3), 1.05 (6H, t, J 7.2 Hz, 
N-(CH2-CH3)2); δc (100 MHz, CDCl3) 192.0 (C=O), 164.6 (C-3), 164.2 (C-4a), 153.8 
(d, 2JCF 10.6 Hz, C-6), 151.3 (C-1), 147.1 (d, 
1JCF 261.2 Hz, C-5), 129.3 (d, 
3JCF 4.3 Hz, 
C-8a), 128.6 (d, 2JCF 9.0 Hz, C-4b), 119.6 (d, 
3JCF 3.2 Hz, C-7), 112.9 (C-8), 109.0 
(C-9a), 105.0 (C-2), 56.8 (O-CH3), 52.5 (C-4’), 47.7 (C-1’), 46.8 (N-(CH2-CH3)2), 34.9 
(C-2’), 25.8 (C-3’), 23.2 (1’-CH3), 21.1 (3-CH3), 11.2 (N-(CH2-CH3)2); δF (376 MHz, 
CDCl3) -137.4 (s); m/z (ESI) 400 [M+H]
+ (Found: [M+H]+, 400.2390. C23H30N3O2F 














A mixture of 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (150 mg, 
0.54 mmol, 1.0 equiv.), 300 (376 µL, 2.16 mmol, 4.0 equiv.), phenol 
(203 mg, 2.16 mmol, 4.0 equiv.) and sodium iodide (15 mg) was stirred at 130 ºC for 2 
h. After being cooled to rt, sodium hydroxide solution (1 M, 20 mL) was added to the 
reaction mixture. The mixture was extracted with chloroform (3  250 mL) and the 
combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
aluminium oxide column chromatography (0.66% methanol-dichloromethane) afforded 
1-(4-diethylamino-butylamino)-5-fluoro-6-methoxy-3-methyl-4-azafluoren- 9-one 123 
(140 mg, 67%) as a yellow oil; Rf  0.31 (1% methanol-dichloromethane, aluminium 
oxide TLC plate); νmax (neat) 3381, 2970, 1675 (C=O), 1602, 1579, 1495, 1280, 1231, 
1044, 986, 789, 776 cm-1; δH (400 MHz, CDCl3) 7.35 (d, 1H, J 7.6 Hz, H-8), 6.90 (t, 1H, 
J 5.6 Hz, NH), 6.81 (t, 1H, J 7.6 Hz, H-7), 6.27 (s, 1H, H-2), 3.93 (s, 3H, O-CH3), 
3.32-3.21 (m, 2H, H-1’), 2.54-2.43 (m, 9H, H-4’, N-(CH2-CH3)2, 3-CH3), 1.72-1.62 (m, 
2H, H-3’), 1.59-1.50 (m, 2H, H-3’), 1.00 (6H, t, J 7.1 Hz, N-(CH2-CH3)2); δc (100 MHz, 
CDCl3) 192.0 (C=O), 164.6 (C-3), 164.0 (C-4a), 153.8 (d, 
2JCF 10.5 Hz, C-6), 
151.9 (C-1), 147.1 (d, 1JCF 261.2 Hz, C-5), 129.3 (d, 
3JCF 2.1 Hz, C-8a), 128.7 (d, 
2JCF 
9.0 Hz, C-4b), 119.6 (d, 3JCF 3.3 Hz, C-7), 112.9 (C-8), 109.1 (C-9a), 104.8 (C-2), 
56.8 (O-CH3), 52.5 (C-4’), 46.9 (N-(CH2-CH3)2), 42.1 (C-1’), 27.5 (C-2’), 25.7 (C-3’), 
24.6 (3-CH3), 11.8 (N-(CH2-CH3)2); δF (376 MHz, CDCl3) -137.4 (s); m/z (ESI) 
386 [M+H]+ (Found: [M+H]+, 386.2227. C22H28N3O2F requires [M+H]
+, 386.2244); 
HPLC analysis: tR1 = 13.134 min, tR2 = 15.240 min, tR3 = 24.672 min. 
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1-(4-Diethylamino-ethylamino)-5-fluoro-6-methoxy-3-methyl-4- azafluoren-9-one  
 
 
A mixture of 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (100 mg, 
0.36 mmol, 1.0 equiv.), 299 (303 µL, 2.16 mmol, 6.0 equiv.), phenol 
(203 mg, 2.16 mmol, 6.0 equiv.) and sodium iodide (10 mg) was stirred at 130 ºC for 
2.5 h. After being cooled to rt, sodium hydroxide solution (1 M, 20 mL) was added to 
the reaction mixture. The mixture was extracted with chloroform (3  250 mL) and the 
combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
aluminium oxide column chromatography (0.4% methanol-dichloromethane) afforded 
1-(4-diethylamino-ethylamino)-5-fluoro- 6-methoxy-3-methyl-4-azafluoren-9-one 124 
(60 mg, 47%) as a yellow oil; Rf  0.26 (0.4% methanol-dichloromethane, aluminium 
oxide TLC plate); νmax (neat) 3365, 2966, 1683 (C=O), 1560, 1495, 1371, 1276, 1233, 
1051, 987, 790, 772 cm-1; δH (400 MHz, CDCl3) 7.38 (d, 1H, J 7.6 Hz, H-8), 7.35 (t, 1H, 
J 4.8 Hz, NH), 6.83 (t, 1H, J 7.6 Hz, H-7), 6.27 (s, 1H, H-2), 3.94 (s, 3H, O-CH3), 
3.32-3.23 (m, 2H, H-1’), 2.71 (t, 2H, J 6.2 Hz, H-2’), 2.59 (q, 4H, J 7.1 Hz, 
N-(CH2-CH3)2), 2.53 (s, 3H, 3-CH3), 1.08 (6H, t, J 7.1 Hz, N-(CH2-CH3)2); δc 
(100 MHz, CDCl3) 191.8 (C=O), 164.5 (C-3), 164.1 (C-4a), 153.8 (d, 
2JCF 10.6 Hz, 
C-6), 151.6 (C-1), 147.1 (d, 1JCF 261.0 Hz, C-5), 129.4 (d, 
3JCF 1.9 Hz, C-8a), 128.8 (d, 
2JCF 9.1 Hz, C-4b), 119.6 (d, 
3JCF 3.2 Hz, C-7), 113.0 (C-8), 109.3 (C-9a), 105.2 (C-2), 
56.8 (O-CH3), 51.2 (C-2’), 47.1 (N-(CH2-CH3)2), 39.9 (C-1’), 25.8 (3-CH3), 
12.2 (N-(CH2-CH3)2); δF (376 MHz, CDCl3) -137.6 (s); m/z (ESI) 358 [M+H]+ (Found: 
[M+H]+, 358.1925. C20H24N3O2F requires [M+H]
+, 358.1931); HPLC analysis: tR1 







A mixture of 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (150 mg, 
0.54 mmol, 1.0 equiv.), 301 (418 µL, 3.24 mmol, 6.0 equiv.), phenol 
(686 mg, 7.29 mmol, 13.5 equiv.) and sodium iodide (30 mg) was stirred at 100 ºC for 
2 h. After being cooled to rt, sodium hydroxide solution (1 M, 20 mL) was added to the 
reaction mixture. The mixture was extracted with chloroform (3  250 mL) and the 
combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
aluminium oxide column chromatography  (11.1% acetone-hexane) afforded 125 
(112 mg, 60%) as a yellow oil; Rf  0.13 (10% acetone-hexane, aluminium oxide TLC 
plate); νmax (neat) 3361, 2946, 1681 (C=O), 1596, 1582, 1494, 1369, 1275, 1237, 1071, 
1027, 988, 789, 775 cm-1; δH (400 MHz, CDCl3) 7.38 (d, 1H, J 7.6 Hz, H-8), 7.01 (d, 
1H, J 7.4 Hz, NH), 6.83 (t, 1H, J 7.6 Hz, H-7), 6.31 (s, 1H, H-2), 3.94 (s, 3H, O-CH3), 
3.78-3.72 (m, 1H, H-1’), 2.53 (s, 3H, 3-CH3), 2.51-2.48 (m, 1H, H-2’a), 2.41-2.37 (m, 
1H, H-2’b), 2.32 (s, 6H, N-(CH3)2), 1.28 (d, 3H, J 6.4 Hz, 1’-CH3); δc (100 MHz, 
CDCl3) 192.0 (C=O), 164.6 (C-3), 164.2 (C-4a), 153.8 (d, 
2JCF 10.6 Hz, C-6), 
151.3 (C-1), 147.1 (d, 1JCF 261.2 Hz, C-5), 129.3 (C-8a), 128.7 (d, 
2JCF 9.0 Hz, 
C-4b), 119.6 (d, 3JCF 3.4 Hz, C-7), 113.0 (C-8), 109.4  (C-9a), 105.1  (C-2), 
65.0 (C-2’), 56.8  (O-CH3), 46.0 (N-(CH3)2), 42.9 (C-1’), 25.8 (3-CH3), 19.7 (1’-CH3); 
δF (376 MHz, CDCl3) – 137.4 (s); m/z (ESI) 344 [M+H]+ (Found: [M+H]+, 344.1769. 
C19H22N3O2F requires [M+H]
+, 344.1774); HPLC analysis: tR1 = 11.601 min, tR2 







A mixture of 1-chloro-5-fluoro-3-methyl-6-methoxy-4-azafluoren-9-one 117 (120 mg, 
0.43 mmol, 1.0 equiv.), 302 (127 mg, 0.48 mmol, 1.1 equiv.) and 2-ethoxyethanol (14 
mL) was stirred at 120 ºC for 6.5 h. After being cooled to rt, the mixture was adjusted 
to pH 9 with aqueous ammonia. The resulting mixture was extracted with chloroform 
(3  250 mL) and the combined organic phases dried (Na2SO4). Concentration under 
reduced pressure and aluminium oxide column chromatography (12.5% acetone-hexane) 
afforded 126 (107 mg, 57%) as a yellow oil; Rf  0.19 (12.5% acetone-hexane, 
aluminium oxide TLC plate); νmax (neat) 3347, 2971, 1681 (C=O), 1587, 1496, 1369, 
1233, 1073, 988, 824, 790 cm-1; δH (400 MHz, CDCl3) 8.41 (s, 1H, NH), 7.41 (d, 1H, J 
7.6 Hz, H-8), 7.06 (dd, 1H, J 8.5, 2.6 Hz, H-6’), 6.87-6.82 (m, 3H, H-7, H-2’, H-5’), 
6.42 (s, 1H, H-2), 3.95 (s, 3H, O-CH3), 3.78 (s, 2H, CH2-N-(CH2-CH3)2), 2.64 (q, 4H, J 
7.2 Hz, N-(CH2-CH3)2), 2.46 (s, 3H, 3-CH3), 1.12 (6H, t, J 7.2 Hz, N-(CH2-CH3)2); δc 
(100 MHz, CDCl3) 191.9 (C=O), 164.7 (C-3), 164.1 (C-4a), 157.0 (C-1), 154.0 (d, 
2JCF 
10.5 Hz, C-6), 150.7 (C-4’), 147.1 (d, 1JCF 261.3 Hz, C-5), 129.2 (d, 3JCF 2.0 Hz, C-8a), 
128.8 (d, 2JCF 9.0 Hz, C-4b), 128.5 (C-3’), 125.4 (d, 3JCF 18.4 Hz, C-7), 123.2 (C-2’), 
119.9 (d, 3JCF 3.3 Hz, C-8), 117.0 (C-6’), 113.0 (C-5’), 109.4 (C-9a), 105.9 (C-2), 56.9 
(O-CH3), 56.8 (CH2-N(C2H5)2), 46.5 (N-(CH2-CH3)2), 25.7 (3-CH3), 
11.3 (N-(CH2-CH3)2); δF (376 MHz, CDCl3) -137.1 (s); m/z (ESI) 436 [M+H]+ (Found: 
[M+H]+, 436.2038. C25H26N3O3F requires [M+H]
+, 436.2036); HPLC analysis: tR1 






Thermal reaction conditions: 
A mixture of 2-chloronicotinonitrile (70 mg, 0.51 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (84 mg, 0.61 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (58 mg, 0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (5.0 mL) was stirred at 80 ºC for 1 h, then water (0.5 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.0 mL, 1.02 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (16.7% ethyl acetate-hexane) 
afforded pyrido[3,2-c]coumarin (85 mg, 85%) as a white solid; Rf 0.39 (20% ethyl 
acetate-hexane); mp 165-166 °C; νmax (solid) 3074, 1724 (C=O), 1604, 1448, 1260, 
1087, 755, 728 cm-1; δH (400 MHz, CDCl3) 9.03 (dd, 1H, J 4.7, 1.8 Hz, H-2), 8.65-8.59 
(m, 2H, H-10, H-8), 7.62-7.56 (m, 1H, H-7), 7.53 (dd, 1H, J 8.0, 4.7 Hz, H-3), 
7.62-7.57 (m, 2H, H-4, H-9); δc (100 MHz, CDCl3) 161.3 (C=O), 155.9 (C-2), 
152.8 (C-10b), 152.1 (C-6a), 138.4 (C-4), 132.4 (C-8), 125.1 (C-10), 124.9 (C-9), 
123.9 (C-3), 119.5 (C-10a), 117.6 (C-4a), 117.4 (C-7). In agreement with published 
data.135 
 
Microwave-assisted reaction conditions:  
A mixture of 2-chloronicotinonitrile (50 mg, 0.36 mmol, 1.0 equiv.), 
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2-hydroxyphenylboronic acid (59 mg, 0.43 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.04 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.6 mL), water (0.36 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.72 mL, 1.44 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 








Thermal reaction conditions: 
A mixture of 2-chloronicotinonitrile (50 mg, 0.36 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (75 mg, 0.43 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (3.6 mL) was stirred at 80 ºC for 1 h, then water (0.36 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.72 mL, 1.44 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
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with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (14.3% ethyl acetate-hexane) 
afforded 9-chloropyrido[3,2-c]coumarin (63 mg, 75%) as a white solid; Rf (25% ethyl 
acetate-hexane); mp 189-190 °C; νmax (solid) 3075, 1732 (C=O), 1563, 1445, 1394, 
1254, 1096, 1070, 1038, 825, 788, 723 cm-1; δH (400 MHz, CDCl3) 9.04 (dd, 1H, J 4.7, 
1.7 Hz, H-2), 8.63 (dd, 1H, J 8.0, 1.7 Hz, H-4), 8.59 (d, 1H, J 2.6 Hz, H-10), 7.59-7.52 
(m, 2H, H-8, H-3), 7.34 (d, 1H, J 8.8 Hz, H-7); δc (100 MHz, CDCl3) 160.8 (C=O), 
156.0 (C-2), 151.1 (C-10b), 151.0 (C-6a), 138.5 (C-4), 132.2 (C-8), 130.8 (C-9), 
124.6 (C-10), 124.5 (C-3), 120.7 (C-10a), 118.9 (C-7), 117.7 (C-4a); m/z (ESI) 
232 [M+H]+ (Found: [M+H]+, 232.0159. C12H6NO2Cl requires [M+H]
+, 232.0160). 
 
Microwave-assisted reaction conditions:  
A mixture of 2-chloronicotinonitrile (50 mg, 0.36 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (75 mg, 0.43 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.04 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.6 mL), water (0.36 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.72 mL, 1.44 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(14.3% ethyl acetate-hexane) afforded 9-chloropyrido[3,2-c]coumarin (63 mg, 76%) as 









Thermal reaction conditions: 
A mixture of 2-chloronicotinonitrile (50 mg, 0.36 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid ( 68 mg, 0.43 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (3.6 mL) was stirred at 80 ºC for 1 h, then water (0.36 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.72 mL, 1.44 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (18.2% ethyl acetate-hexane) 
afforded 9-fluoropyrido[3,2-c]coumarin (60 mg, 77%) as a white solid; Rf 0.51 (25% 
ethyl acetate-petrol); mp 187-188 °C; νmax (solid) 3082, 1742 (C=O), 1570, 1470, 1450, 
1260, 1176, 1129, 1097, 1040, 882, 818, 786 cm-1; δH (400 MHz, CDCl3) 9.04 (dd, 1H, 
J 4.7, 1.8 Hz, H-2), 8.64 (dd, 1H, J 8.0, 1.8 Hz, H-4), 8.26 (dd, 1H, J 8.7, 3.0 Hz, H-10), 
7.57 (dd, 1H, J 8.0, 4.7 Hz, H-3), 7.38 (dd, 1H, J 9.0, 4.4 Hz, H-7), 7.29 (ddd, 1H, J 9.0, 
7.0, 3.0 Hz, H-8); δc (100 MHz, CDCl3) 160.9 (C=O), 159.7 (d, 1JCF 244.3 Hz, C-9), 
155.9 (C-2), 151.3 (d, 4JCF 2.8 Hz, C-10b), 148.8 (d, 
4JCF 2.2 Hz, C-6a), 138.4 (C-4), 
124.5 (C-3), 120.8 (d, 3JCF 8.7 Hz, C-10a), 119.7 (d, 
2JCF 24.7 Hz, C-8), 119.0 (d, 
3JCF 8.3 Hz, C-7), 117.7 (C-4a), 110.7 (
2JCF 25.4 Hz, C-10); δF (376 MHz, CDCl3) 
-116.4 (s); m/z (ESI) 216 [M+H]+ (Found: [M+H]+, 216.0455. C12H6NO2F requires 
[M+H]+, 216.0455). In agreement with published data.136 
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Microwave-assisted reaction conditions:  
A mixture of 2-chloronicotinonitrile (50 mg, 0.36 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (68 mg, 0.43 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.04 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.6 mL), water (0.36 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.72 mL, 1.44 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(18.2% ethyl acetate-hexane) afforded 9-fluoropyrido[3,2-c]coumarin (52 mg, 66%) as 





Thermal reaction conditions: 
A mixture of 2-chloro-6-methylnicotinonitrile (50 mg, 0.33 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (54 mg, 0.39 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (3.3 mL) was stirred at 80 ºC for 1 h, then water (0.33 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
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organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 2-methylpyrido[3,2-c]coumarin (54 mg, 78%) as a white solid; Rf 0.67 (43.5% 
ethyl acetate-petrol); mp 162-163 °C; νmax (solid) 2923, 1723 (C=O), 1569, 1430, 1268, 
1099, 755, 735 cm-1; δH (400 MHz, CDCl3) 8.60 (dd, 1H, J 7.8, 1.3 Hz, H-10), 8.47 (d, 
1H, J 8.1 Hz, H-4), 7.60-7.50 (m, 1H, H-8), 7.41-7.31 (m, 3H, H-7, H-9, H-3), 2.76 (s, 
3H, 2-CH3); δc (100 MHz, CDCl3) 166.2 (C-2), 161.5 (C=O), 152.8 (C-10b), 
151.5 (C-6a), 138.2 (C-4), 132.1 (C-8), 124.9 (C-10), 124.8 (C-9), 124.0 (C-3), 119.5 
(C-10a), 117.3 (C-7), 115.0 (C-4a), 25.7 (2-CH3); m/z (ESI) 212 [M+H]
+ (Found: 
[M+H]+, 212.0705. C13H9NO2 requires [M+H]
+, 212.0712).  
 
Microwave-assisted reaction conditions:  
A mixture of 2-chloro-6-methylnicotinonitrile (50 mg, 0.33 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (54 mg, 0.39 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.3 mL), water (0.36 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(11.1% ethyl acetate-hexane) afforded 2-methylpyrido[3,2-c]coumarin (51 mg, 74%) as 









Thermal reaction conditions: 
A mixture of 2-chloro-6-methylnicotinonitrile (50 mg, 0.33 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (68 mg, 0.39 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (3.3 mL) was stirred at 80 ºC for 1 h, then water (0.33 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 9-chloro-2-methylpyrido[3,2-c]coumarin (58 mg, 71%) as a white solid; Rf 
0.64 (33.3% ethyl acetate-hexane); mp 192-193 °C; νmax (solid) 3068, 1757 (C=O), 
1568, 1386, 1249, 1103, 1041, 821, 792 cm-1; δH (400 MHz, CDCl3) 8.59 (d, 1H, J 2.6 
Hz, H-10), 8.48 (d, 1H, J 8.1 Hz, H-4), 7.51 (dd, 1H, J 8.8, 2.6 Hz, H-8), 7.41 (d, 1H, J 
8.1 Hz, H-3), 7.32 (d, 1H, J 8.8 Hz, H-7), 2.77 (s, 3H, 2-CH3); δc (100 MHz, CDCl3) 
166.5 (C-2), 161.0 (C=O), 151.2 (C-10b), 150.5 (C-6a), 138.3 (C-4), 132.0 (C-8), 
130.6 (C-9), 124.6 (C-10), 124.6 (C-3), 120.9 (C-10a), 118.8 (C-7), 115.2 (C-4a), 
25.7 (2-CH3); δF (376 MHz, CDCl3) –116.8 (s); m/z (ESI) 246 [M+H]+ (Found: [M+H]+, 
246.0317. C13H8NO2Cl requires [M+H]
+, 246.0316). 
 
Microwave-assisted reaction conditions:  
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A mixture of 2-chloro-6-methylnicotinonitrile (50 mg, 0.33 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (68 mg, 0.39 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.3 mL), water (0.33 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(11.1% ethyl acetate-hexane) afforded 9-chloro-2-methylpyrido[3,2-c]coumarin (51 mg, 







Thermal reaction conditions: 
A mixture of 2-chloro-6-methylnicotinonitrile (53 mg, 0.35mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (65 mg, 0.42 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (40 mg, 0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (3.5 mL) was stirred at 80 ºC for 1 h, then water (0.35 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.70 mL, 1.40 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
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organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (13.3% ethyl acetate-hexane) 
afforded 9-fluoro-2-methylpyrido[3,2-c]coumarin (56 mg, 70%) as a white solid; Rf 
0.74 (38.5% ethyl acetate-hexane); mp 186-187 °C; νmax (solid) 3078, 1717 (C=O), 
1572, 1473, 1430, 1246, 1172, 1125, 1071, 1044, 884, 830, 793 cm-1; δH (400 MHz, 
CDCl3) 8.49 (d, 1H, J 8.1, H-4), 8.29 (dd, 1H, J 8.7, 3.1 Hz, H-10), 7.41 (d, 1H, J 8.1 
Hz, H-3), 7.36 (dd, 1H, J 9.0, 4.4 Hz, H-7), 7.30-7.27 (m, 1H, H-8), 2.77 (s, 3H, 2-CH3); 
δc (100 MHz, CDCl3) 166.3 (C-2), 161.2 (C=O), 159.6 (d, 1JCF 243.9 Hz, C-9), 150.8 (d, 
4JCF 2.8 Hz, C-10b), 149.0 (d, 
4JCF 2.1 Hz, C-6a), 138.3 (C-4), 124.6 (C-3), 120.9 (d, 
3JCF 8.7 Hz, C-10a), 119.4 (d, 
2JCF 24.7 Hz, C-8), 118.9 (d, 
3JCF 8.3 Hz, C-7), 
115.1 (C-4a), 110.7 (2JCF 25.3 Hz, C-10), 25.6 (2-CH3); δF (376 MHz, CDCl3) – 
116.8 (s); m/z (ESI) 230 [M+H]+ (Found: [M+H]+, 230.0610. C13H8NO2F requires 
[M+H]+, 230.0612). 
 
Microwave-assisted reaction conditions:  
A mixture of 2-chloro-6-methylnicotinonitrile (50 mg, 0.33 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (61 mg, 0.39 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (3.3 mL), water (0.33 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(13.3% ethyl acetate-hexane) afforded 9-fluoro-2-methylpyrido[3,2-c]coumarin (53 mg, 







Thermal reaction conditions: 
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (52 mg, 0.25 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (42 mg, 0.30 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (29 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (2.5 mL) was stirred at 80 ºC for 1 h, then water (0.25 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.50 mL, 1.00 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 2-trifluoromethylpyrido[3,2-c]coumarin (60 mg, 90%) as a white solid; Rf 0.76 
(20% ethyl acetate-hexane); mp 176-178°C; νmax (solid) 3094, 1744 (C=O), 1346, 1260, 
1190, 1147, 1131, 1113, 1103, 861, 762, 742, 720 cm-1; δH (400 MHz, CDCl3) 8.82 (d, 
1H, J 8.2 Hz, H-4), 8.66 (dd, 1H, J 7.9, 1.6 Hz, H-10), 7.87 (d, 1H, J 8.2 Hz, H-3), 
7.67-7.83 (m, 1H, H-8), 7.47-7.41 (m, 2H, H-7, H-9); δc (100 MHz, CDCl3) 
160.1 (C=O), 153.5 (q, 2JCF 35.6 Hz, C-2), 153.0 (C-10b), 152.4 (C-6a), 140.7 (C-4), 
133.4 (C-8), 125.5 (C-10), 125.4 (C-9), 121.0 (q, 1JCF 275.5 Hz, CF3), 120.0 (q, 
3JCF 2.5 Hz, C-3), 119.4 (C-10a), 118.5 (C-4a), 117.5 (C-7); δF (376 MHz, CDCl3) -68.5 





Microwave-assisted reaction conditions:  
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (50 mg, 0.24 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (40 mg, 0.29 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (28 mg, 0.02 mmol, 0.1 equiv.) was degassed 
with N2. 1,4-Dioxane (2.4 mL), water (0.24 mL) and potassium carbonate solution (2 M 
aqueous solution; 0.48 mL, 0.96 mmol, 4.0 equiv.) were added at rt, and the resulting 
mixture stirred in the microwave reactor at 125 ºC for 30 min (power 300 W). The 
mixture was diluted with dichloromethane (150 mL) and water (20 mL). The layers were 
separated and the organic phase washed with brine (20 mL). The combined aqueous 
phases were extracted with dichloromethane (3  150 mL) and the combined organic 
phases dried (Na2SO4). Concentration under reduced pressure and chromatography 
(11.1% ethyl acetate-hexane) afforded 2-trifluoromethylpyrido[3,2-c]coumarin (52 mg, 





Thermal reaction conditions: 
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (55 mg, 0.26 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (55 mg, 0.32 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (31 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (2.6 mL) was stirred at 80 ºC for 1 h, then water (0.26 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.52 mL,1.04 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
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dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.8% ethyl acetate-hexane) 
afforded 9-chloro-2-(trifluoromethyl)pyrido[3,2-c]coumarin (64 mg, 81%) as a white 
solid; Rf 0.83 (25% ethyl acetate-hexane); mp 193-194 °C; νmax (solid) 3107, 1743 
(C=O), 1339, 1261, 1177, 1157, 1106, 1088, 864, 828, 724 cm-1; δH (400 MHz, CDCl3) 
8.83 (d, 1H, J 8.2 Hz, H-4), 8.60 (d, 1H, J 2.6 Hz, H-10), 7.91 (d, 1H, J 8.2 Hz, H-3), 
7.59 (dd, 1H, J 8.8, 2.6 Hz, H-8), 7.37 (d, 1H, J 8.8 Hz, H-7); δc (100 MHz, CDCl3) 
159.5 (C=O), 153.7 (q, 2JCF  Hz, C-2), 151.4 (C-10b), 151.3 (C-6a), 140.9 (C-4), 
133.4 (C-8), 131.2 (C-9), 125.0 (C-10), 120.9 (q, 1JCF 275.7 Hz, CF3), 120.7 (q, 
3JCF 2.4 Hz, C-3), 119.7 (C-10a), 119.6 (C-4a), 119.0 (C-7); δF (376 MHz, CDCl3) -68.5 




Microwave-assisted reaction conditions:  
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (68.3 mg, 0.33 mmol, 1.0 
equiv.), 5-chloro-2-hydroxyphenylboronic acid (68.4 mg, 0.40 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38.2 mg, 0.03 mmol, 0.1 equiv.) was 
degassed with N2. 1,4-Dioxane (3.3 mL), water (0.33 mL) and potassium carbonate 
solution (2 M aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added at rt, and 
the resulting mixture stirred in the microwave reactor at 125 ºC for 30 min 
(power 300 W). The mixture was diluted with dichloromethane (150 mL) and water 
(20 mL). The layers were separated and the organic phase washed with brine (20 mL). 
The combined aqueous phases were extracted with dichloromethane (3  150 mL) and 
the combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
chromatography (11.8% ethyl acetate-hexane) afforded 




Thermal reaction conditions: 
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (58 mg, 0.28 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (52 mg, 0.34 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (2.8 mL) was stirred at 80 ºC for 1 h, then water (0.28 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.56 mL, 1.12 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.8% ethyl acetate-hexane) 
afforded 9-fluoro-2-(trifluoromethyl)pyrido[3,2-c]coumarin (62 mg, 78%) as a white 
solid; Rf 0.82 (25% ethyl acetate-hexane); mp 150-151 °C; νmax (solid) 3102, 1742 
(C=O), 1440, 1342, 1261, 1156, 1113, 1098, 1038, 887, 834, 808, 723; δH (400 MHz, 
CDCl3) 8.83 (d, 1H, J 8.2 Hz, H-4), 8.30 (dd, 1H, J 8.4, 3.0 Hz, H-10), 7.90 (d, 1H, J 
8.2 Hz, H-3), 7.41 (dd, 1H, J 9.0, 4.4 Hz, H-7), 7.35 (ddd, 1H, J 9.0, 7.5, 3.0 Hz, H-8); 
δc (100 MHz, CDCl3) 159.8 (q, 2JCF 245.5 Hz, C-2), 159.7 (C=O), 153.6 (q, 
2JCF 35.7 Hz, C-2), 151.6 (d, 
4JCF 2.7 Hz, C-6a),  149.1 (d, 
4JCF 2.2 Hz, C-10b), 
140.9 (C-4), 120.9 (q, 1JCF 275.5 Hz, CF3), 120.86 (d, 
2JCF 24.8 Hz, C-8),  120.7 (q, 
3JCF 2.4 Hz, C-3), 119.8 (d, 
3JCF 8.8 Hz, C-10a),  119.5 (C-4a), 119.2 (d, 
3JCF 8.3 Hz, 
C-7), 111.2 (2JCF 25.5 Hz, C-10); δF (376 MHz, CDCl3) -68.3 (s), -115.5 (s); m/z (ESI) 




Microwave-assisted reaction conditions:  
A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (70 mg, 0.34 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (70 mg, 0.41 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (39.1 mg, 0.03 mmol, 0.1 equiv.) was 
degassed with N2. 1,4-Dioxane (3.4 mL), water (0.34 mL) and potassium carbonate 
solution (2 M aqueous solution; 0.68 mL, 1.36 mmol, 4.0 equiv.) were added at rt, and 
the resulting mixture stirred in the microwave reactor at 125 ºC for 30 min 
(power 300 W). The mixture was diluted with dichloromethane (150 mL) and water 
(20 mL). The layers were separated and the organic phase washed with brine (20 mL). 
The combined aqueous phases were extracted with dichloromethane (3  150 mL) and 
the combined organic phases dried (Na2SO4). Concentration under reduced pressure and 
chromatography (11.8% ethyl acetate-hexane) afforded 





A mixture of 2-chloronicotinonitrile (51 mg, 0.37 mmol, 1.0 equiv.), 
2-hydroxy-3-methoxyphenylboronic acid (75 mg, 0.44 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (43 mg, 0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (3.7 mL) was stirred at 80 ºC for 1 h, then water (0.37 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.74 mL, 1.48 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
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with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (20% ethyl acetate-hexane) 
afforded 7-methoxypyrido[3,2-c]coumarin (64 mg, 76%) as a white solid; Rf 0.34 (20% 
ethyl acetate-hexane); mp 215-217 °C; νmax (solid) 2918, 1721 (C=O), 1436, 1388, 
1269, 1188, 1093, 1029, 754, 723, 691 cm-1; δH (400 MHz, CDCl3) 9.03 (dd, 1H, J 4.6, 
1.6 Hz, H-2), 8.64 (dd, 1H, J 8.0, 1.6 Hz, H-4), 8.18 (dd, 1H, J 8.0, 1.2 Hz, H-10), 7.53 
(dd, 1H, J 8.0, 4.6 Hz, H-3), 7.34 (t, 1H, J 8.0 Hz, H-9), 7.15 (dd, 1H, J 8.0, 1.2 Hz, 
H-8), 4.01 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 160.8 (C=O), 155.8 (C-10b), 
152.3 (C-2), 147.8 (C-6a), 142.6 (C-7), 138.4 (C-4), 124.8 (C-9), 124.0 (C-10a), 
120.4 (C-4a), 117.7 (C-3), 116.2 (C-10), 114.3 (C-8), 56.5 (O-CH3); m/z (ESI) 








A mixture of 2-chloro-6-methylnicotinonitrile (51 mg, 0.33 mmol, 1.0 equiv.), 
2-hydroxy-3-methoxyphenylboronic acid (67 mg, 0.40 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (3.3 mL) was stirred at 80 ºC for 1 h, then water (0.33 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.66 mL, 1.32 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
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Concentration under reduced pressure and chromatography (15.4% ethyl acetate-hexane) 
afforded 7-methoxy-2-methylpyrido[3,2-c]coumarin (58 mg, 72%) as a white solid; Rf 
0.58 (0.7% methanol-dichloromethane); mp 210-212 °C; νmax (film) 2915, 1721 (C=O), 
1582, 1433, 1272, 1134, 1085, 1067, 766, 710; δH (400 MHz, CDCl3) 8.49 (d, 1H, J 8.1 
Hz, H-4), 8.19 (dd, 1H, J 8.0, 1.3 Hz, H-10), 7.36 (d, 1H, J 8.1 Hz, H-3), 7.31 (t, 1H, J 
8.0 Hz, H-9), 7.12 (dd, 1H, J 8.0, 1.3 Hz, H-8), 4.00 (s, 3H, O-CH3), 2.76 (s, 3H, CH3); 
δc (100 MHz, CDCl3) 166.1 (C-2), 161.0 (C=O), 151.7 (C-10b), 147.8 (C-6a), 142.7 
(C-7), 138.3 (C-4), 124.5 (C-9), 124.1 (C-10a), 120.5 (C-4a), 116.2 (C-3), 115.1 (C-10), 
114.0 (C-8), 56.5 (O-CH3), 25.7 (2-CH3); m/z (ESI) 242 [M+H]
+ (Found: [M+H]+, 






A mixture of 2-chloro-6-(trifluoromethyl)nicotinonitrile (57 mg, 0.27 mmol, 1.0 equiv.), 
2-hydroxy-3-methoxyphenylboronic acid (55 mg, 0.33 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (2.7 mL) was stirred at 80 ºC for 1 h, then water (0.27 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.54 mL, 1.08 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (13.3% ethyl acetate-hexane) 
afforded 7-methoxy-2-(trifluoromethyl)pyrido[3,2-c]coumarin (65 mg, 80%) as a white 
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solid; Rf 0.71 (37% ethyl acetate-hexane); mp 180-182 °C; νmax (solid) 3085, 1745 
(C=O), 1586, 1412, 1263, 1179, 1133, 1112, 1053, 782, 732; δH (400 MHz, CDCl3) 8.82 
(d, 1H, J 8.2 Hz, H-4), 8.20 (dd, 1H, J 8.0, 1.2 Hz, H-10), 7.86 (d, 1H, J 8.2 Hz, H-3), 
7.36 (t, 1H, J 8.0 Hz, H-9), 7.15 (dd, 1H, J 8.0, 1.2 Hz, H-8), 4.01 (s, 3H, O-CH3); 
δc (100 MHz, CDCl3) 159.6 (C=O), 153.5 (q, 2JCF 35.5 Hz, C-2), 152.5 (C-10b), 
147.8 (C-7), 142.8 (C-6a), 140.7 (C-4), 125.2 (C-9), 121.0 (q, 1JCF 275.5 Hz, CF3), 
120.1 (q, 3JCF 2.2 Hz, C-3), 119.4 (C-10a), 119.3 (C-4a), 116.6 (C-10), 115.1 (C-8); 









A mixture of 2-chloro5-methylnicotinonitrile (84 mg, 0.55 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (90.7 mg, 0.66 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (63 mg, 0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (5.5 mL) was stirred at 80 ºC for 1 h, then water (0.55 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.10 mL, 2.20 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.8% ethyl acetate-hexane) 
afforded 3-methylpyrido[3,2-c]coumarin (94 mg, 82%) as a white solid; Rf 0.65 (25% 
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ethyl acetate-hexane); mp 183-184 °C; νmax (solid) 2926, 1717 (C=O), 1605, 1456, 1174, 
754, 738 cm-1; δH (400 MHz, CDCl3) 8.84 (d, 1H, J 2.2 Hz, H-2), 8.54 (dd, 1H, J 7.8, 
1.7 Hz, H-10), 8.41 (d, 1H, J 2.2 Hz, H-4), 7.57-7.53 (m, 1H, H-8), 7.42-7.35 (m, 2H, 
H-7, H-9), 2.51 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 161.6 (C=O), 156.8 (C-2), 
152.4 (C-6a), 149.6 (C-10b), 137.8 (C-4), 134.1 (C-3), 131.8 (C-8a), 125.0 (C-10), 
124.5 (C-9), 119.5 (C-10a), 117.3 (C-7), 117.0 (C-4a), 18.6 (3-CH3); m/z (ESI) 









A mixture of 2-chloro-5-methylnicotinonitrile (81 mg, 0.53 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (100 mg, 0.64 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (62 mg, 0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (5.3 mL) was stirred at 80 ºC for 1 h, then water (0.53 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.07 mL, 2.13 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10% ethyl acetate-hexane) 
afforded 9-chloro-3-methylpyrido[3,2-c]coumarin (92 mg, 70%) as a white solid; Rf 
0.74 (25% ethyl acetate-hexane); mp 197-198 °C; νmax (solid) 3060, 1749 (C=O), 1621, 
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1402, 1243, 1109, 819, 715 cm-1; δH (400 MHz, CDCl3) 8.86 (d, 1H, J 2.3 Hz, H-10), 
8.54 (d, 1H, J 2.5 Hz, H-2), 8.42 (d, 1H, J 2.5 Hz, H-4), 7.50 (dd, 1H, J 8.8, 2.3 Hz, 
H-8), 7.32 (d, 1H, J 8.8 Hz, H-7), 2.53 (s, 3H, 3-CH3); δc (100 MHz, CDCl3) 
161.0 (C=O), 157.0 (C-2), 150.8 (C-10b), 148.6 (C-6a), 137.9 (C-4), 134.9 (C-9), 
131.8 (C-8), 130.7 (C-3), 124.3 (C-10), 120.9 (C-10a), 118.8 (C-7), 117.2 (C-4a), 
18.7 (3-CH3); m/z (ESI) 246 [M+H]









A mixture of 2-chloro-5-methylnicotinonitrile (84 mg, 0.55 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (91 mg, 0.66 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (64 mg, 0.06 mmol, 0.1 equiv.) and 
1,4-dioxane (5.5 mL) was stirred at 80 ºC for 1 h, then water (0.55 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.10 mL, 2.20 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 9-fluoro-3-methylpyrido[3,2-c]coumarin (94 mg, 74%) as a white solid; Rf 
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0.69 (25% ethyl acetate-hexane); mp 173-175°C; νmax (solid) 3054, 1732 (C=O), 1562, 
1466, 1251, 1160, 1078, 874, 823, 797, 722 cm-1; δH (400 MHz, CDCl3) 8.85 (d, 1H, J 
2.2 Hz, H-2), 8.41 (d, 1H, J 2.2 Hz, H-4), 8.20 (dd, 1H, J 8.7, 3.1 Hz, H-10), 7.35 (dd, 
1H, J 9.0, 4.4 Hz, H-7), 7.27-7.22 (m, 1H, H-8), 2.53 (s, 3H, 3-CH3); δc (100 MHz, 
CDCl3) 161.2 (C=O), 159.6 (d, 
1JCF 244.0 Hz, C-9), 156.9 (C-2), 148.8 (d, 
4JCF 2.8 Hz, 
C-10b), 148.4 (d, 4JCF 2.1 Hz, C-6a), 137.9 (C-4), 134.9 (C-3), 120.9 (d, 
3JCF 8.8 Hz, 
C-10a), 119.1 (d, 2JCF 24.8 Hz, C-8), 118.9 (d, 
3JCF 8.3 Hz, C-7), 117.1 (C-4a), 
110.4 (2JCF 25.4 Hz, C-10), 18.7 (3-CH3);  δF (376 MHz, CDCl3) -116.6 (s); m/z (ESI) 








A mixture of 2-chloro-4-methylnicotinonitrile (88 mg, 0.58 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (96 mg, 0.69 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (67 mg, 0.06 mmol, 0.1 equiv.) and 
1,4-dioxane (5.8 mL) was stirred at 80 ºC for 1 h, then water (0.58 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.16 mL, 2.31 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10.5% ethyl acetate-hexane) 
afforded 4-methylpyrido[3,2-c]coumarin (93 mg, 76%) as a white solid; Rf 0.58 (25% 
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ethyl acetate-hexane); mp 156-158 °C; νmax (solid) 2957, 1731 (C=O), 1580, 1506, 
1472, 762 cm-1; δH (400 MHz, CDCl3) 8.74 (d, 1H, J 4.9 Hz, H-2), 8.53 (dd, 1H, J 7.4, 
1.2 Hz, H-10), 7.50 (td, 1H, J 7.4, 1.2 Hz, H-8), 7.33-7.27 (m, 2H, H-7, H-9), 7.24 (d, 
1H, J 4.9 Hz, H-3), 2.84 (s, 3H, 4-CH3); δc (100 MHz, CDCl3) 160.7 (C=O), 
154.4 (C-2), 153.7 (C-6a), 153.1 (C-10b), 152.5 (C-4), 132.2 (C-8), 126.9 (C-10), 
125.4 (C-9), 124.8 (C-3), 119.7 (C-10a), 116.9 (C-7), 116.7 (C-4a), 23.1 (4-CH3); m/z 
(ESI) 212 [M+H]+ (Found: [M+H]+, 212.0704. C13H9NO2 requires [M+H]
+, 212.0712). 







A mixture of 2-chloro-4-methylnicotinonitrile (87 mg, 0.57 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (118 mg, 0.68 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (66 mg, 0.06 mmol, 0.1 equiv.) and 
1,4-dioxane (5.7 mL) was stirred at 80 ºC for 1 h, then water (0.57 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.14 mL, 2.28 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10% ethyl acetate-hexane) 
afforded 9-chloro-4-methylpyrido[3,2-c]coumarin (96 mg, 69%) as a white solid; Rf 
0.69 (25% ethyl acetate-hexane); mp 190-192 °C; νmax (solid) 3051, 1744 (C=O), 1658, 
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1572, 1435, 1241, 1114, 811, 692 cm-1; δH (400 MHz, CDCl3) 8.80 (d, 1H, J 4.9 Hz, 
H-2), 8.58 (d, 1H, J 2.6 Hz, H-10), 7.50 (dd, 1H, J 8.7, 2.6 Hz, H-8), 7.34 (d, 1H, J 4.9 
Hz, H-3), 7.29 (d, 1H, J 8.7 Hz, H-7), 2.88 (s, 3H, 4-CH3); δc (100 MHz, CDCl3) 
160.1 (C=O), 154.5 (C-2), 153.8 (C-10b), 152.1 (C-6a), 151.0 (C-4), 132.2 (C-8), 
130.5 (C-9), 127.4 (C-10), 125.2 (C-3), 121.0 (C-10a), 118.4 (C-7), 116.8 (C-4a), 
23.0 (4-CH3); m/z (ESI) 246 [M+H]










A mixture of 2-chloro-4-methylnicotinonitrile (91 mg, 0.60 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (112 mg, 0.72 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (69 mg, 0.06 mmol, 0.1 equiv.) and 
1,4-dioxane (6.0 mL) was stirred at 80 ºC for 1 h, then water (0.30 mL) and potassium 
carbonate solution (2 M aqueous solution; 1.20 mL, 2.40 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10.5 % ethyl acetate-hexane) 
afforded 9-fluoro-4-methylpyrido[3,2-c]coumarin (86 mg, 62%) as a white solid; Rf 
0.62(25% ethyl acetate-hexane); mp 180-182 °C; νmax (solid) 3084, 1735 (C=O), 1578, 
1466, 1241, 1111, 1175, 1042, 891, 840, 813 cm-1; δH (400 MHz, CDCl3) 8.81 (d, 1H, J 
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4.9 Hz, H-2), 8.27 (dd, 1H, J 8.9, 2.9 Hz, H-10), 7.35-7.31 (m, 2H, H-7, H-3), 7.29-7.24 
(m, 1H, H-8), 2.89 (s, 3H, 4-CH3); δc (100 MHz, CDCl3) 160.3 (C=O), 159.5 (d, 1JCF 
243.4 Hz, C-9), 154.4 (C-2), 153.8 (C-4), 152.3 (d, 4JCF 2.8 Hz, C-10b), 148.6 (d, 
4JCF 
1.9 Hz, C-6a), 127.4 (C-3), 121.0 (d, 3JCF 8.7 Hz, C-10a), 119.6 (d, 
2JCF 24.8 Hz, C-8), 
118.4 (d, 3JCF 8.3 Hz, C-7), 116.7 (C-4a), 111.2 (d, 
2JCF 25.5 Hz, C-10), 
23.1 (4-CH3); δF (376 MHz, CDCl3) -117.1 (s); m/z (ESI) 230 [M+H]+ (Found: [M+H]+, 








A mixture of 2-chloro-4-methoxynicotinonitrile (50.0 mg, 0.30 mmol, 1.0 equiv.), 
2-hydroxyphenylboronic acid (49 mg, 0.36 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (34 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (3.0 mL) was stirred at 80 ºC for 1 h, then water (0.30 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.60 mL, 1.20 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (33.3% ethyl acetate-hexane) 
afforded 4-methoxypyrido[3,2-c]coumarin (48 mg, 72%) as a white solid; Rf 0.54 (80% 
ethyl acetate-hexane); mp 193-195 °C; νmax (solid) 3092, 1729 (C=O), 1552, 1440, 
1355, 1243, 1165, 1095, 1042, 762 cm-1; δH (400 MHz, CDCl3) 8.81 (d, 1H, J 5.8 Hz, 
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H-2), 8.57 (dd, 1H, J 7.9, 1.2 Hz, H-10), 7.61-7.53 (m, 1H, H-8), 7.41-7.32 (m, 2H, H-7, 
H-9), 6.98 (d, 1H, J 5.8 Hz, H-3), 4.11 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 
168.1 (C-4), 158.1 (C=O), 156.4 (C-2), 154.9 (C-10b), 152.9 (C-6a), 132.5 (C-8), 
125.6 (C-10), 124.6 (C-9), 119.3 (C-10a), 116.9 (C-7), 107.3 (C-4a), 106.6 (C-3), 
56.9 (O-CH3); m/z (ESI) 228 [M+H]









A mixture of 2-chloro-4-methoxynicotinonitrile (49 mg, 0.29 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (60 mg, 0.35 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (34 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (2.9 mL) was stirred at 80 ºC for 1 h, then water (0.29 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.58 mL, 1.16 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (25% ethyl acetate-hexane) 
afforded 9-chloro-4-methoxypyrido[3,2-c]coumarin (51 mg, 66%) as a white solid; 
Rf 0.66 (80% ethyl acetate-hexane); mp 209-211 °C; νmax (solid) 3087, 1749 (C=O), 
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1567, 1430, 1310, 1232, 1023, 839, 815 cm-1; δH (400 MHz, CDCl3) 8.81 (d, 1H, J 5.8 
Hz, H-2), 8.56 (d, 1H, J 2.6 Hz, H-10), 7.50 (dd, 1H, J 8.8, 2.6 Hz, H-8), 7.01 (d, 1H, J 
5.8 Hz, H-3), 4.11 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 168.1 (C-4), 157.4 (C=O), 
156.5 (C-2), 153.8 (C-10b), 151.3 (C-6a), 132.4 (C-8), 130.3 (C-9), 125.3 (C-10), 
120.5 (C-10a), 118.4 (C-7), 107.1 (C-3), 106.0 (C-4a), 57.0 (O-CH3); m/z (ESI) 








A mixture of 2-chloro-4-methoxynicotinonitrile (52 mg, 0.31 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (58 mg, 0.37 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.03 mmol, 0.1 equiv.) and 
1,4-dioxane (3.1 mL) was stirred at 80 ºC for 1 h, then water (0.31 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.62 mL, 1.24 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (28.6% ethyl acetate-hexane) 
afforded 9-fluoro-4-methoxypyrido[3,2-c]coumarin (46 mg, 60%) as a white solid; Rf 
0.82 (55.6% acetone-hexane); mp 204-206 °C; νmax (solid) 3073, 1720, 1567, 1466, 
1243, 1173, 1080, 1021, 891, 824 cm-1; δH (400 MHz, CDCl3) 8.80 (d, 1H, J 5.8 Hz, 
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H-2), 8.22 (dd, 1H, J 8.9, 2.9 Hz, H-10), 7.33-7.27 (m, 2H, H-7, H-8), 7.00 (d, 1H, J 5.8 
Hz, H-3), 4.11 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 168.0 (C-4), 159.4 (d, 1JCF  Hz, 
C-9), 157.8 (C=O), 156.5 (C-2), 154.0 (d, 4JCF 2.8 Hz, C-10b), 148.9 (d, 
4JCF 1.9 Hz, 
C-6a), 120.5 (d, 3JCF 8.8 Hz, C-10a), 119.9 (d, 
2JCF 24.8 Hz, C-8), 118.5 (d, 
3JCF 8.2 Hz, 
C-7), 111.3 (2JCF 25.4 Hz, C-10), 107.3 (C-4a), 107.1 (C-3), 57.0 (O-CH3); δF (376 MHz, 
CDCl3) -117.2 (s); m/z (ESI) 246 [M+H]
+ (Found: [M+H]+, 246.0560. C13H8NO3F 







A mixture of 2-chloro-6-(4-fluorophenyl)nicotinonitrile (105 mg, 0.45 mmol, 
1.0 equiv.), 2-hydroxyphenylboronic acid (75 mg, 0.54 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (52 mg, 0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (4.5 mL) was stirred at 80 ºC for 1 h, then water (0.45 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.91 mL, 1.82 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (250 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  250 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 2-(4-fluorophenyl)pyrido[3,2-c]coumarin (106 mg, 80%) as a white solid; Rf 
0.55 (22.2% ethyl acetate-hexane); mp 225-226 °C; νmax (solid) 3077, 1727 (C=O), 
1599, 1575, 1422, 1230, 1106, 829, 801, 752 cm-1; δH (400 MHz, CDCl3) 8.74 (dd, 1H, 
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J 7.9, 1.6 Hz, H-10), 8.65 (d, 1H, J 8.4 Hz, H-3), 8.30-8.25 (m, 2H, H-2’, H-6’), 7.92 (d, 
1H, J 8.4 Hz, H-4), 7.61 (ddd, 1H, J 8.3, 7.4, 1.6 Hz, H-8), 7.46-7.40 (m, 2H, H-7, H-9), 
7.30-7.22 (m, 2H, H-3’, H-5’); δc (100 MHz, CDCl3) 164.8 (d, 1JCF 251.8 Hz, C-4’), 
161.6 (C-2), 161.3 (C=O), 153.1 (C-6a), 151.9 (C-10b), 139.3 (C-4), 134.2 (d, 4JCF 3.0 
Hz, C-1’), 132.4 (C-8), 130.0 (C-10), 129.9 (C-9), 125.0 (d, 3JCF 8.4 Hz, C-2’, C-6’), 
120.1 (C-7), 119.7 (C-10a), 117.4 (C-3), 116.3 (d, 2JCF 21.8 Hz, C-3’, C-5’), 
115.7 (C-4a); δF (376 MHz, CDCl3) -109.7 (s); m/z (ESI) 292 [M+H]+ (Found: [M+H]+, 








A mixture of 2-chloro-6-(4-fluorophenyl)nicotinonitrile (99 mg, 0.42 mmol, 1.0 equiv.), 
5-chloro-2-hydroxyphenylboronic acid (79 mg, 0.51 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (49 mg,  0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (4.2 mL) was stirred at 80 ºC for 1 h, then water (0.42  mL) and potassium 
carbonate solution (2 M aqueous solution; 0.85 mL, 1.69 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (250 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  250 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10.5% ethyl acetate-hexane) 
afforded 9-chloro-2-(4-fluorophenyl)pyrido[3,2-c]coumarin (103 mg, 75%) as a white 
solid; Rf 0.71 (29.4% ethyl acetate-hexane); mp 234-235 °C; νmax (solid) 3097, 1740 
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(C=O), 1598, 1574, 1405, 1233, 1160, 833, 813, 797 cm-1; δH (400 MHz, CDCl3) 8.69 
(d, 1H, J 2.6 Hz, H-10), 8.66 (d, 1H, J 8.4 Hz, H-4), 8.30-8.25 (m, 2H, H-2’, H-6’), 
7.97 (d, 1H, J 8.4 Hz, H-4), 7.55 (dd, 1H, J 8.8, 2.6 Hz, H-8), 7.36 (d, 1H, J 8.8 Hz, 
H-7), 7.30-7.24 (m, 2H, H-3’, H-5’); δc (100 MHz, CDCl3) 164.8 (d, 1JCF 252.3 Hz, 
C-4’), 161.7 (C-2), 160.6 (C=O), 151.3 (C-10b), 150.7 (C-6a), 139.2 (C-4), 133.7 (d, 
4JCF 3.1 Hz, C-1’), 132.2 (C-8), 130.5 (C-9), 129.9 (d, 3JCF 8.8 Hz, C-2’, C-6’), 
124.5 (C-10),  120.8 (C-10a), 120.6 (C-3), 118.8 (C-7), 116.2(d, 2JCF 21.9 Hz, C-3’, 
C-5’), 115.7 (C-4a); δF (376 MHz, CDCl3) -109.2 (s); m/z (ESI) 326 [M+H]+ (Found: 





A mixture of 2-chloro-6-(4-fluorophenyl)nicotinonitrile (97 mg, 0.42 mmol, 1.0 equiv.), 
5-fluoro-2-hydroxyphenylboronic acid (86 mg, 0.50 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (48 mg,  0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (4.2 mL) was stirred at 80 ºC for 1 h, then water (0.42 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.83 mL, 1.66 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (250 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  250 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 2-(4-fluorophenyl)-9-fluoropyrido[3,2-c]coumarin (93 mg, 72%) as a white 
solid; Rf 0.61 (22.2% ethyl acetate-hexane); mp 224-226 °C; νmax (solid) 3086, 1727 
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(C=O), 1579, 1567, 1470, 1231, 1157, 827, 799, 792 cm-1; δH (400 MHz, CDCl3) 8.66 
(d, 1H, J 8.4, H-3), 8.38 (dd, 1H, J 8.6, 3.0 Hz, H-10), 8.29-8.23 (m, 2H, H-2’, H-6’), 
7.96 (d, 1H, J 8.4 Hz, H-4), 7.39 (dd, 1H, J 9.0, 4.4 Hz, H-7), 7.34-7.30 (m, 1H, H-8), 
7.29-7.23 (m, 2H, H-3’, H-5’); δc (100 MHz, CDCl3) 164.9 (d, 1JCF 252.1 Hz, C-4’), 
161.7 (C-2), 160.9 (C=O), 159.6 (d, 1JCF 244.1 Hz, C-9), 151.1 (d, 
4JCF 2.8 Hz, C-6a), 
149.1 (d, 4JCF 2.1 Hz, C-10b), 139.3 (C-4), 133.9 (d, 
4JCF 3.2 Hz, C-1’),  130.0 (d, 3JCF 
8.7 Hz, C-2’, C-6’), 121.0 (d, 3JCF 8.6 Hz, C-10a), 120.7 (C-3), 119.7 (d, 2JCF 27.8 Hz, 
C-8), 119.1 (d, 3JCF 8.3 Hz, C-7), 116.3 (d, 
2JCF 21.8 Hz, C-3’, C-5’), 
115.8 (C-4a), 110.7 (2JCF 25.2 Hz, C-10); δF (376 MHz, CDCl3) -109.3 (s), -116.6 (s); 






A mixture of 2-chloro-7-methoxyquinoline-3-carbonitrile (97 mg, 0.45 mmol, 
1.0 equiv.), 2-hydroxyphenylboronic acid (74 mg, 0.53 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (51 mg, 0.04 mmol, 0.1 equiv.) and 
1,4-dioxane (4.5 mL) was stirred at 80 ºC for 1 h, then water (0.45 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.89 mL, 1.78 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (11.1% ethyl acetate-hexane) 
afforded 10-methoxy-6H-chromeno[4,3-b]quinolin-6-one (92 mg, 75%) as a white 
solid; Rf 0.69 (20% ethyl acetate-hexane); mp 231-233°C; νmax (solid) 2985, 1735 
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(C=O), 1603, 1482, 1242, 1177, 831, 728 cm-1; δH (400 MHz, CDCl3) 9.11 (s, 1H, H-7), 
8.76 (dd, 1H, J 7.9, 1.7 Hz, H-1), 7.89 (d, 1H, J 9.0 Hz, H-8), 7.59 (ddd, 1H, J 8.2, 7.4, 
1.7 Hz, H-3), 7.52 (d, 1H, J 2.4 Hz, H-11), 7.46-7.37 (m, 2H, H-4, H-2), 7.28 (dd, 1H, J 
9.0, 2.4 Hz, H-9), 4.05 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 164.2 (C-10), 
161.8 (C=O), 153.6 (C-4a), 153.0 (C-12a), 150.3 (C-11a), 140.4 (C-7), 132.4 (C-3), 
130.7 (C-8), 125.3 (C-1), 125.0 (C-2), 123.2 (C-7a), 121.7 (C-12b), 119.9 (C-9), 
117.6 (C-4), 113.9 (C-6a), 107.1 (C-11), 56.0 (O-CH3); m/z (ESI) 278 [M+H]
+ (Found: 







A mixture of 2-chloro-7-methoxyquinoline-3-carbonitrile (99 mg, 0.45 mmol, 
1.0 equiv.), 5-chloro-2-hydroxyphenylboronic acid (94 mg, 0.54 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (52 mg,  0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (4.5 mL) was stirred at 80 ºC for 1 h, then water (0.45 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.91 mL, 1.81 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10% ethyl acetate-hexane) 
afforded 2-chloro-10-methoxy-6H-chromeno[4,3-b]quinolin-6-one (94 mg, 67%) as a 
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white solid; Rf  0.78 (20% ethyl acetate-hexane); mp 241-242 °C; νmax (solid) 2997, 
1738 (C=O), 1607, 1473, 1231, 1172, 1015, 821, 724 cm-1; δH (400 MHz, CDCl3) 9.10 
(s, 1H, H-7), 8.73 (d, 1H, J 2.5 Hz, H-1), 7.90 (d, 1H, J 9.0 Hz, H-8), 7.54-7.51 (m, 2H, 
H-11, H-3), 7.35-7.29 (m, 2H, H-9, H-4), 4.06 (s, 3H, O-CH3); δc (100 MHz, CDCl3) 
164.4(C-10), 161.3 (C=O), 153.5 (C-4a), 151.3 (C-12a), 149.1 (C-11a), 140.5 (C-7), 
132.2 (C-3), 130.7 (C-8), 130.6 (C-2), 124.8 (C-1), 123.3 (C-7a), 122.1 (C-9), 
121.2 (C-12b), 119.0 (C-4), 113.6 (C-6a), 107.0 (C-11), 56.1 (O-CH3); m/z (ESI) 









A mixture of 2-chloro-7-methoxyquinoline-3-carbonitrile (104 mg, 0.47 mmol, 
1.0 equiv.), 5-fluoro-2-hydroxyphenylboronic acid (89 mg, 0.57 mmol, 1.2 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (55 mg,  0.05 mmol, 0.1 equiv.) and 
1,4-dioxane (4.7 mL) was stirred at 80 ºC for 1 h, then water ( 0.47 mL) and potassium 
carbonate solution (2 M aqueous solution; 0.95 mL, 1.90 mmol, 4.0 equiv.) were added 
at rt and the resulting mixture stirred at 80 ºC for 12 h. The mixture was diluted with 
dichloromethane (150 mL) and water (20 mL). The layers were separated and the 
organic phase washed with brine (20 mL). The combined aqueous phases were extracted 
with dichloromethane (3  150 mL) and the combined organic phases dried (Na2SO4). 
Concentration under reduced pressure and chromatography (10.5% ethyl acetate-hexane) 
afforded 2-fluoro-10-methoxy-6H-chromeno[4,3-b]quinolin-6-one (87 mg, 62%) as a 
white solid; Rf  0.75 (20% ethyl acetate-hexane); mp 222-224 °C; νmax 2954, 1740 
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(C=O), 1467, 1228, 1161, 1119, 1006, 815, 720 cm-1; δH (400 MHz, CDCl3) 9.12 (s, 1H, 
H-7), 8.43 (dd, 1H, J 8.8, 3.1 Hz, H-1), 7.91 (d, 1H, J 9.0 Hz, H-8), 7.53 (d, 1H, J 2.4 
Hz, H-11), 7.38 (dd, 1H, J 9.0, 2.4 Hz, H-9), 7.33-7.29 (m, 2H, H-3, H-4), 4.06 (s, 3H, 
O-CH3); δc (100 MHz, CDCl3) 164.4 (C-10), 161.4 (C=O), 159.7 (d, 1JCF 243.9 Hz, 
C-2), 153.5 (C-12a), (d, 4JCF 2.7 Hz, C-4a), 149.1 (C-11a), 140.4 (C-7), 130.7 (C-8), 
123.4 (C-7a), 122.1 (C-9), 121.3 (d, 3JCF 8.4 Hz, C-12b), 119.6 (
2JCF 24.6 Hz, C-3), 
119.2 (d, 3JCF 8.3 Hz, C-4), 113.6 (C-6a), 111.0 (
2JCF 25.2 Hz, C-1), 107.1 (C-11), 
56.1 (O-CH3); δF (376 MHz, CDCl3) -117.0 (s); m/z (ESI) 296 [M+H]+ (Found: [M+H]+, 






A mixture of 2-chloronicotinonitrile (115 mg, 0.83 mmol, 1.0 equiv.), phenylboronic 
acid (122 mg, 1.00 mmol, 1.2 equiv.), tetrakis(triphenylphosphine)palladium(0) 
(96 mg, 0.08 mmol, 0.1 equiv.) and 1,4-dioxane (8.3 mL) was stirred at 80 ºC for 1 h, 
then water (0.83 mL) and potassium carbonate solution (2 M aqueous solution; 1.67 mL, 
3.33 mmol, 4.0 equiv.) were added at rt and the resulting mixture stirred at 80 ºC for 12 
h. The mixture was diluted with dichloromethane (150 mL) and water (20 mL). The 
layers were separated and the organic phase washed with brine (20 mL). The combined 
aqueous phases were extracted with dichloromethane (3  150 mL) and the combined 
organic phases dried (Na2SO4). Concentration under reduced pressure and 
chromatography (20% ethyl acetate-hexane) afforded 2-phenylnicotinonitrile (142 mg, 
94%) as a white solid; Rf 0.38 (20% ethyl acetate-hexane); mp 94-95 °C; νmax (solid) 
3069, 2224 (CN), 1578, 1552, 1430, 806, 740, 691 cm-1; δH (400 MHz, CDCl3) 8.88 (dd, 
1H, J 4.8, 1.8 Hz, H-6), 8.08 (dd, 1H, J 7.9, 1.8 Hz, H-6), 7.94-7.92 (m, 2H, H-2’, H-6’), 
7.56-7.51 (3H, m, H-3’, H-5’, H-4’), 7.38 (dd, 1H, J 7.9, 4.8 Hz, H-5); δc (100 MHz, 
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CDCl3) 161.2 (C-2), 152.8 (C-6), 142.0 (C-4), 137.3 (C-1’), 130.4 (C-4’), 129.0 (C-2’, 
C-6’), 128.8 (C-3’, C-5’), 121.7 (C-5), 117.8 (CN), 107.6 (C-3); m/z (ESI) 181 [M+H]+ 
(Found: [M+H]+, 181.0758. C12H8N2 requires [M+H]














Nonidet P-40 mediated β-haematin formation was performed by the method previously 
described.110 A 25 mM haemin stock solution was prepared by dissolving haemin in 
DMSO and filtering through a 0.22 μm polyvinylidene difluoride (PVDF) membrane 
syringe driven filter unit. Haemin stock (177.8 μL) was suspended in 2.0 M sodium 
acetate-acetic acid buffer solution (pH 4.9, 20 mL), resulting in a 222.2 μM 
homogeneous haematin suspension.  
 
Deionised H2O (80 μL) and NP-40 (305.5 μM; 20 μL) were added to each well, 
followed by the delivery of test sample solutions in DMSO (10 μL) at different 
concentrations in triplicate. The homogeneous haematin suspension (90 μL) was added 
to each well finally. The plate was covered and incubated at 37 °C for 4 h in a water 
bath and shaken at 55 rpm.  
 
The plate was removed from incubation and centrifuged at 1100 × g for 1 h at 25°C in a 
Beckman Coulter Allegra 25R rotor. The supernatant was discarded, and then sodium 
bicarbonate solution (0.15 M; 200 μL) and SDS solution (2 % (w/v)) were added to 
each well. Centrifugation was repeated, and the supernatant was removed again. A final 
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addition of sodium hydroxide solution (0.36 M; 200 μL) and SDS solution (2 % (w/v)) 
was added to dissolve the β-haematin produced. The absorbance of the resulting 








Nonidet P-40 mediated β-haematin formation was performed by the colorimetric 
pyridine-based protocol previously described.108 A 25 mM haemin stock solution was 
prepared by dissolving haemin in DMSO and filtering through a 0.22 μm 
polyvinylidene difluoride (PVDF) membrane syringe driven filter unit. Haemin stock 
(177.8 μL) was suspended in 2.0 M sodium acetate-acetic acid buffer solution (pH 4.9, 
20 mL), resulting in a 222.2 μM homogeneous haematin suspension.  
 
Deionised H2O (73 μL), NP-40 (305.5 μM; 20 μL) and acetone (7 μL) were added to 
each well, followed by the delivery of test sample solutions in DMSO (10 μL) at 
different concentrations in triplicate. The homogeneous haematin suspension (90 μL) 
was added to each well finally. The plate was covered and incubated at 37 °C for 4 h in 
a water bath and shaken at 45 rpm.  
 
The plate was removed from incubation after 4 h. 22.2 μL of the solution of 
50% pyridine, 20% acetone, 20% water and 10% 200 mM HEPES buffer (pH 7.4) was 
added to each well, so that the final concentration of pyridine was 5% (v/v). Following 
the 10 min of shaking, the absorbance of the resulting complex was measured at 405 
nm on a BMG Labtech POLARstar Optima multiplate reader. Sigmoidal 
concentration-response curves and the IC50 values were acquired from the software of 
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Appendix I  Inhibitory activity of azafluorenones against β-haematin formation. 
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Appendix II  Inhibitory activity of azabiaryls against β-haematin formation.  
 
 
      
             
             
 
 
